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Abstract 
 
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative treatment 
for numerous haematological malignancies. Graft-versus-host disease (GVHD) is the 
major complication causing mortality and is classified into acute (aGVHD) and chronic. 
MicroRNAs play a significant role in inflammation and have reported potential as 
biomarkers of different diseases. This study has investigated the role of microRNAs in 
allo-HSCT outcomes and had  two main aims; (1) identification of microRNAs specific to 
the aGVHD target organ, skin and (2) an investigation into the role of immune specific 
miRNAs (miR-146a and miR-155) in peripheral blood. Initially, pathway mining was 
performed on a list of 18 genes that were shown previously, to have deregulated 
expression levels with regards to GVHD. The pathway mining identified specific 
immunological pathways in relation to the genes and potential microRNA targets. 
Global microRNA profiling was performed on a discovery cohort that identified a 
signature microRNA list in skin biopsies obtained from patients at the time of 
cutaneous histopathological aGVHD onset (grades I-III) and healthy volunteers. Twelve 
microRNAs were selected for further validation and it was shown that miR-34a-5p, 
miR-34a-3p, miR-503-5p and let-7c-5p were elevated and significantly involved in allo-
HSCT outcomes. There was an interaction between miR-34a-3p and miR-503-5p which 
was significantly diagnostic of aGVHD and let-7c-5p was significantly predictive of 
disease relapse. MiR-34a-5p protein targets; p53 and c-Myc were then evaluated in the 
same cohort. MiR-34a-5p expression levels and cells stained positively for p53 were 
significantly correlated in the epidermis. Preliminary optimization of miR-34a-5p 
knockdown study was successfully conducted which showed promising results in the 
reduction of T cell proliferation. The whole blood study showed that miR-146a-5p and 
its interaction with miR-155-5p was predictive of aGVHD incidence in pre-disease onset 
(Day+28) samples. Interestingly, the expression levels of miR-146a-5p and miR-155-5p 
negatively correlated with SPI1 (PU.1). In conclusion, these investigations showed that 
(1) the microRNAs studied in this investigation may regulate the expression levels of 
the selected 18 genes, (2) microRNA expression levels in clinical skin biopsies obtained 
at the time of aGVHD onset could potentially be used as diagnostic biomarkers for 
aGVHD and as predictive biomarkers for overall survival as well as relapse and (3) miR-
146a-5p and miR-155-5p expression levels in whole blood could be used as predictive 
biomarkers for aGVHD incidence.  
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Chapter 1. Introduction and Study Aims 
 
 
 
 
 
 
 
 
 
 
“Facts are the air of scientists. Without them, you can never fly.” 
-Linus Pauling 
 
 
 
 
 
 
 
 
Sections of this chapter have been published in a review article.  
Atarod, S. and Dickinson, A.M. (2013). MicroRNAs: the missing link in the biology of 
graft-versus-host disease? Frontiers in Immunology 4.   
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1.1 Haematopoietic Stem Cell Transplantation  
 
As a consequence of the nuclear power development and the Cold War, individuals 
were affected by high doses of radiation. This led to haematopoietic stem cell 
transplantation (HSCT) being used for the treatment of patients exposed to these 
radiations (Welniak et al., 2007). Investigations by Lorenz et al. (Lorenz et al., 1952) 
showed that the intravenous injection of bone marrow in mice exposed to lethal doses 
of radiation was the cure. As a result, complete depletion of bone marrow cells using 
high doses of radiation and intravenous administration of bone marrow from 
genetically identical or non-identical mice was used to treat experimental tumors 
(Welniak et al., 2007). However, it was Thomas and colleagues (Thomas et al., 1957) 
who carried out the first human allogeneic haematopoietic stem cell transplantation 
(allo-HSCT) more than 50 years ago, on six patients. The patients were subjected to 
radiation and had undergone chemotherapy as part of the treatment regimen (Thomas 
et al., 1957). Tragically, all the patients developed severe graft-versus-host disease 
(GVHD) and failed to survive (Appelbaum, 2007). The first successful non-identical 
sibling allo-HSCT was performed in 1968 (Fredhutch.org, 2014). Since then, allo-HSCT 
has become the treatment of choice to cure numerous haematological neoplasia and 
diseases. At present more than 25,000 allo-HSCTs are carried out globally, with a 
transplant mortality rate (time to death without disease relapse) of 25% (7-9% for 
matched sibling and 22% for matched unrelated donor) (Pasquini MC, 2011).   
Patients undergo allo-HSCT when either their bone marrow or immune system is 
impaired. Allo-HSCT is a treatment of choice under specific conditions for 
haematological malignancies such as acute myeloid leukemia, non-hodgkins and 
hodgkins lymphoma . Therefore, only patients who are non-responsive to 
chemotherapy or earlier treatments (refractory) and those who have had disease 
relapse undergo allo-HSCTs. There are still serious complications associated with 
transplantation such as disease relapse, GVHD, graft rejection and infections as a 
consequence of long-term immune-suppression (Welniak et al., 2007). The extent of 
the complications vary depending on the disease type, stage of diagnosis, age of the 
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transplant patient, overall health of the patient and the relationship of donor to 
patient (Passweg et al., 2004; Gratwohl, 2012). 
Until the 1990s, bone marrow (BM) was the only source of donor haematopoietic stem 
cells (HSCs) and it was only in 1995 that peripheral blood (PB) products were reported 
as a source of HSCs (Schmitz et al., 1995). Since the last two decades, umbilical cord 
blood (UCB) has been recognized as a rich source of HSCs and this was initially used for 
paediatric allo-HSCT, due to the limited volume of the product (Wagner et al., 1995). It 
was in 2004 that UCB from unrelated donors were first successfully transplanted in 
adults. 
1.2 Graft-Versus-Host Disease 
 
Graft-Versus-Host Disease is still the major risk factor of any allo-HSCT, irrespective of 
the improvements made in treatment methods, Human Leukocyte Antigen typing 
(HLA) (Section 1.3.1), patient support and earlier diagnosis of the haematological 
disorder. The complexity of GVHD is further expanded with the manifestation of the 
disease in two classes; acute and chronic phase. However, Graft-Versus-Host Reaction 
(GVHR) is present in all allo-HSCTs regardless of the risk factors. The overall incidence 
of GVHD is approximately 50% in allo-HSCT patients (Pavletic and Fowler, 2012). Acute 
GVHD (aGVHD) has been classically described as onset within the first 100 days of 
transplantation (Shlomchik, 2007) [incidence of moderate to severe aGVHD grade II-IV 
being 39% in sibling donors and 59% in Matched Unrelated Donor (MUD)] (Jagasia et 
al., 2012) where damage is seen in the skin, liver and gastrointestinal tract. Chronic 
GVHD (cGVHD) classically occurs after 100 days post-transplant (Shlomchik, 2007)  in 
40% of HLA identical sibling transplants, 50% of HLA non-identical sibling transplants 
and 70% of MUD transplants (Apperley and Masszi, 2012). Acute and cGVHD vary in 
pathophysiology, etiology and response to treatment regimens (Welniak et al., 2007). 
Acute GVHD is commonly characterized by a T-helper 1 (Th1)-type cellular response 
(Mohty et al., 2005), while cGVHD may resemble autoimmune disorders as the balance 
between B-cells is disturbed which results in elevated levels of B-cell Activating Factor 
(BAFF) (Graze and Gale, 1979; Sarantopoulos et al., 2009). However, aGVHD and 
cGVHD have been observed to overlap, making an accurate diagnosis between them 
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difficult. This simultaneous presentation of acute and cGVHD after day 100 has been 
termed as ‘overlap syndrome’ (Filipovich et al., 2005). The incidence of overlap 
syndrome appears to be increasingly common due to improved treatment methods 
(calcineurin inhibitors and reduced intensity conditioning regimens) (Welniak et al., 
2007). Moreover, involvement of populations of regulatory T cells (Treg), regulatory 
Antigen Presenting Cells (APCs), regulatory B cells (Breg) (Shimabukuro-Vornhagen et 
al., 2009) and Mesenchymal Stem Cells (MSCs) have further extended the 
pathophysiological complexity of aGVHD. 
1.2.1 Pathophysiology of aGVHD 
 
According to the classical model of aGVHD, there are three quite distinct phases in the 
development of the disease. The first two phases are the afferent phase while the 
third phase is the efferent phase of GVHD (Antin and Ferrara, 1992; Krenger et al., 
1997).  
Phase 1: Effects of Conditioning Regimen: The primary phase of aGVHD begins when 
the patient is undergoing conditioning therapy prior to transplantation (Figure 1.1). 
There are various conditioning treatments involved, including; irradiation and 
chemotherapy, all of which cause damage to the host tissues depending on the toxic 
level of the treatment (Jaksch and Mattsson, 2005). As a consequence, the host tissues 
signal the presence of injury to the immune system via the generation of cytokines, 
chemokines and adhesion molecules (Ferrara, 1993). The host epithelium is damaged 
due to conditioning regimens resulting in the cytokine storm ( TNF-α and IL-1) via the 
endothelium (Xun et al., 1994). The signals generated cause the host APCs such as 
Dendritic Cells (DC) to be stimulated (Matzinger, 2002). Endotoxins such as 
Lipopolysaccharides (LPS) are also translocated across the damaged intestinal mucosa, 
resulting in a further activation of the host’s innate immune system and cytokine 
storm (Teshima and Ferrara, 2002). There are 11 Toll-like receptors (TLRs 1-11) that 
recognize different pathogens as part of the innate immune system (Takeda and Akira, 
2005). LPS is recognized by TLR4 (Pålsson-McDermott and O'Neill, 2004) (See Section 
6.1.1.1) 
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Figure 1.1 Conditioning regimen damages the host tissues (adopted from (Markey 
et al., 2014)). In Phase 1, the gut homeostasis of the allo-HSCT patient is distorted due 
to either radiation and/or chemotherapy. Danger and/Pathogen Associated Molecular 
Patterns (DAMPs/PAMPs) and LPS are released in the blood. Following this, the 
recipient cells secrete proinflammatory cytokines such as TNF, IL-1 and IL-6. The 
cytokines activate the host APCs both in the gut and lymphatics.   
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Phase 2: Activation of Donor T cells: As a result of the cytokine storm naïve donor 
CD4+ T cells are recruited, activated and expanded leading to interaction with host 
APCs (Figure 1.2). At this stage, DCs initiate GVHD and prime naïve T cells (Matzinger, 
2002). The level of T cell response depends on the disparity between the donor and 
recipient major (MHC) and minor histocompatibility complexes. CD8+ T cells are 
activated by the variations in MHC class I and CD4+ T cells by MHC class II (Sprent et 
al., 1988). The recipient haematopoietic APCs activate the donor CD8+ T cells while, in 
the gut, the non-haematopoietic APCs can activate the donor CD4+ T cells for the 
induction of aGVHD (Koyama et al., 2012).  
 
 
Figure 1.2 Donor T cells are activated by APCs (adopted from (Blazar et al., 2012)). 
The Phase 2 of aGVHD pathophysiology involves the priming and activation of T cells in 
the graft which results in the release of several cytokines such as IFN-γ, TNF, IL-1, IL-2, 
IL-6, IL-12, IL-21, IL-22 and IL-23. This cytokine storm initiates the differentiation of T-
cells along various lineages. Natural Killer (NK) cells and neutrophils also secrete 
cytokines that further damages host tissues. 
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 Phase 3: The efferent phase: In this phase, the donor T cells are involved in specific as 
well as non-specific mechanisms to cause further injury to the host tissues. Secretion 
of inflammatory cytokines such as TNF- α, IL-1 and macrophage- derived nitric oxide 
(NO) as well as the involvement of cytotoxic T lymphocytes (CTLs) with Fas- and 
perforin- mediated mechanisms, NK cells and large granular lymphocytes (LGLs) leads 
to development of a complex cascade in the efferent phase (Reddy and Ferrara, 2003). 
The interaction of innate Large Granular Lymphocytes (LGL) and allo-reactive T-cells 
(CD8+) results in organ damage.  
 
Figure 1.3 Cytotoxic T cells and NK cells cause end organ damage in the host 
(adopted from (Blazar et al., 2012)). In Phase 3, as a result of the cytokine storm and 
continuous activation of T cells damage is caused to several host organs such as the 
skin, lungs, liver and gut.   
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 1.2.2 Pathophysiology of cGVHD 
 
More than 50% of allo-HSCT patients suffer from cGVHD (NIH consensus disease 
classification), with the long-term survivors of the transplant experiencing major 
complications and a high rate of mortality (Socie and Ritz, 2014). Chronic GVHD can 
manifest simultaneously from aGVHD, develop after treatment of aGVHD or develops 
as de novo disease (Shimabukuro-Vornhagen et al., 2009). As mentioned earlier, 
classically, cGVHD develops after 100 days and up to three years post allo-HSCT.  
There are several risk factors that are attributed to the development of cGVHD 
including; disparity in HLA typing, source of stem cells, exhibition of aGVHD, age and 
patient/ donor gender (Carlens et al., 1998). The use of Peripheral Blood Stem Cells 
(PBSCs) has been accounted for an increased risk of cGVHD (Mohty et al., 2002).  
Chronic GVHD can manifest in several organs of which the main ones are, the liver, gut, 
skin, lungs and mucous membranes. It may also involve serous membranes and 
exocrine glands, which leads to the disease resembling collagen vascular diseases 
(Deeg and Storb, 1986). Chronic GVHD is more complex with no distinguishable phases 
as in aGVHD, therefore, making accurate diagnosis more difficult. The main players in 
cGVHD are the donor T and B cells (Socie and Ritz, 2014). Studies have shown that low 
Treg level was associated with higher cGVHD incidence (Zorn et al., 2005). Activation of 
tissue fibroblasts by Transforming Growth Factor beta (TGFβ) caused fibrosis that is the 
chief hallmark of cGVHD (Socie and Ritz, 2014). The main stages and key factors 
involved in cGVHD are depicted in Figure 1.4. 
8 
 
 Figure 1.4 Chronic GVHD pathophysiology (Blazer, Murphy, et al., 2012). (a) 
Damage to thymic epithelium either due to a prior aGVHD incidence or damage caused 
during the conditioning regimen (b) Lower allo-reactive CD4+ T cells (c) Deactivation of 
immune cells T helper 2 cells and T helper 17 cells (d) Activation of macrophages 
results in the secretion of TGFβ that enhances fibrosis in host tissues (e) Reduction in 
regulatory T cells (f) Activation of B cells which leads to higher levels of BAFF (B cell 
activating Factor) in cGVHD patients.  
 
1.2.3 Histopathology and grading of GVHD 
 
The main histologic feature of GVHD is the observance of apoptotic cells in the 
epithelial layer of skin, intestine and biliary duct as well as basal and suprabasal layer 
of the epidermis. Skin biopsies are mainly used to diagnose GVHD while gut biopsies 
are taken to analyze the gastrointestinal symptoms of transplant patients. Liver 
biopsies can provide further information on whether the patient is suffering from a 
viral infection, experiencing drug toxicity or hepatic GVHD (Devergie, 2008). However, 
liver biopsies are rarely taken while skin and gut biopsies are more frequently taken 
from patients.  
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1.2.3.1 Grading of aGVHD 
 
Classically, patients were diagnosed with aGVHD if they developed histopathological 
and clinical symptoms within 100 day's post allo-HSCT. Acute GVHD has been graded 
since 1974 according to the guidelines set by Glucksberg and the aGVHD consensus in 
1994 (Glucksberg H, 1974; Przepiorka et al., 1995). In the Glucksberg classification 
system, the skin, liver and gut are staged from 0 to IV (Table 1.1). The sum of the 
stages is then used to calculate an overall clinical grade for the GVHD patient (Table 
1.2). Nearly 25% of patients manifesting grade III GVHD survive while only 5% of those 
with grade IV GVHD survive (Cahn et al., 2005). However, the National Institute of 
Health (NIH) consensus criteria is commonly used now and it classifies aGVHD  taking 
into consideration the time of disease onset as well as symptoms (Filipovich et al., 
2005). The NIH criteria categories aGVHD into two distinct groups, (1) classic aGVHD 
that manifests within 100 days post allo-HSCT and present the clinical features 
associated with aGVHD and (2) persistent, recurrent, late onset aGVHD which 
develops after 100 days post allo-HSCT and presents with aGVHD symptoms (Table 
1.3). In both groups, cGVHD is absent in patients at the time of aGVHD diagnosis. If 
cGVHD is present, the disease is classed as overlap syndrome. Acute GVHD presents 
with various intensities that are classified into mild, moderate and severe based on the 
severity of histopathological and clinical symptoms presented in the patients at the 
time of diagnosis (Filipovich et al., 2005).  
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 Acute Chronic
Overlap
<100 days
≥100 days
Late Onset
 
Figure 1.5 Classification of aGVHD as per the NIH consensus criteria (adopted 
from (Pasquini, 2008)). The Venn diagram shows classic aGVHD and persistent, 
recurrent or late aGVHD onset as two groups within aGVHD. It also shows the overlap 
syndrome which is the presentation of both aGVHD and cGVHD features at the time of 
disease diagnosis.  
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Skin Liver Gut
(Maculo-papular rash %) (Bilirubin mg/dL) (Diarrhoea mL/d)
0 No rash <2 None
1 <25% of body surface 2 to <3 >500- 1000
2 25-50% of body surface 3 to <6 >1000 - 1500
3 Generalised erythroderma 6 to <15 >1500
Generalised erythroderma with Severe abdominal pain with 
bullae formation & desquamation or without lieus involvement
Grading System: Stage for each organ
Stage
4 ≥ 15
Time of symptoms
 after HSCT or DLI
Classic ≤100 days Yes No
Persistent, recurrent or late onset >100 days Yes No
Classic No time limit No Yes
Overlap syndrome No time limit Yes Yes
Acute 
Chronic 
GVHD Classification Category  aGVHD features cGVHD features
 
 
Table 1.1 Clinical aGVHD staging system for each organ (adopted from 
(Przepiorka et al., 1995)). 
 
 
Grade Severity Degree of organ involvement
0 None None
I Mild Skin: 1-2
Skin:3
Gut and/or liver:1
Mild decrease in clinical performance
Skin: 2-3
Gut and/or Liver: 2-3
Marked decrease in clinical performance
Skin: 2-4
Gut and/or Liver: 2-4
Extreme decrease in clinical performance
Glucksberg: Overall Grading System
II 
III 
IV Life threatening
Severe
Moderate
 
Table 1.2 Overall clinical aGVHD grading system for each organ (adopted from 
(Przepiorka et al., 1995; Pavan and Reddy, 2013)). 
 
Table 1.3 Acute and chronic GVHD categories based on the NIH consensus 
(Filipovich et al., 2005). 
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1.2.3.2 Classification of cGVHD 
 
Classically, cGVHD was categorized as per the Seattle study (Shulman et al., 1980) into 
limited and extensive. This system only considered the number of organs or sites 
involved in the disease and not severity (Socie, 2009). Nowadays, cGVHD is classified 
based on the presentation of diagnostic features as per the NIH consensus (Filipovich 
et al., 2005) as well as a distinctive difference from aGVHD. At least one symptom is 
required in order to class the disease as cGVHD. This classification has a scoring system 
where both the organ and/or the site of cGVHD involvement are scored (0-3). The 
primary organs that manifest cGVHD features are;  skin, nails, scalp and body hair, 
mouth, eyes, genitalia, liver, gastrointestinal tract, lungs, joins and fascia (Pavan and 
Reddy, 2013). Disease severity is classified into mild, moderate and severe which is the 
summation of organ and site scores (Filipovich et al., 2005).  
 
1.3 Important Cells, Cytokines and Chemokines Involved in 
the Pathogenesis of GVHD 
1.3.1 Human leukocyte antigens 
 
Human Leukocyte Antigens (HLAs) are polymorphic and are expressed by the Major 
Histocompatibility Complex (MHC) (Figure 1.6). There are three classes of HLA proteins 
of which HLA class I; A, B and C are present in all nucleated cells, class II: DR, DQ and 
DP are expressed on haematopoietic cells (York IA, 1996; Boss, 1997) and class III: 
encode the components of the complement system (Beck and Trowsdale, 2000). HLA 
class II proteins can also be stimulated by other types of cells as a consequence of 
inflammation or damage to the cells.  Siblings have a 25% possibility of being a match 
at all the MHC loci while parents and other family members can differ from zero to 
three loci at HLA-A, HLA-B and HLA-DR on the second haplotype. It is the mis-matching 
of the HLA proteins between the donor and the recipient that result in the 
manifestation of aGVHD in bone marrow transplantations (Lee et al., 2007). However, 
minor histocompatibility antigens are also present and are encoded outside of the 
MHC locus. The minor histocompatibility antigens are polymorphic peptides that arise 
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due to either SNPs or gene deletions. They are immunogenic and bind to the HLA class 
I or class II receptors and are thereby presented to the T-cells (Dzierzak-Mietla et al., 
2012). It is the disparity between the donor and recipient’s minor histocompatibility 
antigens that further increases the incidence of GVHD in matched unrelated 
transplantations in comparison to identical donor grafts (Welniak et al., 2007). 
However, approximately, 40% of recipients who have undergone HLA-identical or 
matched sibling transplants may still develop GVHD (Ferrara et al., 2009). 
 
Figure 1.6 The Major Histocompatibility Complex (adopted from (Ayala et al., 
2012)). The MHC complex is present on the p arm of Chromosome 6. It encodes for the 
three classes of HLA; class I, II and III. HLA class I  are present on all nucleated cells 
while HLA class II are present only on monocytes and macrophages as well as on B, 
activated T, dendritic, endothelium and epithelial cells. HLA class III encodes the genes 
of the complement system. 
 
1.3.2 Human killer cell immunoglobulin-like receptors 
 
Human Killer Cell Immunoglobulin-like Receptors (KIR) have also been recently 
associated with the risk of GVHD. KIRs are inherited independent of HLA and are 
expressed on natural killer cells (NK) (Welniak et al., 2007) as well as on a subset of 
activated T cells, mainly the CD8+ cells (Mingari et al., 1996; Mingari et al., 1998)KIRs 
recognize HLA-A, HLA-B, and HLA-C alleles and function both as an inhibitor and an 
activator (Barao and Murphy, 2003). Activation of NK cells is regulated by the balance 
of signals (inhibitory and activator) generated from KIRs and other NK cell receptors. It 
is this activation that affects GVHD (Ruggeri et al., 2002). In some instances, KIR/KIR 
ligand incompatibilities have been demonstrated to affect graft rejection, GVHD and 
Graft-Versus-Leukemia effect (GVL) (Ruggeri et al., 2002) 
14 
 
1.3.3 Donor T-cell activation 
 
There are several signals that can co-stimulate T cells (Figure 1.7). Engagement of T cell 
receptors with specific antigens presented by MHC molecules (autologous MHC for 
bacterial or virus induced T cell response; allogeneic & autologous MHC for allo-
antigen stimulated T cell response - GVHD pertains to the allo-antigen stimulated T cell 
response). The second critical signal is from the engagement of CD28 expressed on T 
cells with CD80 and CD86 expressed on APCs. Both first and second signal must exist to 
induce T cell activation. In the absence of the second signal, the presence of the first 
signal induces T cell anergy rather than T cell activation. The third signal involves the 
engagement of certain cytokines with corresponding receptors expressed on T cells 
and/or APCs - an important example is IL-2 and CD25 engagement. The third signal 
mainly contributes to the polarisation (magnitude) of a T cell response (Yu et al., 1998; 
Snanoudj et al., 2007).  
 
Figure 1.7 Three signals activate T cells (adopted from (Snanoudj et al., 2007)). (1) 
Signal 1 involves the Donor APCs presentation of antigens to T Cell Receptors (TCR) and 
(2) Signal 2 involves the linkage between donor APCs and the CD28 on T cells.  This 
results in the activation of the Nuclear Factor-κB (NFκB), the mitogen-activated protein 
(MAP) kinase and the calcium-calcineurin pathway.  CD40-L also binds to the CD40 
present on APCs that results in antibody secretion and induction of the MHCs and (3) 
Signal 3 involves the binding of IL-2 to CD25 which activates the mTOR and results in T 
cell proliferation.  
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1.3.4 Chemokines and cytokines 
 
Monocytes, macrophages, resident cells, epithelial, endothelial or fibroblastic cells are 
stimulated by pro-inflammatory cytokines such as IL-1, TNF-α or IFN-γ and stimuli such 
as LPS (Jaksch and Mattsson, 2005). This stimulation results in the expression of 
inflammatory chemokines in these infiltrated cells. Effector T cells, monocytes and 
granulocytes are recruited by these inflammatory chemokines. Thus, chemokines as 
well as their receptors have been shown to be involved in the manifestation of GVHD. 
Chemokine Receptors; (CCR-number) CCR1, CCR2, CCR3 and CCR5 have all been shown 
to be associated with aGVHD (Jaksch et al., 2005).  
Interleukins: IL-2 is the initial cytokine that is involved in aGVHD. This has been 
established due to its pivotal role as a T cell growth factor and also because inhibition 
of IL-2 by the prophylactic drug, cyclosporine (CsA) is an effective treatment for aGVHD 
(Goker H, 2001). Moreover, it has also been shown in both animal and clinical studies 
that aGVHD can be prevented by administration of monoclonal antibodies against IL-2 
after stem-cell transplantation (SCT) (Ferrara et al., 1986). Cytokines such as IL-15 have 
also been investigated in humans showing that IL-15 could also induce aGVHD by 
activating T cells and NK cells (Kumaki S, 1998; Xian Chang Li, 2001). Il-1 has been 
shown in murine investigations to elevate GVHD and increase the risk of transplant 
related mortality (Atkinson et al., 1991). The main cellular targets of IL-18 are 
macrophages, NK cells, T cells and B cells. Both Th 1- and Th 2-mediated reactions are 
influenced by the production of IL-18 (Jaksch and Mattsson, 2005). The effect of IL-18 
production or clinical administration on aGVHD varies depending on the type of T cells 
involved. Min et al., have demonstrated this in a GVHD model study, wherein 
administration of IL-18 decreased the survival of CD8+- mediated GVHD but increased 
survival in CD4+-mediated GVHD (Min et al., 2004). 
IFN-γ:  In murine models it has been shown that mice with aGVHD have higher levels 
of Ifn-γ compared to the no-GVHD group (Hill et al., 1997). IFN-γ and IL-2 both play a 
role in T cell proliferation, stimulation of CTL and NK-cell responses, recruitment of 
mononuclear phagocytes to generate IL-1 and TNF-α (Jaksch and Mattsson, 2005). 
Moreover, both TNF-α and IFN-γ directly cause tissue injury in GVHD (Dickinson AM, 
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1991). IFN-γ suppresses the immune system via stimulation of nitric oxide (NO) and 
expression of Fas-ligand (Klimpel et al., 1990; Wall DA, 1994). IFN- γ can both reduce 
and increase GVHD similar to IL-2, depending on the conditions (Heremans H, 1987). 
Acute GVHD is augmented by IFN-γ which leads to the maturation of DC, stimulation of 
macrophages to generate cytokines and NOs (Jaksch and Mattsson, 2005). However, 
donor T cell response to host antigens can be reduced through enhancing the 
expression of Fas receptors on donor T cells, which leads to activated cell death. As a 
consequence of this the degree of aGVHD is reduced (Yang YG, 1998).  
Granulocyte- Colony Stimulating Factor: There is contradictory evidence regarding the 
function of granulocyte colony-stimulating factor (G-CSF) in GVHD. In a murine model 
of HSCT, pretreatment of donor PBSCs decreased early transplant mortality in aGVHD 
mice (Pan et al., 1995). The study assumed that as a result of G-CSF treatment, the 
donor T cells were polarized to Th2 (Pan et al., 1999). However, administration of G-
CSF to patients after HSCT actually enhanced the risk of aGVHD and transplant related 
mortality in patients (Ringdén O, 2004).  
1.3.5 Cellular components 
 
Natural Killer cells: These cells exhibit effector as well as suppressive effects on 
aGVHD. Rapidly reconstituted NK cells can be major producers of IFN-γ, TNF-α and NO 
upon induction and as a result associated with tissue injury in GVHD (Ferrara et al., 
1989; Filep et al., 1996). On the other hand, in both murine and human models it has 
been demonstrated that NK cells can inhibit GVHD and enhance GVL effect either by 
producing TGF-β or stimulating its production in other cells (Asai et al., 1998; Ruggeri 
et al., 2001; Ruggeri et al., 2002).  
Regulatory T cells: Regulatory T (Tregs) cells comprise only 5-10% of the whole CD4+ T 
cell population in humans and play a role in GVHD inhibition. However, the results on 
their mechanism of action are still controversial. Tregs suppress the activation of CD4+ 
and CD8+ T cells upon directly affecting the target T cells or APCs.  Reduction of CD25+ 
T cells has been shown to increase the development of GVHD in murine models of SCT 
as reviewed by (Jaksch and Mattsson, 2005) . In mismatched HSCT, it has been 
demonstrated that Tregs when administered along with conventional T cells can aid in 
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more rapid immune reconstitution and prevent manifestation of GVHD without a 
decline in the GVL effect. The patients in the study did not receive any post-transplant 
immune-suppressive treatment (Di Ianni et al., 2011).  
Regulatory B cells: Recipient B cells have been shown to inhibit the manifestation of 
aGVHD by reducing the expansion of CD4+ T cells and repressing Th1 differentiation. 
The majority of the host B cells are destroyed by the irradiation regimen but those 
producing IL-10 have been shown to be resistant and thus become APC in the host. 
Furthermore, regulatory B cells can generate other immunomodulatory cytokines such 
as TGFβ that can also inhibit T-cell responses (Mauri and Ehrenstein, 2008). 
In a murine study, donor B cells inhibited aGVHD in a MHC-II and Treg-dependent 
manner. However, the role of B lymphocytes in GVHD has proven to be controversial 
and interventions by  microRNA (miRNA) and proteomic studies are required to further 
elucidate the main role and mechanism of action of these specialized cells in GVHD 
(Segalen et al., 2010).  
1.3.6 Inflammatory effectors 
 
Donor T-cell derived TNF-alpha: Cytotoxic T Lymphocytes are involved via the classical 
pathways of perforin/granzyme and Fas/FasL (Jaksch and Mattsson, 2005). The 
function of TNF-α in the pathogenesis of GVHD has been well established and it has 
been shown to be caused by monocytes and macrophages of donors or the host 
(Ferrara et al., 1999). Donor-derived TNF has been shown to increase the incidence of 
GVHD (Cooke et al., 1998; Couriel et al., 2004). 
Macrophage-secreted TNF-alpha: TNF-α is responsible for numerous inflammatory 
effects in the immune system such as activating DC, increasing alloantigen 
presentation and stimulation of inflammatory chemokines and recruitment of 
neutrophils, T cells and monocytes into the target organs (Jaksch and Mattsson, 2005). 
It also directly results in tissue damage through necrosis and apoptosis (Wall DA, 
1994). It has been shown that serum levels of TNF-α increase in GVHD patients after 
allo-HSCT (Holler et al., 1990).  
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Nitric oxide: Nitric Oxide (NO) plays an essential function in host defense as well as the 
antimicrobial and tumouricidal role of macrophages (Jaksch and Mattsson, 2005). In 
acute GVHD, macrophages are activated as a consequence of increased secretion of 
IFN-γ and accumulation of LPS. This leads to the secretion of inflammatory compounds 
such as TNF-α, NO and IL-1. High levels of IFN-γ have been shown to decrease the 
levels of LPS needed to induce macrophages to secrete inflammatory products (Gifford 
GE, 1987; Ding et al., 1988). However, macrophages are primed as a consequence and 
very low levels of LPS stimulate the macrophages to produce NO and TNF-α (Nestel FP, 
1992). NO inhibits immune activation and also inactivates non-heme iron-containing 
enzymes that are responsible for expansion of epithelial stem cells in the intestine and 
skin as reviewed by (Jaksch and Mattsson, 2005).  
1.4 Graft-versus-Host Disease Prophylaxis and Treatment 
 
Both prophylaxis and treatment regimens of GVHD have severe toxic effects on not 
only the immune system, but the entire biological system of the patient. Thus, 
extensive care and monitoring of the patient is required to ensure earlier diagnosis and 
detection of infections as well as to reduce side-effects. Since allo-HSCT patients are 
immuno-compromised, anti-fungal drugs are administered prophylactically to all 
patients as a preventive measure against fungal infections (Ferrara et al., 2009). Figure 
1.8 illustrates the various time-points for conditioning and prophylaxis in allo-HSCT 
patients.  
 
Figure 1.8 Prophylaxis, treatment and factors influencing the outcome of HSCT, 
adopted from (Barker and Wagner, 2003a). Chemotherapy and/ radiation start pre-
transplant (day -7) as shown in the therapeutic timeline. At day 0, the patients receive 
HSC and immunosuppressive drugs are administered to patients undergoing allo-HSCT 
(Barker and Wagner, 2003b). 
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In some of the present transplant protocols when the patient is predicted of high 
GVHD risk, T-cell depleted grafts are used for the transplantation procedure. 
Transplant protocols vary, based on whether the donor is a sibling or MUD. There are 
also various medications administered to the patients. Calcineurin inhibitors 
(Cyclosporine A and Tacrolimus) block the production of interleukin (IL)-2 and 
proliferation of T cells. Cytokine response inhibitors (Rapamycin) expand regulatory T 
cells. Lympholytic agents such as corticosteroids are administered alone or in 
combination with the other drugs. In vivo T cells depletion is achieved with either anti-
thymocyte globulin or humanized antibody against CD25 (CAMPATH-1H) for the 
control of GVHD as well as graft failure or rejection (reviewed by Welniak et al. 
(Welniak et al., 2007)). Globally, there is a difference between the transplantation 
protocols in one centre to another which adds to the heterogeneity of disease 
population studied at the various sites. Therefore, this factor must be considered when 
analyzing investigations at individual sites and necessitates multi-centre studies to 
validate findings from one site at another centre.  
Steroids are still the current treatment of choice for aGVHD and are included as part of 
first-line therapy. Topical steroids are administered for the treatment of mild GVHD 
(Grade I- skin) while systemic steroids are used for more severe GVHD (Ferrara et al., 
2009). Studies have shown that the use of steroids for GVHD treatment results in 50% 
remission in less than half of the patients (MacMillan et al., 2002). However, at the 
same time steroid refractoriness can be a problem in some patients.  
 As a primary treatment in some centres, methyl-prednisolone is administered to 
patients who manifest aGVHD. It has been shown that 25-40% of those with severe 
aGVHD (II-IV) respond positively to this treatment. In cases where the patient does not 
respond to the primary treatment regimen, a secondary treatment is administered. For 
those exhibiting GVHD of the skin phototherapy may be used and in severe visceral 
GVHD, monoclonal and polyclonal (Atgam and Thymoglobuline) antibodies are 
administered (Devergie, 2008).  
Monoclonal antibodies directly target specific antigens, while the polyclonal antibodies 
(e.g. Atgam and Thymoglobulin) suppress T lymphocytes and result in their lysis. 
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Commonly administered monoclonal antibodies are Inolinomab, Basiliximab, 
Daclizumab, Denileukin Difitox (target IL-2 receptor), Infliximab and Etanercept (target 
TNFα antibody), CAMPATH-1H/ Alemtuzumab (targets CD25), ABX/CBL (targets CD-147 
antibody) and Visilizumab (targets CD3) (Devergie, 2008). Although a major predictor 
of cGVHD is the manifestation of aGVHD, control and remission of aGVHD has not 
been shown to be effective in decreasing the risk of cGVHD (Fraser and Scott Baker, 
2007). 
At present, cyclosporine or tacrolimus are administered for the treatment of cGVHD in 
combination with prednisolone (Sullivan et al., 1988). Immuno-suppressants used in 
the treatment of cGVHD are extremely toxic and lead to lower survival of these 
patients as they tend to suffer more from infections due to the suppression of their 
immune system.  
Presently, no effective secondary treatment is used for patients who have failed the 
primary treatment regimen (Devergie, 2008). However, extracorporeal 
photochemotherapy (ECP) has been successful in the treatment of cutaneous and 
drug-resistant cGVHD as reviewed by (Horwitz and Sullivan, 2006). In addition, recent 
studies using rituximab which is an anti-CD20 monoclonal antibody have shown 
promising results (Cutler et al., 2006).  
1.5 Other allo-HSCT outcomes  
1.5.1 Graft-versus-leukemia/ Graft-versus-tumor effect 
 
Graft-Versus-Tumor (GVT) effect was recognized as early as 1961 (Reshchikov et al., 
1961). Donor T cells not only attack the patient’s normal hematopoietic cells but also 
react against leukemia/ tumor cells resulting in GVL or GVT effect (Weiden et al., 
1979). The recognition of restricted minor HLA present on haematopoietic cells by 
donor T cells may initiate the GVL effect (Figure 1.9). On the other hand, when the 
donor T cells recognize mismatches in the HLA of recipient epithelial and 
haematopoietic tissues GVHD is induced (Bleakley and Riddell, 2004). The GVL effect 
has been clearly demonstrated in studies of relapsed transplant patients with Chronic 
Myelogenous Leukemia (CML) where in infusion of donor lymphocytes resulted in 
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remission of the disease in SCT patient (Kolb et al., 1995). As a result of the 
advantageous effects of GVL, in instances of high relapse risk, donor lymphocyte 
infusions (DLI) and mobilized donor cells are used as part of an adoptive 
immunotherapy (Kolb, 2008). Indeed, every patient undergoing the transplant 
procedure has some degree of GVH reaction otherwise the underlying disease for 
which the patient had been transplanted for would not be eliminated. Therefore, in 
the clinic, it is important to maintain the balance between GVH and GVL as this can 
ensure no disease relapse and patient recovery from cancer.  
 
Figure 1.9 Graft-versus-host reaction in allo-HSCT patient (adopted from (Bleakley 
and Riddell, 2004)). GVHR is present in every allo-HSCT patient. However, what may 
determine the severity and extent of the reaction is the recognition of mismatches by 
donor T cells in the recipient epithelial and haematopoietic stem cells. When donor T 
cells react to haematopoietic- restricted minor HLA, GVL effect is induced while when 
the same cells react to the broadly presented minor HLA, GVHD is initiated. The 
balance between GVH and GVL effect is crucial in the treatment of allo-HSCT patients.  
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1.5.2 Overall survival, relapse and non-relapse mortality 
 
The ultimate goal of allo-HSCT is to cure patients of the underlying disease. Thus, 
several outcomes are assessed in addition to GVHD such as disease relapse, overall 
survival (OS) and non-relapse mortality (NRM). There are three main types of clinical 
risk factors: pre-transplant, peri-transplant and post-transplant factors (Figure 1.10). 
Pre-transplant factors are assessed and used to calculate risk scores for patients to 
predict transplantation outcome and in turn, alter specific allo-HSCT criteria to 
improve outcome. Peri-transplant factors encompass the transplantation procedure 
which includes patient-care, the conditioning regimen, GVHD prophylaxis and also the 
source of stem cells (Bone Marrow/Peripheral Blood Stem Cells) (Gratwohl, 2012). In 
contrast, post-transplant risks are far more complicated as they are relatively 
unpredictable at the time of allo-HSCT such as GVHD or risk of relapse (Gratwohl, 
2012). Infections are also a major post allo-HSCT complication as the patient’s immune 
system is compromised to receive the donor cells.  
 
Figure 1.10 The three categories of risk factors associated with allo-HSCT. There 
are pre-, peri- and post-transplant risk factors that may determine allo-HSCT outcome. 
Pre-transplant factors are used to calculate the EBMT risk score and decide upon the 
type of transplant protocols and procedures performed for the patients. Peri-
transplant risk factors also stem from the pre-transplant factors but it is the post-
transplant factors that are difficult to determine.   
 
The EBMT risk score was developed to assist clinicians in predicting post allo-HSCT 
outcomes: relapse, OS and NRM (Gratwohl et al., 1998; Gratwohl, 2012). The risk score 
is comprised of five main clinical factors: patient age, disease stage, and time from 
diagnosis to transplant, donor type and the gender combination of donor to recipient 
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(Thomas et al., 1975; Goulmy et al., 1976; Armitage, 1994; Sierra et al., 1997; Kroger et 
al., 2009; Gupta et al., 2010). The EBMT risk score is commendatory especially as it is 
independent of the underlying disease (Gratwohl et al., 2009; Gratwohl et al., 2010). 
The risk score is simple and is a summation of the different points on a scale that 
ranges 0-7, with 0 being the ideal and 7 being the worst score (Table 1.4). As an 
example of EBMT risk score generation, a male patient of 25 years (score 1), having 
late stage disease (score 2), having 17 months from diagnosis to transplant (score 1), 
having an HLA-identical sibling donor (score 0) and having a male donor (score 0) 
would have an EBMT risk score of 1+2+1+0+0=4. 
Clinical Risk factor Score points
1. Patient age at time of Transplant (years)
 <20 0
 20–40 1
 >40 2
2. Disease stagea
 Early 0
 Intermediate 1
 Late 2
3. Time interval from diagnosis to transplant (months)b
 <12 0
 >12 1
4. Donor type
 HLA-identical sibling donor 0
 Unrelated donor 1
5. Donor recipient sex combination
 All other 0
 Female donor, male recipient 1  
Table 1.4 The EBMT risk score points for all the five different clinical risk factors 
(adopted from (Gratwohl, 2012)). a does not apply for aplastic anemia: score 0. b does 
not apply for patients transplanted in first complete remission: score 0. 
 
The effects of the five pre-transplant clinical risk factors have been established in the 
literature. The intensity and extent of post allo-HSCT complications are directly 
proportional to the age at which the patients undergo the transplantation procedure. 
Therefore, in the EBMT risk score, age is divided into three ranges covering the young 
(below 20 years), the intermediate group (20-40 years) and the higher risk group (40 
and above years). Due to an aging population and advancements in the clinical science 
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of transplantation (RIC regimens), more elderly patients undergo allo-HSCTs. Similarly, 
there are three different stages of disease as per the EBMT scoring guideline (early, 
intermediate and late). The staging in this case is disease specific. Aplastic anemia is 
not categorized into stages; all the other hematological malignancies are classed into 
stages.  Since the EBMT score was first developed for patients diagnosed with CML, the 
time interval from diagnosis to transplantation was very critical and a main risk factor. 
However, for other diseases (Acute Myeloid Leukemia, Myelodysplastic Syndrome and 
Non-Hodgkin’s Lymphoma) the time interval can only be considered when information 
on the time from diagnosis to first remission and then to transplantation is present. 
Generally, a short time interval of less than a year is considered to lead to better allo-
HSCT outcome. Recently, more patients undergo allo-HSCT with MUDs which is mainly 
due to the advancements in HLA typing and also the increasing number of donors 
available in transplantation banks. Some studies have shown that a younger MUD 
donor can improve allo-HSCT outcome in comparison to an identical SIB donor 
(Schlenk et al., 2010). Yet, the degree of HLA matching is an important indicator of allo-
HSCT and its outcome. It is well established that sex incompatibility is a major risk 
factor in particular for male patients who have female donors as they tend to have 
shorter OS even though lower incidence of relapse. The sex incompatibility arises due 
to fact that male-specific chromosome Y has H-Y (male specific histocompatibility) 
(Simpson et al., 1997) antigens that stimulate female T and B cells and thus lead to 
allogeneic reactions with fatal complications such as allo-HSCT failure and/or severe 
GVHD (Goulmy et al., 1976).  
The concordance index (c-index) quantifies the concordance between the risk score 
and actual survival time (Harrell et al., 1984). The c-index ranges from 0.5 to 1; 0.5 
signifies no diagnostic ability; 1 indicates perfect diagnostic ability.  The c-index for the 
EBMT risk score has been calculated as being just 0.621 (n=56,505) (Gratwohl et al., 
2009). In recent years, researchers have focused on trying to improve risk score as 
regards predictive value. These efforts have included addition of other factors such as 
the patient-donor CMV status and genomic factors for instance the presence or 
absence of specific SNPS in genes (Dickinson et al., 2010; Ljungman et al., 2010).  
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1.6 MicroRNAs  
 
MicroRNAs (miRNAs) are 19-22 nucleotide RNAs that are produced in every animal and 
plant cell. These short, single stranded RNAs have crucial regulatory roles by targeting 
messenger RNAS (mRNAs). MicroRNAs target nearly 30% of mRNAs and are thus 
classed as one of the major and most abundant group of translational regulators 
(Lewis et al., 2003). They not only suppress translation of mRNA but can activate it 
depending on their role. In 1991, Wightman et al. (Wightman et al., 1993) 
demonstrated that lin-4 was repressed via the product of the gene itself, however at 
that time, miRNAs had not yet been discovered and so the repression was not 
attributed to their involvement. MicroRNAs were first officially discovered in 1993 by 
Rosalind Lee and Rhonda Feinbaum in the nematode, C. elegans (Lee et al., 1993). 
Their study demonstrated that lin-4, which is associated with the control of temporal 
larval development in C. elegans, is not transcribed into mRNA but results in the 
generation of two single-stranded small RNAs. One RNA strand is 19-22 nucleotides, 
while the other strand is 61 nucleotides. Ambros and Ruvkun were able to 
demonstrate that lin-4 miRNA was complimentary to several sites in the 3’UTR 
(untranslated region) of lin-14. Their study showed that miRNAs bind to the 3’UTR of 
the mRNA and hypothesized that the repression of lin-14 was due to lin-4 miRNA 
activity (as reviewed by (Bartel, 2004a)). The main function of lin-4 was found to be the 
transition of the nematode from the first larval stage to the second stage, of its 
developmental cycle. The groups established the importance of the complimentary 
sites in the regulatory function of miRNAs and that the level of lin-14 mRNA did not 
significantly change, even though the level of LIN-14 protein decreased (as reviewed by 
Bartel et al. (Bartel, 2004a)). 
Recognition of the important roles of miRNAs through the discovery of lin-4 spurred on 
research in this area of molecular biology. Hence, the list of functions attributed to 
miRNAs has expanded over the past several years which encompasses; control of 
apoptosis, cell proliferation, metabolism of lipids in flies (Brennecke et al., 2003; Xu et 
al., 2003), mammalian transition of haematopoietic lineage differentiation (Chen et al., 
2004; Gangaraju and Lin, 2009), development of haematopoietic disorders such as 
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leukemia  (Zhao et al., 2010), and as prognostic biomarkers of diseases such as 
diabetes (Zampetaki et al., 2010) and rheumatic diseases (Alevizos and Illei, 2010). 
MicroRNAs have been shown to exhibit unique expression patterns depending on 
which cell or organ they are expressed in (Bartel, 2004a). For instance, miR-1 is a heart-
specific miRNA (Lee and Ambros, 2001; Lagos-Quintana et al., 2002) while miR-122 is 
mainly expressed in the liver (Lagos-Quintana et al., 2002). Moreover, certain miRNAs 
have a high copy number per cell, for instance, miR-2 and miR-58 are each present at 
more than 50,000 molecules per adult worm cell (Lim et al., 2003). On the other hand, 
there are certain miRNAs such as miR-124 that have a very low copy number per cell 
(Lim et al., 2003). As a result of the variable and distinct expression pattern of miRNAs, 
determining an expression profile of miRNAs in a particular disease can lead to the 
identification of biomarkers that could aid disease diagnosis and prognosis.  
Since cloning of miRNAs in low count cells and those expressed under specific 
conditions can be missed; the use of computational approaches has proven to be more 
effective at identifying these small miRNAs (Bartel, 2004a). Hence, several strategies 
have been implemented to more accurately determine this variable class of miRNAs by 
performing homology searches to identify orthologs and paralogs of the already 
known miRNA genes, proximity searches for looking at other stem-loops that could be 
representative of genes in a cluster and also by looking at the conserved regions that 
are in the intronic segment of the genome and could possibly form stem loops. 
MiRscan and MiRseeker were the first bioinformatics search engines that were able to 
identify genes associated with the expression of miRNAs (as reviewed by Bartel et al. 
(Bartel, 2004a)). Due to associated functions of miRNAs in numerous conditions there 
has been an upsurge of databases that assist in miRNA target prediction, analysis of 
expression data, pathway involvement and interpretation of their roles in diseases, 
such as DIANA LAB (Alexiou et al., 2010), mimiRNA (Ritchie et al., 2009), FERROLAB 
(Lagana  et al., 2009), HOCTAR (Gennarino et al., 2008), in addition to the initial and 
accessible databases such as PicTar (Lall et al., 2006), miRanda (Betel et al., 2008) and 
TargetScan (Lewis et al., 2005). Studies have shown that around 50% of all the genes 
are regulated by microRNAs, thereby further increasing the importance of 
understanding their involvement in disease (Bentwich, 2005). According to the 
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miRbase version 20, there are nearly 2000 miRNAs in humans (Kozomara and Griffiths-
Jones, 2014). In humans the miRNA genes are present on every chromosome except 
on the Y chromosome (Sun et al., 2009). 
1.6.1 MicroRNA nomenclature 
 
MicroRNAs are named starting with a three letter identifier which signifies the 
organism (example- hsa in homo sapiens), followed by ‘miR’ prefix, a specific number 
and then a single letter (example –a, -b ) (Ambros et al., 2003). The number is assigned 
in a sequence depending on the time of miRNA discovery. It must be noted that 
identical miRNAs are assigned the same number independent of the organism in which 
they are present in. The last letters in the miRNA name which are after the unique 
number shows the relationship of one miRNA with another (example: hsa-miR-146a is 
related to hsa-miR-146b) (Griffiths-Jones et al., 2006). Mature miRNAs are noted as 
‘miR’ whilst the precursors as ‘mir.' MiRNAs have two strands, and it was initially 
assumed that only the -5p strand was functional while the -3p strand was degraded. 
Now it is known that -3p strand that was previously denoted as miR*can also function 
(Yang et al., 2011). Due to the various complications in using miR*, the new 
nomenclature has adopted -5p and -3p instead of miR and miR*, respectively 
(Griffiths-Jones et al., 2006). The miRNA genes are called the same way but are written 
in italics, capitalized or hyphenated (Ambros et al., 2003).   
1.7 MicroRNA Biogenesis 
 
1.7.1 MicroRNA transcription 
 
The majority of miRNA genes are derived from the earlier non-annotated parts of the 
genome, while substantial small groups are derived from the non-coding regions of 
pre-mRNAs (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). 
MiRNAs may also be transcribed as a cluster in the genome rather than as individual 
regulatory molecules. The expression pattern of these clustered miRNAs suggests that 
the transcription is from a primary transcript (Lagos-Quintana et al., 2001; Lau et al., 
2001; Lee and Ambros, 2001). It was assumed that miRNAs in a cluster are related to 
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one another (Lagos-Quintana et al., 2001; Lau et al., 2001) with a similar expression 
pattern, however, with studies have shown that not only they may vary in expression 
pattern but are also not related to one another and may have unique functions. A few 
examples of miRNA clusters include the Hox and miR-17 to miR-92 clusters in humans. 
The Hox cluster has been shown to play a role in animal development (Lagos-Quintana 
et al., 2003) while miR-17-92 clusters commonly act as an oncogene (Mendell, 2008).  
It has also been shown that all cloned miRNAs are evolutionary conserved among 
humans and mouse (Lagos-Quintana et al., 2003). There are two sets of miRNAs, those 
that are present in the non-coding region of the genome and those that are present in 
the conserved regions. The intronic miRNAs are assumed to share regulatory elements 
and primary transcripts with the pre-mRNA host gene while the other miRNAs are 
thought to have been transcribed from their own promoters. The primary miRNA 
transcripts are referred to as pri-miRNAs (Lee et al., 2002) and are transcribed in the 
nucleus. Pri-miRNAs are longer than the 19-22 nucleotides stem looped structures 
known as miRNA because their transcription is from a single primary transcript (Lagos-
Quintana et al., 2001; Lau et al., 2001).  
MicroRNA transcription, particularly from the non-coding regions of the genes, are 
performed by polymerase II rather than polymerase III (pol III). This is because pri-
miRNAs are longer than 1 Kb in length with internal uridine residues. These residues 
result in premature halting of the pol III transcription. . (Bartel, 2004a).  
1.7.2 MicroRNA maturation 
 
There are various factors that are involved in the biogenesis of miRNAs these include; 
RNase-III family proteins, double-stranded (ds) binding proteins and the export 
receptor. The RNAse-III family comprises of Drosha and Dicer, which are 
endonucleolytic enzymes (Kim, 2005). The ds-binding protein comprises of the 
DiGeorge Syndrome Critical Region 8 (DGCR8) which is a well-conserved motif with 
numerous functions. It is partly involved in the processing of miRNA by Drosha and 
Dicer (Kim, 2005). The human export receptor (Expotin-5) consists of a nuclear 
transport domain and is commonly present in the Ran-dependent nuclear transport 
factors (Nakielny and Dreyfuss, 1999).  
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Initially the pri-miRNA in the nucleus is cleaved by Drosha RNase III (Lee et al., 2003) 
and this results in the release of an approximately 60-70 nucleotide stem-loop 
structure referred to as precursor miRNA (pre-miRNA) (Lee et al., 2002; Zeng et al., 
2003). Drosha is part of the microprocessor protein complex which also includes 
DGCR8 (Gangaraju and Lin, 2009). P53 has also been shown to function as a modulator 
in the processing of miRNA, due to its involvement in assembling of the Drosha 
complex (Suzuki et al., 2009). As a result of the staggered cut by Drosha RNase III, 
there is a 5’ phosphate and a 3’ overhang (~2nt) (Basyuk et al., 2003; Lee et al., 2003). 
At this point, the pre-miRNA is translocated from the nucleus to the cytoplasm through 
Expotin-5 by Ran-GTP (Yi et al., 2003; Lund et al., 2004).  
Dicer, the second enzyme involved in the maturation of the miRNA, is secreted in the 
cytoplasm (Lee et al., 2003) and has an affinity for the 5’ phosphate and the 3’ 
overhang of the pre-miRNA (Bartel, 2004a). The terminal base pairs of the pre-miRNA 
are cleaved by Dicer through a double-stranded cut at about two helical turns from the 
base of the pre-miRNA. At present it is hypothesized that Drosha makes a cleavage at a 
specific sequence of the RNA while Dicer randomly cuts any double-stranded RNA 
(Zamore et al., 2000; Bernstein et al., 2001; Elbashir et al., 2001; Zhang et al., 2002).   
In addition, it has been recently shown that miRNAs can be processed by other non-
canonical pathways (Gangaraju and Lin, 2009) which involve Dicer or are independent 
of it (Yang et al., 2012). To date two other Dicer dependent pathways have been 
described. The initial part of the first pathway employs a spliceosome and then a 
debranching enzyme to produce the short-hairpin structure for processing by Dicer 
(Gangaraju and Lin, 2009). The second pathway uses unknown nucleases to produce 
the hair-pin structure which is later processed by Dicer. MicroRNAs derived via the first 
pathway are termed as mitrons (Okamura et al., 2007) while those from the second 
pathway are referred to as endogenous short hairpin (sh)-derived miRNAs (Babiarz et 
al., 2008). In the Dicer independent pathway, the pre-miRNA is cleaved by Argonaute 2 
(Ago2) which results in the generation of mature miRNA (Figure 1.11).  
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 Figure 1.11 Dicer independent non-canonical pathway (adopted from (Dueck and 
Meister, 2010)). Maturation of miR-451 that is an erythropoiesis specific miRNA via 
Ago2 mediated pathway. Pre-miRNA once exported into the cytoplasm can either be 
processed via the canonical pathway or Ago2-mediated pathway. Pre-miR-144 is 
cleaved by Dicer while pre-miR-451 is processed into the mature miR-451 by Ago-2. 
 
1.7.3 Assembly of microRNA in RNA-induced silencing complex 
 
The ribonucleoprotein complex consists of a member of the Argonaute protein family 
and is called the RNA Induced Silencing Complex (RISC). Argonaute proteins act as the 
catalytic part of the RISC complexes and are located in certain parts of the cytoplasm 
referred to as the P-bodies (Filipowicz et al., 2008). The P-body is the region where the 
majority of mRNA degradation and miRNA activity occurs in the cytoplasm (Filipowicz 
et al., 2008; Williams, 2008). The duplex (miRNA-5p: miRNA-3p) comprises both 
strands of miRNA of which only the guide strand (miRNA-5p) will be incorporated into 
the RISC (Sonkoly and Pivarcsi, 2009). As mentioned earlier, it has been shown that 
miRNA-3p is not always degraded. Studies have revealed that both the guide miRNA-
5p and miRNA-3p are active and their roles depend on the particular condition under 
which they are expressed and processed (Ro et al., 2007; Okamura et al., 2008). The 
incorporation of the single-stranded miRNA onto the RISC is the first step in achieving 
target repression. Strand selection is based on the relative internal stability of the two 
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ends of the duplex and it is usually the strand with the less stable -5p end that is 
selected (Khvorova et al., 2003; Schwarz et al., 2003). The RISC can identify target 
mRNA based on extensive complementarity in the exons or UTR of the specific miRNA 
and the target mRNA. The majority of miRNAs are tightly associated with RISC 
complexes, and only less than 3% are present on their own. It is due to this fact that 
miRNAs are stable in cells with an extremely long half-life of days to several months 
(Liu et al., 2004; Martinez and Tuschl, 2004; Tang et al., 2008).   
1.7.4 Messenger RNA cleavage 
 
MicroRNAs down-regulate gene expression via RISC by either mRNA cleavage or 
translational repression (Bartel, 2004a). The mechanism of regulation is dependent on 
the target mRNA. Messenger RNA cleavage is achieved when the incorporated miRNA 
in the RISC has extensive complementarity with the target mRNA and in cases of lesser 
complementarity, translational repression is performed (Figure 1.12). Upon cleavage, 
the miRNA remains incorporated in the RISC to perform additional cleavages.  
Olsen and Ambros (Olsen and Ambros, 1999) explained translational repression 
through two hypotheses with respect to lin-4 miRNA. In the first hypothesis, 
translational repression might occur at a later stage after initiation of translation such 
that the number of ribosome’s are not changed directly but decline gradually to a halt. 
In the second hypothesis, suppression is achieved as a consequence of product 
degradation, whilst the rate of translation remains unaltered.  
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Figure 1.12 MicroRNA biogenesis (Esquela-Kerscher and Slack, 2006).  Pri-miRNA is 
transcribed from the miRNA gene and processed by Drosha in the nucleus. This pre-
miRNA is then exported into the cytoplasm by Exportin 5 and cleaved into mature 
miRNA by Dicer. Mature miRNA is loaded onto RISC/miRISC and delivered to the mRNA 
where it represses translation and/or results in mRNA cleavage. Pol II: Polymerase II; 
Pri-miRNA: Primary MicroRNA; Pre-miRNA: Precursor MicroRNA; miRISC: MicroRNA 
Induced Silencing Complex; ORF: Open Reading Frame; UTR: Untranslated Region; 
mRNA: Messenger RNA. 
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1.7.5 Target recognition 
 
The complementarity of the -5p end of the miRNA to the mRNA is crucial for the 
regulation of gene expression (Bartel, 2004a). Wightman (Wightman et al., 1993) was 
first to observe this complementarity between the -5p end of lin-4 miRNA and the lin-
14 UTR. Lai (2002) showed that residues 2-8 of several miRNAs have nearly perfect 
complementarity to the 3’UTR region of the target mRNA. These residues are now 
referred to as the miRNA seed and are located in the -5p end of the miRNA (Sonkoly 
and Pivarcsi, 2009). In a later study by Stark et al. (Stark et al., 2003), it was 
demonstrated that the imperfect complementarity of the mRNA residues with the 
seed sequence are conserved in orthologous messages of other species. Also, the seed 
sequences are conserved among homologous miRNAs. Furthermore, miRNA target 
recognition via seed sequence is more productive than to any other region of the 
miRNA. In plants, there should be total complementarity between the miRNA and the 
mRNA sequence while in animals partial complementarity at only the seed sequence is 
required for translational inhibition.  
1.8 MicroRNAs as Biomarkers of Diseases 
 
Recent biomarker literature has focused on the numerous characteristics of miRNAs as 
potential and specific biomarkers of various diseases, including rheumatoid arthritis 
(Alevizos and Illei, 2010) and cancer (Lawrie et al., 2007).  Studies have shown that 
around 50% of all genes are regulated by miRNAs, thereby further emphasizing the 
importance of understanding their involvement in disease (Bentwich, 2005). Hence, 
miRNAs are classed as one of the primary and most abundant group of translational 
regulators (Lewis et al., 2003). Since most of the miRNAs in cells and tissues have been 
identified, it is now possible to perform expression studies in GVHD samples in order to 
develop a miRNA signature for the disease. 
As mentioned earlier, miRNAs are not only abundant but are also highly stable due to 
their resistance to nucleases (Lau et al., 2001). This fact enables expression studies 
using formalin fixed-paraffin-embedded (FFPE) samples (Hasemeier et al., 2008) and 
salivary samples possible (Park et al., 2009). The fixation process involved in making 
34 
 
FFPEs does not degrade miRNAs as they are very short and highly stable as mentioned 
above, therefore, they are ideal sources for profiling experiments (Culpin et al., 2013). 
Since most research institutions possess archives of patient samples, a substantial 
number of relevant patient materials (serum, plasma, FFPE, urine) are available for 
biomarker discovery investigations. Also, studies have shown that there is a correlation 
between serum and biopsy miRNA profiles in a number of cancer studies as reviewed 
by Alevizos and Illei (2010). Mitchell et al. (2008)  have demonstrated that circulating 
miRNAs in plasma and serum are stable and that their measurements correlate with 
each other. This finding strengthens the hypothesis that tumor-derived miRNAs are 
translocated into the blood and hence, measurement of plasma or serum derived 
miRNAs may serve as cancer biomarkers (Mitchell et al., 2008). The availability of 
potential circulatory diagnostic miRNAs (Alevizos and Illei, 2010) could reduce the need 
for invasive methods such as skin biopsies for the diagnosis of GVHD in allo-HSCT 
patients and aid in disease monitoring. Moreover, miRNAs are expressed under certain 
conditions that can be representative of the physiological and pathological state of the 
disease such as rheumatic diseases (Alevizos and Illei, 2010). Since, miRNA expression 
patterns may be disease specific, distinguishing between normal, inflamed and 
damaged organs are possible (Babak et al., 2004). MicroRNA patterns already 
established in systemic lupus erythematosus and other systemic autoimmune diseases 
can be useful in understanding the pathogenesis of cGVHD (Shen et al., 2012).  
Although a single prognostic marker may be clinically useful, a series of validated 
markers which can provide, in addition to clinical factors, information regarding 
survival, disease progression and patient’s response to treatment would be 
advantageous. Thus, identification of a signature miRNA profile for GVHD could serve 
both as a prognostic biomarker of the disease as well as aid in further understanding 
the complexity of the disease biology. Specific biomarkers can also assist in the 
development of new therapies and more effective drugs for the treatment of GVHD.  
1.8.1 MicroRNAs in skin 
 
Since the skin is one of the first target organs of GVHD, the role of skin-specific miRNAs 
in GVHD skin biopsies is an exciting area of investigation. A number of highly expressed 
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miRNAs in the epidermis and hair follicle have already been discovered to be essential 
for the normal development of the skin (for example: miR-199 family, miR-205, miR-
27b, miR-203, miR-125b, miR-16, miR-126, miR-143, miR-21) (Yi et al., 2006; Banerjee 
et al., 2011). Skin specific miRNAs such as miR-203 are related to skin morphogenesis 
(Yi et al., 2008; Sand et al., 2009). Indeed, expression studies have shown the effect of 
miRNAs in malignant skin conditions such as melanoma, Kaposi’s sarcoma (McClure 
and Sullivan, 2008) and autoimmune diseases such as psoriasis (Sonkoly et al., 2007).  
For instance in psoriasis, miR-146a, miR-203 and miR-21 are up-regulated while miR-
125b is down-regulated (Sonkoly et al., 2008). Up-regulation of TNF-α is observed 
when miR-125b is expressed at low levels (Sand et al., 2009) and similarly, expression 
of miR-21 is shown to be elevated by pro-inflammatory cytokines such as IL-6 (Loffler 
et al., 2007). MiR-21 has also been shown to function as an oncogene in various cancer 
tissues (Liu et al., 2012; Yang et al., 2012b). Although miR-21 has been shown to be 
associated with Tregs (see below) there is lack of evidence to suggest that the impact 
of miR-21 in skin tissue is primarily via Tregs and no other cell type. 
1.8.2 MicroRNAs in immune cells 
 
Thymus-derived natural Treg cells and the peripherally stimulated Tregs are well 
characterized T lymphocytes and their function in GVHD has been highlighted through 
various studies (Di Ianni et al., 2011). Natural Tregs and peripherally induced Tregs are 
distinguished via the expression of the fork head-winged helix transcription factor 
(FOXP3) and the α-chain of the IL-2 receptor (CD25) (Rouas et al., 2009). A study 
performed ex vivo in humans by Rouas et al. (2009) has identified five main miRNAs 
(miR-21, miR-31, miR-125a, miR-181c and miR-374) particular to non-activated natural 
Tregs (Rouas et al., 2009). Natural Tregs affect both the innate and adaptive immune 
system (Sakaguchi, 2004). Moreover, the same group demonstrated the direct 
negative regulation of miR-31 through targeting of FOXP3 mRNA and positive indirect 
regulation of FOXP3 by miR-21 (Rouas et al., 2009).  
Furthermore, Allantaz et al. (Allantaz et al., 2012) have shown the existence of cell-
specific miRNAs in the whole blood of healthy individuals (Table 1.5). Initially, the 
authors examined miRNA expression in nine different types of immune cells 
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comprising of; neutrophils, eosinophils, B, NK, CD4+ T and CD8+ T-cells, myeloid DCs, 
plasmacytoid DCs and monocytes (Allantaz et al., 2012). Four miRNAs were 
characterized as cell specific (miR-378, miR-31, miR-143 and miR-935) while nine 
miRNAs were common in two to three other cell types (miR-362-5p, miR-532-5p, miR-
500*, miR-663, miR-125a-5p, miR-150, miR-223 and miR-652) (Allantaz et al., 2012). 
The group also investigated mRNA expression of the miRNA targets in the same 
samples to validate whether the cell-specific miRNAs regulated their predicted mRNA 
targets, as identified via miRNA target prediction databases.  MiRs -143, -125, -500, -
150, -652 and -223 were all found to regulate their mRNA target transcripts (Allantaz 
et al., 2012). These investigations reiterate the critical regulatory roles of miRNAs in 
immune cells and provide a valuable starting point for miRNA studies in GVHD.  
MicroRNAs Cell type
miR-378 Monocytes
miR-31 T cells
miR-935 Eosinophils
miR-143 Neutrophils
miR-362-5p
miR-532-5p
miR-500*
miR-663 B cells,NK cells
miR-125a-5p T cells, Neutrophils
miR-150 B cells, T cells, NK cells
miR-223
miR-652
Monocytes, pDCs
Monocytes, Eosinophils, Neutrophils
 
Table 1.5 List of cell-specific miRNAs in whole blood of healthy individuals    
(adopted from (Allantaz et al., 2012)). 
 
1.8.3 MicroRNAs in GVHD 
 
In a recent murine study, it has been shown that miR-146a is under-expressed in 
aGVHD and correlates with its severity (Stickel et al., 2014). Additionally, the 
established miR-146a target, Traf6 was over-expressed in aGVHD, thereby inducing 
NFκB activity.  The authors also showed that in humans, the SNP rs2910164 in grafts 
caused a reduction in miR-146a levels that escalated severe aGVHD (Grades III-IV) in 
allo-HSCT patients (Stickel et al., 2014). The rs2910164 SNP (G/C) is located in the stem 
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region of pre-miR-146a. It causes a C: U miss-pair rather than a G: U pair. It is a 
functional SNP and therefore effects the processing of pre-miR-146a into miR-146a, 
the mature strand (Iwai and Naraba, 2005).  A panel comprising of four miRNAs (miR-
423, miR-199-3p, miR-93-3p and miR-377) has been shown to be over-expressed 16 
days pre-clinical diagnosis, in the plasma of aGVHD patients when compared to the 
non-GVHD patient cohort (Xiao et al., 2013). All the up-regulated miRNAs have been 
suggested to have critical functions in the regulation of inflammation, cell 
proliferation, apoptosis and autophagy (Xiao et al., 2013). The authors hypothesized 
that plasma identified miRNAs may have significant functions in the ‘donor T-cells 
attacking process’ and play a potential role in injury-mediated responses in aGVHD 
target organs. In addition, miR-100 (Leonhardt et al., 2013), miR-34a (Wang et al., 
2013) and miR-155 (Ranganathan et al., 2012) have also been implicated in GVHD. 
MiR-100 was shown to be up-regulated in the gut of mice without GVHD, thereby 
preventing neovasularization in the tissue and demonstrating a possible protective role 
of miR-100 in GVHD (Leonhardt et al., 2013). Likewise, miR-34a expression was studied 
in the gut of pre- and post-transplanted Fanconi anaemia patients with aGVHD (Wang 
et al., 2013). MiR-34a was shown to be up-regulated in the gut of the transplanted 
Fanconi anaemia patients with grades II-IV aGVHD in comparison to patients with 
grades 0-I aGVHD and pre-transplant biopsies (Wang et al., 2013). DNA repair 
mechanisms are disrupted in Fanconi anaemia patients and this result in the activation 
of p53 pathways, ultimately leading to apoptosis (Freie et al., 2003). Thus, the 
investigators assessed the number of apoptotic cells in relation to the levels of miR-
34a and TP53 (Wang et al., 2013). The authors found that miR-34a levels in the gut 
correlated with the number of apoptotic cells and not TP53 levels (Wang et al., 2013). 
Therefore, the authors hypothesized that it was the elevation of miR-34a in the 
epithelial gut cells which was responsible for the damage observed in the gut tissues 
rather than TP53 expression (Wang et al., 2013). Similarly, the regulatory role of miR-
155, which is required for the normal function of B and T lymphocytes in humans, has 
been demonstrated in an aGVHD study (Ranganathan et al., 2012). This investigation 
showed an up-regulation of miR-155 in the gut of aGVHD patients, while expression 
was absent in the gut of normal volunteers (Ranganathan et al., 2012). A clinical trial to 
further establish the significance of miR-155 in aGVHD is ongoing at present 
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(ClinicalTrials.gov identifier: NCT01521039). Thus, miRNAs evidently not only play a 
role in the manifestation of GVHD but could potentially be used as prognostic and 
diagnostic biomarkers of  disease because of their highly specialized roles. Moreover, 
Schulte et al. (2013) have demonstrated that miRNAs have specialized functions and a 
hierarchy in controlling inflammation. In their research, miR-155 is significantly 
involved in the regulation of inflammation only when the statutory limit of miR-146a 
has been exceeded (Schulte et al., 2013). Their study highlights the combinatorial 
effect of miRNAs in regulating inflammation and also shows that investigating several 
miRNAs important in a disease-type can provide a more informative outlook on the 
pathophysiology of the disease.  
The review by Paczesny lists the array of potential prognostic and diagnostic 
biomarkers that have been identified for the detection of GVHD in allo-HSCT patients 
(Paczesny, 2012) (Table 1.6). However, despite the tremendous advances in our 
knowledge of GVHD there are no precise clinical disease markers available in the clinic 
that can aid in early detection of GVHD and monitor its severity. At present, there is 
extensive knowledge on the cellular mechanism of GVHD but less is known about the 
molecular biology of the disease. The molecular studies carried out so far have focused 
on identifying Single Nucleotide Polymorphisms (SNPs) (Dickinson and Holler, 2008) 
and specific genes involved in the development of GVHD (Baron et al., 2007)  However, 
there have been fewer studies focusing on the molecular regulation of GVHD.  
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Biomarkers of aGVHD
Interleukin-2 receptor α chain, CD25 (IL-2Rα)
Interleukin-6 (IL-6)
Interleukin-8 (IL-8)
Interleukin-10 (IL-10)
Interleukin-12 (IL-12)
Interleukin-18 (IL-18)
Chemokine (C-C motif) l igand 8 (CCL8)
Chemokine (C-X-C motif) l igand 10 (CXCL10)
Tumor necrosis factor α (TNFα)
Tumor necrosis factor receptor-1 (TNFR-1)
Heptocyte growth factor (HGF)
Cytokeratin-18 fragments (KRT18)
Elafin (PI3)
Regenerating islet-derived 3 α (REG3α)
Biomarker of cGVHD
B cell-activating factor (BAFF)
 
 
 
 
 
 
 
 
 
 
 
Table 1.6 Potential prognostic and diagnostic biomarkers of GVHD (adopted 
from (Levine et al., 2012; Paczesny, 2012)) 
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1.8.4 MicroRNAs in umbilical cord blood 
 
Weitzel et al. (Weitzel et al., 2009) have described miR-184 as a regulator of nuclear 
factor of activated T cells-1 (NFAT1) protein expression in umbilical cord blood (UCB) 
CD4+ T cells. Expression of miR-184 inhibits NFAT1, which results in a reduced 
inflammatory response. The lower expression of NFAT1 in UCB CD4+ T cells in 
comparison to adult blood is one of the main differences between UCB-derived CD4+ T 
cells and those obtained from adult blood. This study has shown that over-expression 
of miR-184 in UCB CD4+ T cells may be a reason for the decreased incidence of GVHD 
in UCB grafts compared to adult HSCT (Weitzel et al., 2009). In addition, Charrier et al. 
(2012) have also shown that UCBs express significantly higher levels of miR-146a and 
miR-155 compared to adult blood. Previous studies have shown that miR-146a 
(Sonkoly et al., 2007; Sonkoly et al., 2008) and miR-155 (Ranganathan et al., 2012; 
Zhong et al., 2012) are associated with immune regulation. Thus, the authors 
hypothesize that the lower incidence of GVHD which occurs when UCB is used instead 
of adult blood is due to the up-regulated expression of immune-regulatory miRNAs 
(miR-146a and miR-155), resulting in the down-regulation of target proteins (toll-like 
receptor 9, myeloid differentiation primary response 88, interleukin-1 receptor-
associated kinase 1, interferon regulatory factor 7) in the toll-like receptor 9 signaling 
pathway (Charrier et al., 2012). This post-transcriptional regulation leads to a decrease 
in the interferon-α mediated response, which dampens down the inflammatory 
reaction in UCBs as opposed to adult blood (Charrier et al., 2012). In addition, it has 
also been shown that miR-155 is over-expressed in UCB derived CD14+ cells and not in 
the adult peripheral blood CD14+ cells when stimulated with either IFN-γ or LPS 
(Takahashi et al., 2012). This may be reflective of the biological response in GVHD or 
infection. However, in the same study miR-146a was under-expressed in UCB derived 
CD14+ cells after stimulation with IFN-γ. The controversy regarding miR-146a 
expression may be reflective of study populations investigated. Indeed, Charrier et al. 
(2012) have looked at whole UCB and adult blood rather than an isolated CD14+ subset 
as used by Takahashi et al (2012). Merkerova et al. (2010) compared UCB and bone 
marrow miRNA signatures in cell lineages CD34+ cells, T cells, monocytes and 
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granulocytes and found distinct miRNA expression patterns indicating differences in 
regulation of the cells within bone marrow and UCB. 
1.8.5 MicroRNAs in graft rejection 
 
Investigations in renal allograft rejection have shown the existence of 17 specific 
miRNAs involved in the acute rejection process (let-7c, miR-10a, miR-10b, miR-125a, 
miR-200a, miR-30a-3p, miR-30b, miR-30c, miR-30e-3p, miR-32, miR-142-5p, miR-142-
3p, miR-223, miR-155, miR-146b, miR-146a and miR-342) (Anglicheau et al., 2009). This 
study also highlights the application of miRNAs as prognostic biomarkers for disease 
and in particular for transplantation. The significance of miRNAs in graft failure has 
also been determined in liver, lung and bowel solid organ transplantations as reviewed 
by Sarma et al. (2012). Furthermore as in HSCT some residual host T cells or natural 
killer cells can reject incoming grafts (Martin, 2000), and high levels of CD34+ cells can 
improve engraftment (Weaver et al., 1995). A study in the role of miRNAs in these 
situations would aid in the understanding of haematopoiesis, engraftment and 
rejection settings. 
1.9 MicroRNAs in therapeutics 
 
Recently, the potential of miRNAs in the development of new therapies has been 
investigated. There are two models via which miRNAs may be used for the treatment 
of diseases. Firstly, miRNA antagonists can be used to dampen up-regulated 
endogenous miRNA expression in diseased tissues. For instance, miR-122, which is a 
liver-specific miRNA, has a crucial role in the replication of hepatitis C virus (HCV) and 
is up-regulated in HCV positive patients (Haussecker and Kay, 2010;Lanford et al., 
2010;Iorio et al., 2012). Miravirsen (anti-miR-122) which consists of modified locked 
nucleic acids (LNA) is now in a phase II clinical trial (ClinicalTrials.gov Identifier: 
NCT01727934).  Miravirsen efficacy, activity and safety have been shown in a multi 
centre Phase I (ClinicalTrials.gov Identifiers: NCT00688012, NCT00979927) and Phase 
IIa (ClinicalTrials.gov Identifier: NCT01200420) clinical trial. Miravirsen sequesters miR-
122 and inhibits it from binding to the HCV genome thereby preventing its RNA 
multiplication (Janssen et al., 2013). Thus, miravirsen is a potential new therapy for the 
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treatment of HCV-positive patients. Secondly, miRNA mimics (synthesized miRNA-like 
strands), such as miR-34a (Wiggins et al., 2010)  and let-7 (Trang et al., 2010),  can be 
used to restore the function of miRNAs which are lost in the diseased cells (Bader et 
al., 2010). Unlike gene therapy that can be difficult to achieve because of the need to 
introduce large plasmids into the target tissue, miRNA mimics can be delivered using 
silencing RNA technology (Figure 1.13). The fact that miRNA mimics is small and 
representative of the endogenous miRNA sequences means that mRNA target 
specificity is increased and thus off- target effects (targeting many mRNAs) are less 
problematic. MicroRNA mimics target the same mRNAs as the endogenous miRNA 
population which is lost due to the disease (Bader et al., 2010). With the array of 
technologies that are constantly being developed and made available in the miRNA 
field, normalization of deregulated miRNAs may, therefore, be feasible in particular 
disease settings.  
 
 
Figure 1.13 Therapeutic applications of miRNAs. MiRNA antagonists, which are 
modified oligonucleotides with complementary sequences to the endogenous miRNAs, 
can be used to degrade over-expressed miRNAs. Loss of function of the endogenous 
miRNA prevents it being processed by RISC. MiRNA mimics are also oligonucleotides, 
but they replace the lost function due to the disease state of the cell (Bader et al., 
2010). 
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1.9.1 The current outlook for this investigation 
 
Although miRNA studies in the field of GVHD are in their infancy, recent investigations 
have demonstrated the tremendous potential for these small regulatory molecules as 
diagnostic, prognostic and therapeutic markers. Clinical applications exploiting our 
knowledge of miRNA function may play a crucial role in the future of GVHD 
management and treatment. An early diagnosis of GVHD can prevent patient’s 
suffering from severe GVHD (grades III-IV) as appropriate clinical interventions such as 
immunosuppressive drugs and steroids can be administered or their doses modulated 
accordingly. It will also increase the patient’s quality of life and decrease mortality due 
to GVHD severity.   
Thus, the overall aims of this investigation was to identify a signature list of miRNAs for 
aGVHD disease diagnosis using clinical skin biopsies and also to understand the role of 
immune related miRNAs in whole blood for investigating the potential of these miRNAs 
in monitoring GVHD and its response to therapy. 
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1.10   Hypotheses and Aims 
 
General hypotheses and overall aim 
Biomarkers that can be used in the transplantation clinic are absent. MicroRNAs have 
established roles in inflammatory and immune-related diseases. They are highly 
specific, sensitive, and reliable and can be quantified from various tissues and 
peripheral blood. The overall aim was to better understand the regulatory molecular 
mechanism involved in   the pathophysiology of aGVHD which may aid patient 
stratification for improved therapies and also result in the identification of robust 
diagnostic and predictive biomarkers for use in the clinic.  
Chapter 3. Pathway mining is a useful tool in identifying genes, proteins and miRNAs 
that may be directly or indirectly related to a set of disease specific genes. Previous 
experiments in our group had shown that there was an association between a list of 18 
genes and allo-HSCT outcome (i.e GVHD). 
Specific aims 
(1) Determination of specific pathways that the 18 genes associate with during allo-
HSCT and GVHD. 
(2) Identification of miRNAs that may target the 18 genes and therefore control their 
expression levels. 
Chapter 4. MicroRNAs are deregulated in the skin as a result of allo-HSCT and aGVHD. 
Specific aims 
(1) Identification and validation of a signature list of miRNAs in cutaneous aGVHD 
biopsies that could have diagnostic biomarker application for aGVHD and also 
predict OS and disease relapse. 
(2) Assessment of whether the miRNAs identified in the signature list targeted the 18 
genes.  
(3) Identification of downstream miRNA targets for the identified miRNA signature list.  
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Chapter 5. MicroRNAs impact their downstream targets at the protein translation 
stage.  
Specific aims 
(1) To test the correlation between the miRNA targets and the most significant miRNA 
from the identified signature list in Chapter 4. 
(2) To establish the preliminary optimization methods required to conduct future 
miRNA-based functional experiments.  
Chapter 6. MiR-146a-5p and miR-155-5p have immune-specific functions in several 
inflammatory and autoimmune conditions. Their expression has been detected in the 
peripheral blood of both allo-HSCT patients and healthy volunteers. 
Specific aims 
(1) Evaluate whether miR-146a-5p and miR-155-5p are differentially expressed prior to 
aGVHD disease onset. 
(2) Assess whether the expression levels of both miR146a-5p and miR-155-5p could be 
used to predict aGVHD onset and severity as well as OS, relapse and NRM.  
 (4) To assess the correlation between miR-146a-5p and miR-155-5p with their 
established targets (IRAK1, TRAF6, STAT1-α, IRF5 and the transcription factor SPI1) 
both at the mRNA and protein level.  
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Chapter 2. Materials and Methods 
 
 
 
 
“You never change things by fighting the existing reality. 
To change something, build a new model that makes the existing model obsolete.” 
- R. Buckminster Fuller 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter includes all the reagents, experimental methods and statistical analyses 
used for all the investigations mentioned throughout this thesis.  
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2.1 Patients and Healthy Volunteer Cohort 
 
2.1.1 Ethics and consent 
 
The patients and healthy volunteers consented for both the skin and whole blood 
collection and molecular testing. Consent was taken prospectively by trained 
personnel. The project was approved by the Newcastle and North Tyneside I Research 
Ethics Committee (Whole Blood study: STEMDiagnostics: 07/H0906/131, Allo-HSCT 
skin study: 05/Q0905/200 and Healthy Volunteers skin: 2002/204). For further 
information on the approvals see Ethics Approval Section (page 258). All the 
investigations were conducted in accordance with the Helsinki Declaration.  
2.1.2 Clinical information 
 
The overall clinical aGVHD grade was diagnosed by clinicians in accordance with the 
NIH consensus. All the clinical data were collected from the ProMISE database (Project 
Manager Internet Server) as used by the European Society for Blood and Marrow 
Transplantation. Overall clinical aGVHD grades and cutaneous histopathological grades 
were assessed using standard criteria (Glucksberg H, 1974; Lerner et al., 1974).  
2.2 Tissue Culture Methods 
 
All tissue culture work was performed in a Class II safety cabinet under aseptic 
conditions. Incubation of cultures was at 37°C in a humidified incubator (Flow 
Laboratories IR 1500 incubator) with 5 % carbon dioxide and 95% air. 
2.2.1 General cell culture media  
 
Peripheral blood mononuclear cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium (PAA) supplemented with 2 mM L-glutamine (Life Technologies), 
10% Heat Inactivated Fetal Calf Serum (Life Technologies), 100 IU/ml penicillin and 100 
µg/ml streptomycin (Sigma).  
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2.2.2 Isolation of PBMCs 
 
PBMCs were isolated from peripheral blood or leukocyte reduction system cones using 
the density centrifugation method. Peripheral blood was collected from patients and 
healthy volunteers in Universal Container (Sterilin) that had 500 IU sodium-heparin as 
the anti-coagulant. Peripheral blood was then diluted (1:1) with Earle’s Balanced Salt 
Solution (EBSS, Gibco) and then carefully layered onto LymphoprepTM (Axis Sheilds). 
Samples were centrifuged (Fischer) at 800 g for 15 minutes at room temperature. 
Supernatant was discarded and PBMCs were collected from the interphase layer using 
sterile Pasteur pipette. PBMCs were washed in EBSS twice by centrifugation at 500 g, 
room temperature for 5 minutes. Washed cells were resuspended in RPMI 1640 
supplemented medium. Cells were counted on an Improved Neubauer 
Haemocytometer (Weber Scientific International Ltd) and percentage viability was 
determined by the Trypan Blue (Sigma) exclusion test.  
Acknowledgement: Dr Emily Mavin provided some of the healthy volunteer PBMCs. 
2.2.3 Cryopreservation of PBMCs 
 
Cryopreservation of cells was performed by using freezing solution containing 70% 
RPMI 1640 medium, 20% HI FCS and 10% dimethyl sulphoxide (DMSO) (DMSO, 
Kocklight Ltd). Cell pellets were resuspended in cold freezing solution and aliquoted 
into cryovials (3x106- 10x106 cells/ vial) (Nunclon). To regulate the freezing process the 
cryovials were wrapped in bubble plastic and stored at -80 °C for approximately 24 
hours and then transferred for long term storage to -140 °C freezers.  
2.2.4 Preparation of serum 
 
Peripheral blood was collected into 7 ml vacutainer tubes coated with potassium 
Ethylenediaminetetraacetic acid (EDTA) (Becton Dickinson). The blood clot was 
allowed to retract for 4-7 hours at 4 °C and then centrifuged at 500g, room 
temperature for 5 minutes. Serum was collected from the supernatant and dispensed 
into sterile Eppendorf tubes (250 µl). All sera were stored immediately on collection at     
-80 °C freezer.  
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2.2.5 Thawing of cryopreserved PBMCs 
Cryopreserved PBMCs were retrieved from the -140 °C freezer and quickly transferred 
to 37 °C water bath. Thawed cells were transferred into 10 ml warmed RPMI 1640 
supplemented medium using sterile Pasteur pipette. Cells were washed twice by 
centrifuging at 500 g, room temperature for 5 minutes. The pellet was resuspended in 
RPMI 1640 supplemented medium or Phosphate Buffered Saline (PBS), counted and 
Trypan Blue exclusion test performed for viability.  
2.3 Total RNA Extraction from Different Tissues 
 
2.3.1 Clinical skin biopsies and in vitro skin explant model 
 
Total RNA was extracted from clinical skin biopsies (1- 4mm) and skin from the in vitro 
skin explant model using the mirVana miRNA Isolation kit (Life Technologies, USA) 
(Figure 2.1). Initially, the skin biopsies were homogenised on a sterile petri-dish, in 60 
µl of Lysis Buffer using sterile scalpel. The lysate was transferred into an Eppendorf and 
made up to 300 µl with the Lysis Buffer. To enhance homogenisation, the Homogenate 
Additive (30 µl) was added to each sample and incubated on ice for 10 minutes. The 
organic extraction was performed by adding phenol:chloroform (300 µl) to the 
samples, vortexing for 60 seconds and centrifugation at 10, 000 g for 5 minutes. The 
upper phase was carefully transferred to a fresh Eppendorf and 100% Ethanol (375 µl) 
added. The mix was then loaded onto a Filter Cartridge and centrifuged at 10,000 g for 
15 seconds. The flow through was discarded and the Wash Buffer 1 (700 µl) added 
onto the filter and centrifuged at 10,000 g for 15 seconds. The flow through was again 
discarded and total RNA was washed twice with Wash Buffer 2/3 (500 µl) and 
centrifuged at 10, 000 g for 1 minute. The Filter Cartridge was dried by centrifugation 
at 14,000 g for 1 minute to remove all the chemicals. Then the Filter was transferred to 
a new Eppendorf and pre-heated nuclease-free water (100 µl) at 95°C was used to 
elute the total RNA by centrifugation at 14,000 g for 20-30 seconds.  
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 Figure 2.1 Total RNA was extracted from clinical skin biopsies using the mirVana 
miRNA isolation kit (adopted from Life Technologies). There are three steps main 
steps performed in the extraction of total RNA from clinical skin biopsies; (1) Lysis and 
cell disruption, (2) organic extraction and (3) total RNA isolation and elution.  
 
2.3.2 Whole blood 
 
Peripheral blood (2.5 ml) was collected in PAXgene Blood RNA Tubes containing a 
reagent that results in immediate cell lyses and RNA stabilization (Figure 2.2). Two 
tubes were collected from each allo-HSCT patient at the following time-points, 7 days 
pre-transplant and post-transplant at: 28 days and 3 months. For healthy volunteers 
only 2.5 ml of peripheral blood was collected. Total RNA was extracted using PAXgene 
Blood miRNA kit (Qiagen/BD Company) which is phenol/chloroform free and a silica 
membrane based protocol. PAXgene Blood RNA Tubes were stored at -20°C untill 
extraction and incubated overnight at room temperature to increase total RNA yield. 
To collect pellet PAXgene Blood RNA Tubes were centrifuged at 3,500 g for 10 minutes 
(Fisher Scientific) (Figure 2.2). The pellet was washed in 4 mls of RNase-Free water and 
spun as above. The cell pellets were re-suspended in 350 μl buffer BM1. Then 300 μl of 
the binding buffer BM2 was added and 40 μl proteinase K and incubated for 10 min at 
55°C on a shaker- incubator set at 400- 1400 rpm to degrade any proteins. Lysate 
clumps have active RNases that can degrade RNA and decrease its integrity thus to de-
clump, lysates were shredded further using needle-syringe (1 ml), transferred into the 
PAXgene Shredder spin Column and centrifuged for 3 min at 14,000 rpm. Gently, the 
entire supernatant was transferred from the flow-through to a fresh Eppendorf and 
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Isopropanol (Fisher Scientific) added (700 µl) to increase the binding of total RNA to 
silica membrane. This mix was loaded onto the Spin Column that contained the silica 
membrane and centrifuged at 14,000 rpm for 1 minute. After every spun the 
processing tube was discarded and a new one used for the next step. The wash buffer 
(BM3) was then added (350 µl) to the Spin column and centrifuged for 1 min at 14,000 
rpm. DNase 1 mix was made by adding 10 µl of the stock DNAse 1 (1500 Kunitz) to 70 
µl DNA digestion buffer (RDD) per sample. Gentle mixing was performed as DNase 1 is 
sensitive to denaturation. DNase 1 mix was loaded to every Spin Column and 
incubated at room temperature for 15 minutes. This treatment ensured that all DNA 
was digested in order to obtain purified RNA. The reaction was stopped by adding BM3 
(350 µl) to the Spin Column and centrifuged for 1 minute at 14, 000 rpm. Wash Buffer 
2 (BM4) (500 µl) was loaded onto the Spin Column and centrifuged for 15 seconds at 
14,000 rpm. This step was carried twice to completely remove any of the chemicals 
from the RNA. The Spin Column was then spun empty for 1 minute at 14,000 rpm to 
dry the silica membrane. The Spin Column was transferred to a fresh Eppendorf (1.5 
ml) and the total RNA was eluted using elution buffer BR5 (80 µl). The Spin Column 
was centrifuged for 1 minute at 14,000 rpm. The Spin Column was discarded and total 
RNA concentration and purity of the total RNA was determined using the 
spectrophotometer, Nanodrop 1000 (Thermoscientific). Total RNA was stored at -20 °C 
until further use.  
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 Figure 2.2 Total RNA was extracted from whole blood using the PAXgene Blood 
miRNA kit (adopted from Qiagen). Firstly, the cells were pelleted and then 
resuspended using BM1. Proteins were degraded by incubating samples at 55 °C with 
buffer BM2 and proteinase K, respectively. Samples were then homogenized using 1 ml 
syringe and then loaded onto the Shredder column for additional homogenisation. 
Supernatant was collected into a new Eppendorf; Isopropanol was added onto the Spin 
Column and then centrifuged. BM3 was added in the wash step and centrifuged again. 
DNAse 1 treatment was performed for 15 minutes. Two wash steps were performed, 
one with BM3 and twice with BM4, respectively. Purified total RNA was then eluted 
using buffer BR5 and the concentration was determined using the Nanodrop.  
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2.3.3 Peripheral blood mononuclear cells 
 
The mirVana PARIS kit allowed the extraction of total RNA, DNA as well as protein from 
the same sample. Therefore, it was used for experiments were both total RNA and 
protein isolation from the same sample was required. All the steps are depicted in 
Figure 2.3. 
Working solutions were prepared as follows;  2-mercaptoethanol (375 μL) (Life 
Technologies) was added to 2X Denaturing Solution, 100% ethanol (21 mL) was added 
to Wash Solution 1 and (40 mL) to Wash Solution 2/3.  
Three main steps were performed in this method; (1) sample disruption, (2) lysate 
separation for RNA and protein isolation, (3) organic extraction. Initially, cells were 
pelleted via centriguation at 2, 500 rpm for 5 minutes. The pellet was washed with 1 
mL PBS, re-pelleted as above and then stored on ice. Cells were lysed by addition of 
ice-cold Cell Disruption Buffer (100-625 μL depending on cell count, example: 300 μL 
for more than 106cells) and vortexing for 10-15 seconds. Lysate was stored on ice and 
split into two, one-half for total RNA extraction and the other for protein isolation.  
The lysate that was used for the protein extraction was incubated on ice for 5-10 min 
and then passed through a syringe needle (1 ml) several times on ice for further 
homogenisation. Extracted protein was then stored at – 20 °C until further use.  
The lysate for RNA isolation was mixed with an equal volume of 2X Denaturing 
Solution (up to 625 μl) at room temperature. If the sample volume was less than 100 
μl, Cell Disruption Buffer was added to bring the volume to 100 μl before the addition 
of 2X Denaturing Solution as mentioned above. Mixtures were incubated on ice for 5 
min. A volume of Acid-Phenol: Chloroform that was equal to the total volume of the 
sample lysate plus 2X Denaturing Solution was added to the mixture and vortexed for 
30-60 seconds. The mixture was centrifuged for 5 min at 10,000 x g to separate it into 
aqueous and organic phase. The upper aqueous phase was removed carefully, without 
disturbing the lower phase or the interphase, and transferred it to a fresh tube. The 
volume recovered was noted for the later steps. Then 100% ethanol (1.25 the volume 
recovered) was added to the aqueous phase and loaded onto a Filter Cartridge that 
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contained glass-fibres to immobilize the total RNA and centrifuged for 30 seconds. The 
flow-through was discarded. Total RNA was washed by addition of Wash Solution 1 
(700 μL) and centrifuged at 14, 000 rpm for 15 seconds. Wash Solution 2/3 (500 μL) 
was then added and centrifuged as above. This step was repeated again. Residual 
fluids were removed and the Filter Cartridge dried by centrifugation at 14,000 rpm for 
1 minute. Total RNA was eluted using nuclease-free water (100 µl) preheated at 95oC 
and centrifugation at 14,000 rpm for 30 seconds. The concentration and purity of total 
RNA was determined using the Nanodrop.  
 
Figure 2.3 Total RNA was extracted from PBMCs using the mirVana PARIS kit 
(adopted from Life Technologies). Cells were washed, pelleted and homogenised 
using Cell Disruption Buffer. Lysate was split into two; (1) protein and (2) total RNA 
isolation. The RNA lysate was mixed with 2X Denaturing solution and then acid-Phenol: 
Chloroform extraction performed. The upper phase was collected and ethanol was 
added and the solution passed through filter cartridge. Total RNA was then washed 
with Wash Buffer 1 and Wash Buffer 2/3. Elution was performed by addition of 
nuclease-free water preheated at 95 °C.  
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 2.4 Real-Time PCR Basic Concepts 
 
2.4.1 Real-time PCR amplification curve 
 
In brief, amplification of cDNA in real-time is a two-step process. In the first step, cDNA 
is synthesized by reverse transcription (RT) and in the second step this cDNA is 
quantified using real-time PCR machine. 
The qPCR amplification curve has three phases: the baseline or background phase, 
exponential phase and plateau phase. Baseline was set between 3-15 cycles of the RT-
qPCR, this eliminated any background fluorescence. At baseline fluorescence is present 
but not sufficient to be detected by the lasers as a positive signal. Threshold was set 
(either automatically or manually depending on the experimental investigation) at the 
exponential phase of the RT-qPCR and this determined the cycle threshold (Ct) or cycle 
quantification (Cq). The aim of setting threshold was to calculate the relative quantity 
(RQ) of input cDNA (template) present at the start of the PCR reaction.  The 
amplification or reaction curve shown in figure 2.4 is representative of RT-qPCR data.  
ΔRn (delta Reaction) values were plotted on the y-axis and cycle numbers on the x-
axis. ΔRn is the ratio of fluorescence of FAM dye by fluorescence of ROX dye. ROX was 
the passive reference (accounts for pipetting variations) dye and was present in the 
Taqman master mixes. The Exiqon LNA-based master reagents did not have ROX. Pilot 
investigation (data not shown) showed that there was no significant pipetting error 
and therefore it was considered not necessary to add ROX to the LNA master mixes. 
Thus, ROX detection was disabled when LNA based primers were used for the qPCR 
reaction.  
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 Figure 2.4 Ideal qPCR amplification curve. The three different phases of the RT-
qPCR are marked on the curve as; background, exponential and plateau phase.  
 
For all of the total RNA extractions, concentration of total RNA was determined using 
the NanoDrop 1000 (Thermo Scientific). For all the qPCRs, each sample was run in 
triplicate on 7900HT Fast Real-Time PCR (Life Technologies), using the standard 
thermal cycling conditions on the machine.  
Two different cDNA synthesis and real-time PCR chemistries were used; (1) Taqman 
labelled hydrolysis probes (Life Technologies, USA) and (2) Locked-Nucleic Acids- SYBR 
1 dye detection (Exiqon, Denmark).  
2.4.2 Taqman chemistry 
 
The Taqman chemistry for quantification of miRNAs was a two-step process. In the first 
step, miRNA specific cDNAs were synthesized. This process involved the addition of 
miRNA specific stem-loop primers that bound to the -3p end of the template. The 
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enzyme reverse transcriptase extended the primer by the addition of nucleotides for 
the cDNA strand to be synthesized (Figure 2.5).  
 
Figure 2.5 Taqman reverse transcription step (adopted from Life Technologies). 
In brief, the specific reverse transcription stem-looped primer was bounds to the 
miRNA template and this resulted in the first strand synthesis of cDNA.  
 
For the Taqman miRNA specific cDNA synthesis, 1- 10 ng of total RNA was reverse 
transcribed in a 15 µl reaction using Taqman specific RT primers and the Taqman 
miRNA Reverse Transcription Kit (Life Technologies). In brief, the master mix consisted 
of the miRNA specific primers, nuclease free water, buffer, reverse transcriptase 
(Rtase), RNAse inhibitor, dNTPs and diluted RNA (Table 2.1). All the steps were 
performed on ice. The following settings were set on the thermal cycler (Applied 
Biosystems, 2720 Thermal Cycler) for cDNA synthesis; 16oC for 30 minutes, 42oC for 30 
minutes and 85oC for 5 minutes to denature the enzyme. The cDNA assay were then 
stored at -4oC till use.  
Taqman cDNA Master Mix 1X (µl)
Nuclease-free H2O 4.16
Buffer 1.5
Rtase 1
Inhibitor 0.19
dNTPs 0.15
Primer 3
Template total RNA (Diluted) 5
Total volume 15  
Table 2.1 Taqman miRNA cDNA synthesis master mix. 
 
Taqman chemistry consisted of a set of primers, both forward and reverse and a 
Taqman probe (Figure 2.6). All the primers used were off-the-shelf and these were 
designed to bind on either side of the template and extend, accordingly. Taqman 
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hydrolysis probes were based on fluorescence resonance energy transfer (FRET). The 
probes consisted of a quencher dye (3’ end) at one end and a reporter fluorescent dye 
(5’ end) at the other end.  The non-fluorescent quencher (NFQ) dye decreased the 
fluorescence emission of the reporter dye when the probe was unbound to the 
template sequence. The NFQ had a minor groove binder (MGB) moiety bound to it 
(MGB-NFQ). This allowed shorter probes to be made with greater stability, in particular 
for miRNA based investigations.  In the presence of the template, the hydrolysis probe 
was bound downstream from one of the primer sites. As the primer extended the 
template, Taq DNA polymerase degraded the reporter dye. The Reporter dye was then 
released as a result and the fluorescence was detected by the laser system in the real-
time PCR machine. The fluorescence was directly proportional to the initial amount of 
template in the reaction.  In all the experiments the dyes bound to the primer 
sequence were 6-carboxyfluorescein (FAM) and the quencher moiety was MGB-NFQ.  
 
Figure 2.6 Real-time PCR steps when using Taqman chemistry (adopted from Life 
Technologies). ‘R’ denotes reporter fluorescent dye and ‘Q’ denotes quencher dye. 
Step 1 shows the polymerisation of the template strand by Taqman polymerase. Step 2 
shows the degradation of the reporter fluorescent dye from the quencher by the 
Taqman polymerase.  
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Real-time PCR Master Mix Volume (µl) per triplicate
Taqman Primer-Probe 1.8
Taqman Universal Master Mix 18
Nuclease Free- Water 13.8
cDNA 2.5
Total Volume 36.1
 
The miRNA specific cDNAs were used for the RT-qPCR step using the miRNA specific 
Taqman probes. In brief, the master mix comprised of the specific cDNA, nuclease-free 
water, Taqman primer-probe sets and TaqMan® Universal Master Mix. Every sample 
was run in triplicate, 10 µl/well. The triplicate volumes included 20% excess for volume 
loss from pipetting (Table 2.2).  
 
 
 
 
Table 2.2 Taqman miRNA RT-qPCR master mix. 
 
2.4.3 LNA™- SYBR 1 dye chemistry 
 
Locked nucleic acids (LNA) are RNA analogs with high affinity. For efficient Watson-
Crick binding the ribose ring is “locked” in the most stable conformation thereby 
leading to rapid hybridisation to the cDNA. Thus, LNA™ oligonucleotides have greater 
thermal stability during cDNA synthesis and are shorter than other DNA or RNA 
oligonucleotides used conventionally. The melting temperature of LNA based primers 
are normalised to increase robustness regardless of varied GC content. The LNA 
primers are therefore specific and sensitive in particular for the detection of miRNAs. 
Universal cDNAs were synthesized using the LNA primers. Initially, poly-A tails were 
added to the mature miRNA template. The primers had a poly-T tail, a 3’ degenerate 
anchor and a 5’ universal tag. The poly-T tail was bound to the poly-A tail while the 
3’degenerate anchor guided the cDNA synthesis (Step 1, Figure 2.7). 
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 Figure 2.7 MiRCURY LNA™ Universal RT microRNA PCR System (adopted from 
Exiqon). Step 1 (A) involves the cDNA synthesis where polyA tail is incorporated to the 
miRNA sequence. Step 1 (B) poly-T primer with a 3’ degenerate anchor and a 5’ 
universal tag were used to synthesise the universal cDNA. 
 
All the reagents and reaction steps for the reverse-transcription step were performed 
at 4oC (on ice). Lyophilised forward and reverse primers were re-suspend by adding 
nuclease-free water (220 µl). The primers were vortexed, spun down and incubated on 
ice for 20-30 minutes before use. First strand cDNA was synthesized by diluting total 
RNA samples (5 ng/µl) using nuclease-free water. The universal cDNA master mix 
(Product No: 203301) comprised of; 5X reaction buffer, nuclease-free water, enzyme 
and the diluted total RNA (Table 2.3). The thermal cycler (Applied Biosystems, 2720 
Thermal Cycler) reactions set up were as follows; 42oC for 60 minutes, 95oC for 5 
minutes and then samples stored at -4oC till use. 
LNA cDNA Master Mix 1X (µl)
5X Reaction buffer 4
Nuclease-free H2O 10
Enzyme mix 2
Template total RNA (5 ng/µl) 4
Total volume 20  
 
Table 2.3 MiRCURY LNA™ Universal cDNA synthesis mater mix. 
In the real-time PCR reaction step, miRNA specific forward and reverse primers were 
used to amplify the miRNA of interest (Step 2, Figure 2.8). SYBR1 Green dye was used 
for the detection of amplified miRNA products. Since, SYBR1 dye could be non-specific 
and bind to primer-dimers in addition to the amplified miRNA, melting curve analysis 
was performed which is explained in more detail in the next section.  
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 Figure 2.8 MiRCURY LNA™ RT-qPCR step (adopted from Exiqon). In Step 2 which 
is the real-time PCR reaction, (A) the universal cDNA is used as the template to amplify 
specific miRNAs. LNA specific forward and reverse primers are used in this process. (B) 
The SYBR 1 Green dye is used to detect the specific miRNAs.  
 
Complementary DNA that was synthesized in the first step was diluted 80x by adding 
nuclease-free water (1580 μl H2O per 20 μl RT). The real-time PCR master mix 
comprised of the following reagents; ExiLENT SYBR® Green (Product No: 203402) 
master mix, specific PCR mix and the diluted cDNA (Table 2.4). The MicroAmp® Optical 
96-well reaction plates without barcodes (Life Technologies) were used for all the qPCR 
steps. The primer names were as per mirbase version 19.0. 
 
Real-time PCR Master Mix Volume (µl) per triplicate
SYBR Green master mix 15
Specific PCR primer mix 3
Diluted cDNA template 12
Total volume 30  
 
Table 2.4 MiRCURY LNA™ RT-qPCR master mix. 
2.4.4 Taqman gene expression assays  
 
The reverse transcription step for gene expression assays comprised of universal 
random hexamers. The cDNA mix was first made using; random hexamers (Thermo 
Scientific), dichloro-diphenyl- trichloroethane (DTT) (Invitrogen), first strand buffer 
(Invitrogen) and dNTPs mix (Roche Diagnostics) (Table 2.5, B). In brief, total RNA was 
denatured at 65 oC for 5 minutes and was reverse transcribed using equal volume of 
master mix (ratio1:1). The cDNA PCR master mix consisted of the cDNA mix, reverse 
transcriptase, MMLV RT (Invitrogen) and Rnase inhibitor, RNAsin (Promega). The 
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reaction mix was incubated using a thermal cycler (ABI 2720) at 37 oC for 2 hrs and 10 
min at 65 oC to denature the enzymes. The cDNA was used to run qPCR for using 
specific Taqman off-the-shelf hydrolysis probes. 
A. dNTP Mix Volume (µl) 3X
dATP 50
dCTP 50
dGTP 50
dTTP 50
Nuclease-free H2O 300
Total volume 500
B. cDNA Mix Volume (µl) 10X
Buffer 332.5
dNTP mix 166.25
Random hexamers 210
DTT 166.25
Total volume 875
C. cDNA PCR Master Mix Volume (µl) 10X
cDNA mix 100
MMLV RT 7
Rnasin 3.5
Total volume 110.5  
 
Table 2.5 Reverse transcription master mix for gene expression assays.   
 
The RT-qPCR mix comprised of; total RNA (10-100 ng), nuclease-free water, 2X Taqman 
Gene Expression Master Mix and target specific primer-probes (Life Technologies) 
(Table 2.6). The MicroAmp® Optical 96-well reaction plates without barcodes were 
used for all the qPCR steps. The qPCR was performed on 7900HT Fast- Real Time PCR 
system (Life Technologies). For all the gene expression studies, Human glyceraldehyde 
3-phosphate dehydrogenase (GAPDH: 4352934E, Life Technologies) was used as the 
reference gene. A summary list of all the assays used in the various investigations is 
mentioned in table 2.7. 
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 qPCR Master Mix Volume (µl) per triplicate
Taqman gene expression master mix 22.5
Specific primer-probe 2.25
Nuclease free water 19.75
cDNA 2.4
Total volume 46.9  
 
Table 2.6 Quantitative PCR master mix for standard gene expression assays.  
 
 
 
Table 2.7 Taqman gene expression prime-probes for qPCR. For the gene 
expression assays, GAPDH was used as the reference control. For the individual miRNA 
assays, miR-103a-3p and SNORD48 were used as the reference controls.  
 
2.5 Real-time PCR Data Analysis 
 
2.5.1 Amplification curve analysis 
 
Efficiency of the hydrolysis probes or LNA primers determined the progress of the 
amplification curve. Efficiency of off-the-shelf assays (Taqman and LNA) was 
64 
 
considered to be 90-100%. Hence, efficiency (E) was set at 2 (RQ= 1/ ECq, when E=2, 
then RQ= 2-Cq). In relative quantification the Cq value for gene/miRNA of interest was 
normalized to the Cq of reference gene/ miRNA (ΔCq= Cq gene of interest - Cq reference gene). This 
resulted in the first derivative of Cq which was ΔCq. The second derivate (ΔΔCq= ΔCq 
(diseased sample) - ΔCq (reference sample)) was determined if there was a reference sample 
present such as normal controls. The RQ was calculated using the formulae, RQ= 2-ΔΔCq 
or RQ=2-ΔCq. Since ΔCq, ΔΔCq and RQ values were all linear values and qPCR data is non-
linear (exponential) the values were transformed (Log transformation= Log2RQ) using 
logarithms. In addition, biological data is usually not normally distributed and thus 
suffers from heterogeneity of variance (McDonald, 2009). In order to be able to use 
parametric statistical tests on qPCR data the RQ values must be transformed 
logarithmically to create a normal distribution of these values. Otherwise, the result 
could be misleading. Log transformation also helps when there are outliers present in 
the data. The higher values are concentrated together while the smaller values are 
spread (Rieu and Powers, 2009). Statistical analysis and plotting of qPCR data were all 
performed on the Log transformed data.  
2.5.2 Melting curve analysis 
 
When LNA-SYBR Green dye was used for the detection of miRNAs in the qPCR reaction, 
melting or dissociation curve analysis was performed to identify any primer-dimer 
formation and/or non-specific amplifications. Melting temperature (Tm) is based on 
the length of the product sequence and its GC content. Therefore, it is an ideal 
indicator for non-specific product amplification such as primer-dimers. A ramp step 
was therefore included after the real-time PCR reaction was completed. In this step 
the temperature was increased gradually (from annealing (62°C) to denaturation 
temperature (95°C) and the SYBR1 Green dye was detected as the products 
dissociated. The Tm was the maximum point of the peak where almost 50% of the 
products had dissociated (Figure 2.9). Any peak before the actual peak of the 
dissociation curve could be indicative of primer-dimers. 
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Figure 2.9 Melting curve analysis. (A) Absence of non-specific amplification as the 
Tm of all the products overlaps and is very similar. (B) The Tm of the products vary and 
there is non-specific primer binding. The reactions for both A and B are contaminant-
free as the no-template control (NTC) is not amplified.  
 
2.6 Global miRNA Profiling and Individual MiRNA Assays 
 
Global miRNA profiling of skin biopsies (Chapter 4) was performed using the Exiqon 
miRNA qPCR services. Total RNA was sent to the Exiqon services and three quality 
control checks were performed for each sample to assess RNA integrity, purity and 
detect PCR inhibitors (if present). The nine (total RNA) samples passed quality control 
checks for use in the global profiling experiment. 
Briefly, 40 ng of total RNA was reverse transcribed to cDNA as per the miRCURY LNATM 
Universal RT miRNA PCR protocol. Each cDNA was diluted 100X and then run on both 
Human panel I (372 miRNAs) and Human panel II (367 miRNAs) consisting of a total of 
739 miRNAs and three inter-plate calibrators, six reference controls and one control 
set (RNA spike-in). No pre-amplification of total RNA was performed for this global 
miRNA profiling experiment. The workflow consisted of five main steps from the 
experimental setup to quality controls and up to analysis. (1) Universal RT miRNA PCR 
(as described in Section 2.4.2) - All the miRNAs were polyadenylated and reverse 
transcribed into cDNA. The cDNAs and the SYBR Green master mix were then 
transferred to the two qPCR panels (Human I and II). The panels had 739 preloaded 
primers. The pipetting was automated (robot) to reduce errors. This was followed by 
the qPCR step which was run on a Roche Light cycler 480. (2) Data was collected and 
A 
 
B 
NTC 
NTC 
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analysed for non-specific amplifications and primer-dimer formations (melting curves). 
Reactions with efficiencies lower than 1.6 were eliminated from further analysis. (3) 
Negative control evaluation- Reactions with Cq values that were within 5 values of the 
NTC were also eliminated from further analysis.(4) All data were then normalized. (5) 
Preliminary data analysis was performed. 
2.6.1 Preliminary quality controls of total RNAs 
 
2.6.1.1 Total RNA was of high quality 
 
The RNA integrity number (RIN) was obtained for each of the nine samples prior to 
performing the profiling experiment. The RIN number was calculated by performing an 
electrophoretic measurement using the bioanalyzer (Agilent 2100). Results showed 
that the quality of total RNA extracted was of high (greater than or equal to 7) for all 
the samples. There were single peaks at the 18 and 28S ribosomal RNA (Figure 2.10).   
A B
Figure 2.10 Representative electropherograms of the total RNA analyzed using the 
Nano assay. (A) The electropherogram of an allo-HSCT skin biopsy and (B) is the gel 
image of the same sample. MicroRNAs were detectable at approximately 25-27s which 
is equivalent to 22-25 nucleotides. The gel image did not show any sign of total RNA 
degradation. Flu: fluorescence that is shown on the y-axis.    
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2.6.1.2 Absence of PCR inhibitors 
 
To ensure that the samples were of the same quality and were extracted reproducibly, 
the number of miRNAs detected as well as the mean Cq values for all the nine samples 
were initially investigated.  RNA spike-in (Sp6) control was also included in the quality 
control analysis to detect any PCR inhibitors. The miRNAs were detectable in all the 
nine samples and there was no RT-qPCR inhibitors present (Figure 2.11).  
 
Figure 2.11 Raw Cq values detected in all the nine samples. The steady state shown 
with minor sample variations was indicative of no-PCR inhibitors. 
To further assess the quality of the total RNAs prior to the profiling experiment, the 
NTCs were analysed. For the profiling experiment it was necessary that the miRNAs 
detected had five Cq values lower than that of the NTCs. A panel of synthetic miRNAs 
were included as positive controls in this analysis (Figure 2.12). For assays that were 
non-detectable on the negative control, the Cq was set to 37.  
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 Figure 2.12 Raw Cq values shown for the positive and negative controls. The mean 
Cq values for all of the nine samples showed that miR-103, miR-191, and miR-423-3p 
were expressed at a steady level in majority of the samples. These microRNAs were 
recommended as the reference controls for the further validation studies. The y-axis 
shows the raw Cq values.  
Acknowledgement:  
The two male normal volunteers were recruited via Alcyomics Limited.  
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 2.6.2 Normalisation of individual miRNA assays 
 
The best reference controls for normalization of individual miRNA assays was 
determined by using Normfinder and the results of the Exiqon quality controls. Mir-
103a-3p and SNORD48 were selected and quantified in 20 skin biopsies. Both were 
stably expressed across all the clinical skin biopsies (Figure 2.13). To reduce variation, 
geometric means were calculated and therefore used in the validation study. 
 
Figure 2.13 Expression of reference controls in clinical skin biopsies. Quantitative 
RT-PCR was used to measure the expression of miR-103a-3p and SNORD48 in 20 
clinical biopsies. Geometric mean was calculated and used as the reference control. 
Cq: Cycle Quantification; SD: Standard Deviation. 
2.7 Enzyme Linked-Immunosorbent Assays  
 
A sandwich Enzyme Linked-Immunosorbent Assay (ELISA) technique was used for the 
detection of protein targets (TRAF6, STAT1-α, IRAK1 and IRF5). The specific antibody 
was pre-coated on the ELISA plates and standards were provided in the kit. Specific 
protein and standards were bound by the antibody. The primary antibody was 
conjugated with biotin and the secondary antibody was avidin-conjugated Horseradish 
Peroxidase (HRP).  All the reagents were incubated for 30 minutes at room 
temperature before performing the experimental steps. All the steps were performed 
as per the manufacturer’s guidelines (CUSABIO, China). 
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2.7.1 General ELISA protocol used for the detection of the four miRNA 
targets 
 
Dilutions: Biotin-antibody required a 100-fold dilution- 10 μl of Biotin-antibody + 990 
μl of Biotin-antibody Diluent. HRP-avidin required a 100-fold dilution- 10 μl of HRP-
avidin + 990 μl of HRP-avidin Diluent. Wash Buffer Concentrate required a 25-fold 
dilution- 20 ml of Wash Buffer Concentrate + distilled water to prepare 500 ml of Wash 
Buffer (1 x). 
The assay procedure was as follows: Standards and samples (100μl/well) were added 
to each well and covered with an adhesive strip. Incubation was for 2 hours at 37°C. 
Standards and samples were removed from each well using an auto-washer system. 
The plate was not washed in this step. Biotin- antibody (1x) (100μl) was added to each 
well and the plate was covered with a new adhesive strip. Incubation was for 1 hour at 
37°C. The plate was aspirated and washed three times using an auto-washer. HRP-
avidin (1x) (100 µl) was added to each well, covered with a new adhesive strip and 
incubated for 1 hour at 37°C. The plate was aspirated and washed five times using an 
auto-washer. TMB Substrate (90 µl) was added to each well and the plate was 
protected from light and incubated for 15-30 minutes at 37°C.  Stop Solution (50μl) 
was added to each well and the plate was gently tapped to ensure thorough mixing. 
Microplate reader was used to detect the colour change that corresponded to protein 
concentration. The plate was read at 450 nm within 5 minutes.  
2.7.2 Standard curve analysis  
 
A representative standard curve for IRF5 and STAT1-α is shown in figure 2.14. The 
standard was diluted in serial steps in the assay buffer provided in the kit. Each point 
on the graph represents the mean of the duplicates. The standards were within the 
linear area of the line of best fit.  
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Protein Catalogue Number Detection Range (pg/ml)
TRAF6 CSB-E14078h 39-2500
IRAK1 CSB-E09933h 312-20000
STAT1-α CSB-E11755h 62.5-4000
IRF5 CSB-EL011820HU 23.5-1500
 
Figure 2.14 Representative standard curve for IRF5 and STAT1-α using the assay 
standard.  
 
 
Table 2.8 Catalogue numbers and detection ranges for the specific ELISA kits 
used in this project. 
2.8 Human in vitro Skin Explant Model for GVHR 
 
The in vitro skin explants were set up as previously reported by Dickinson et al. 
(Dickinson et al., 1998).  
2.8.1 Experimental set-up of the in vitro skin explant assay 
 
Skin biopsies were obtained from allo-HSCT patients, washed with EBSS and then 
dissected using aseptic techniques in a petri-dish. The epidermis and dermis were left 
intact and only the fatty tissue was removed from the skin section. 
 
Irradiated PBMCs (1x106 /ml) from HSCT patients (stimulators) were cultured with 
PBMCs (1x106 /ml) from HLA matched or mismatched donors (responders) in a mixed 
lymphocyte reaction for 7 days at 37°C with 5% CO2 and 95% air. The MLR primed 
responder cells were then co-cultured with skin sections that were autologous to the 
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stimulator in a 96 U-bottomed well plate. In addition, parallel control skins were 
cultured in medium alone. Standard complete medium was used which contained 20% 
heat inactivated patient autologous serum for MLR with skin co-cultures (Wang et al., 
2006). Skin explants were harvested on days 1, 2 and 3. The duplicate skin sections 
cultured in MLR primed responder cells or medium alone were collected for total RNA 
extraction, in RNAlater buffer® and the other fixed in 10% buffered formalin for 
histological staining with hematoxylin and eosin.  
 
Acknowledgement 
The skin explants were set up by Elizabeth Douglas and Cindy Carr. 
2.8.2 Histopathology 
 
Skin tissue fixations and stainings with hematoxylin and eosin were all performed by 
the pathology staff at the Royal Victoria Infirmary. Two independent assessors, who 
were blinded to the origin of the samples, graded the sections according to the 
histological criteria (Lerner et al., 1974). Skin histopathological Grade I in medium 
alone culture was considered as the negative control only. The grading criteria used 
and the histological changes that are evident at each grade are shown in figure 2.15. 
Figure 2.15 Immunohistochemical staining of skin biopsies from the in vitro skin 
explant assay. (A) Grade I (B) Grade II (C) Grade 3 (D) Grade 4. Lerner’s histological 
criterion was used for the grading assessment (Lerner et al., 1974) 
Acknowledgements:  
The pictures were courtesy of Dr Xiao-nong Wang 
Prof Anne Dickinson and Dr Xiao-nong Wang graded the sections. 
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2.9 Transfection experiments 
 
2.9.1 Transfection basics 
 
Delivery of nucleic acids into eukaryotic cells is termed as transfection. There are 
numerous delivery methods either using chemical based reagents or electric current. 
The most commonly used methods are as follows; (1) Lipofection: polymer based 
transfection using positively charged lipid based reagents, (2) Transduction: packaging 
of nucleic acids in a viral vector, (3) Electroporation: disrupting the cell membrane for 
the nucleic acids to enter the cells performed using electric current, (4) utilizing 
chemically modified small interfering RNAs (siRNAs).There are two main controls for 
transfection experiments; (1) mock (2) negative control. A mock control is to control 
for the impact of reagents or the method of transfection on the cells.  
 
2.9.2 Transfection negative controls and inhibitors 
 
The negative control for the transfection experiments introduced a non-targeting 
sequence into a cell to control for any non-specific/off-target effects. C. elegans based 
negative controls were used in the transfection investigations in this project. The C. 
elegans sequences are non-homologous to human sequences.  The miRIDIAN 
microRNA transfection reagents were resuspended in RNase-free water (stock 
concentration= 20 μM). Aliquots were stored at -20 °C to limit freeze-thawing.  
Transfection Control with Dy547 Transfection Inhibitor Transfection Inhibitor
ID cel -miR-67 hsa-miR-34a-5p hsa-miR-34a-3p
Accession No MIMAT0000039 MIMAT0000255 MIMAT0004557
Molecular weight 18379.0 g/ml 18, 053.4 g/mol 18, 121.9 g/mol
Catalog Item IP-004500-01-05 IH-300551-08-0005 IH301145-02-0005
miRIDIAN microRNA Hairpin  Inhibitor
Sequence UCACAACCUCCUAGAAAGAGUAGA UGGCAGUGUCUUAGCUGGUUGU CAAUCAGCAAGUAUACUGCCCU
 
 
Table 2.9  Summary of transfection reagents (Dharmacon, GE Lifesciences). 
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2.9.3 Cytospin 
 
Cytospin is a standard cytology method that is used for concentrating cells onto a slide 
for counting cells, their visualization and acquiring of images. For all the transfection 
experiments using the miRNA hairpin inhibitor, 103-203 cells were harvested for the 
cytopsin procedure so that the transfection efficiency could be determined. The 
procedure was as follows; filters were pre-wet by centrifugation (CytospinTM 
cytocentrifuge, ThermoScientific) with 200 µl of PBS at 500 rpm for 5 minutes. Next, 
300 µl of the cells were spun at 700 rpm for 10 minutes. The filters were removed from 
the slides very carefully and were allowed to air-dry for 30 minutes. DAPI-mounting 
solution was added for visualization of dead cells. All the slides were stored ar 4oC till 
imaging. Coated slides (Shandon Inc) were only used for the cytospin procedure as it 
allowed the fixation of the slides directly upon spinning.  
 
2.9.4 MicroRNA inhibition experiments 
 
Cells (PBMCs/cell lines) were counted and re-suspended at 1x107 cells/ml in complete 
medium (RPMI medium and 10% FCs) but without any antibiotics. Cell lines such as 
Pre- B697 (leukemia cell line) were used as the positive transfection control as they 
had been successfully transfected with siRNAs, previously. The protocol was optimized 
and ten million cells were transfected with the negative control and the miRNA specific 
inhibitor at a final concentration of 500 nM (12.5 µl per transfection). The transfection 
reagents (see table 2.9) were added to the cells (500 µl) in a 4 mm cuvette prior to 
electroporation at 350 V, single pulse for 10 ms, using the EPI 2500 gene pulser 
(Fischer, Heidelberg, Germany).  The cells were incubated for 15 minutes at room 
temperature for the closure of the pores that were opened upon electroporation. The 
cells were then diluted (10x) with complete medium supplemented with antibiotics 
(penicillin/streptomycin). Cells were seeded in multiple wells in either a 96 or a 24 well 
plate and incubated at 37°C with 5% C02 and 95% air. Cells were harvested at 24, 48, 
72, 96 and 144 hrs for viability test and examined by fluorescence microscopy for 
determination of transfection efficiency. Transfection efficiency was calculated by 
counting the number of positive cells over the total number of cells present in a field 
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of view. Cells were allowed to recover for 24 hrs prior to setting up a mixed 
lymphocyte reaction using the transfected cells as responder cells. Levels of 
knockdown were calculated relative to the negative control and assessed by RT-qPCR 
using the LNA chemistry.  
2.10   T cell proliferation assay 
 
T cell proliferation was measured using the 3H-thymidine assay in which dividing cells 
incorporate the radioactive compound. Mis-matched MLRs were cultured in 96-well 
round bottomed plates (200ul/well). Control wells included the auto-MLRs. Triplicate 
wells were set up for each test condition. The MLR was incubated for five days under 
standard tissue culture conditions (37oC, humidified incubator with 5% CO2 and 95% 
air) and were co-cultured with the 3H-thymidine (10 µl/well=0.037 MBq/well) for the 
last 18 hours. The cells were then harvested onto a filter mat using the INOTECH cell 
harvester (CH-5610 Wohlen). 3H-thymidine incorporation was measured by 
scintillation counting with a Direct Beta Counter (MATRIX 9600, Packard Instrument). 
Acknowledgement:  
The 3H-thymidine T cell proliferation assays were setup by Dr Lindsay Nicholson.  
2.11   Mixed Lymphocyte Reaction Assay 
 
Peripheral blood mononuclear cells were obtained from healthy volunteers and mis-
matched MLRs set-up. The principle of mis-matched MLR is that PBMCs from 
incompatible volunteers will stimulate each other and therefore proliferate. In contrast 
to auto-MLRs where the individuals own PBMCs are used as stimulator, the cells will 
not proliferate and therefore there is no allogeneic immune response. In one way, 
MLRs the PBMCs from one volunteer were inactivated using irradiation (20 Gy) and co-
cultured with an incompatible volunteer PBMCs that were the responder cells.   
Mis-matched MLR assays were set-up using equal concentrations of irradiated 
(stimulator or effector) PBMCs collected from one healthy volunteer with non-
irradiated PBMCs from a second normal volunteer (responder). Auto-MLR assays were 
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set up with PBMCs from normal volunteers against themselves. Depending on the 
experiment, the concentrations of cells were adjusted accordingly.  
2.11.1 Mixed lymphocyte reaction stimulated with cyclosporine A 
 
In Chapter 5 and Chapter 6, standard allogeneic (mismatched) MLRs were stimulated 
with different doses of cyclosporine A  to test the impact of the drug and indirectly the 
T cell inhibition on miR-34a, miR-146a-5p and miR-155-5p expression levels, 
respectively. The assays were set-up in 24 well plates. Auto-MLRs were set up as the 
allogeneic response control. The MLRs were co-cultured without cyclosporine A (0 
ng/ml) and with 50, 100, 200 and 300 ng/ml of cyclosporine A for 96 hours before the 
cells were harvested and total RNA extracted using the mirVana PARIS kit.  
Acknowledgement:  
Alcyomics Limited provided the cyclosporine A  (Abcam: ab120114) aliquots.  
2.11.2 PBMCs stimulated with IFN-γ  
 
In Chapter 6, PBMCs were co-cultured with two different doses of recombinant human 
IFN-γ (50 and 100 ng/ml) in 24 well plates. The doses were determined from the 
existing literature on the amount of IFN-γ (R & D Systems) sufficient to host a response 
(Takahashi et al., 2012).  The cells were harvested after 24 and 48 hours, respectively. 
The mirVana PARIS kit was used to extract total RNA from the cells. Taqman based RT 
and qPCRs were then performed, and the relative levels of both miR-146a-5p and miR-
155-5p were determined.  
2.12   Semi-quantitation of c-Myc and p53 proteins 
 
2.12.1    Immunohistochemical staining 
 
The pre (n=5) and post (n=17) allo-HSCT skin biopsies were cut and stained for c-Myc 
(Abcam, Epitomics at 1:10 dilution) and p53 (Pre-diluted from Ventana) proteins using 
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Proportion
1= 0-4%
2= 5-20%
0= no staining 3=21-40%
1= light staining 4= 41-60%
2= moderate staining 5=61-80%
3= strong staining 6=81-100%
Intensity
FFPE immunohistochemistry method. The pathology department performed both 
procedures (Royal Victoria Infirmary, Newcastle upon Tyne).  
2.12.2  Skin histopathological scoring 
 
The well-established quick score semi-quantitative method (Detre et al., 1995) was 
used to score the c-Myc and p53 positive cells. The quick score was calculated 
considering both the intensity and proportion of the cells stained positive. The 
complete section was used for scoring as well scoring the epidermis and dermis 
separately. Two independent researchers, who were both blinded to the origin of the 
sections, scored the samples. The mean quick score was used to perform all the 
statistical calculations. The proportion of cells was defined as per the criteria 
mentioned in table 2.10. Quickscore formula = (Intensity0xProportion) + 
(Intensity1xProportion) + (Intensity2xPrportion) + (Intensity3xProportion) 
 
 
 
 
 
Table 2.10 Quickscore intensity and proportion criteria.  
Acknowledgement:  
Dr Rachel Crossland also scored for p53 and c-Myc positive cells.  
2.13   Cell imaging 
 
The images of the immunohistochemistry sections were obtained using bright field 
microscopy (Zeiss AxioImager). The images of the transfections were acquired using 
fluorescent microscopy (Zeiss AxioImager). 
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2.14    Statistical Analysis 
 
2.14.1   General statistics used in the investigations 
  
In general, statistical analyses were performed using either SPSS version 21 (IBM) 
and/or GraphPad Prism version 5 (GraphPad Software). The Mann-Whitney U tests 
were used to determine the statistical significance when there were two groups only 
and p ≤0.05 was considered as significant. Kruskal-Wallis, which is a non-parametric 
analysis of variance, was performed when there were three or more groups in the 
comparison. Only for the global profiling experiments parametric ANOVA was used as 
it was essential to select the miRNAs based on their significance. Dunn’s or Bonferroni 
post-test were used to safeguard against false positive when performing multiple 
comparisons. Bland-Altman plots were generated for method comparisons that 
showed the agreement between two methods by calculating the difference (bias) 
between them (Bland and Altman, 2012). Spearman correlation was performed to test 
for strength of association between two groups.  
2.14.2   Receiver operating characteristic curves 
 
Receiver Operating Characteristic (ROC) curve is used in clinical research to determine 
the threshold or cut-off value of a particular biomarker or test. The cut-off value 
segregates the normal population from the diseased population. Normal groups are 
usually considered as negative and assigned the binary digit ‘0’ while the diseased 
group is positive and assigned the binary digit ‘1’. In clinical research, not all the 
samples identified by the test as belonging in the diseased group will have the disease. 
True positive or sensitivity is the ratio of the positives identified by a test to the total 
number of individuals that have the disease. Similarly, the analysis also identifies some 
normal or negatives to having the disease. Likewise, true negative rate or specificity is 
the ratio of the number of normal that were determined by the test to have the 
disease over the total number of individuals that were normal. 
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In the ROC curve, sensitivity is plotted on the y-axis and 1-specificity on the x-axis.  The 
area under the ROC curve is a measure of clinical test accuracy. An area under the 
curve= 1 demonstrated that the test is 100% accurate as sensitivity and specificity are 
both= 1. In such a scenario, there are no false positives or false negatives present. In 
contrast, an inaccurate test will have an area that is below 0.5. This test will be unable 
to distinguish the normal from the diseased population. The area under the curve (A) 
of 0.5 signifies that the miRNA is of no diagnostic ability; an area under the curve of 1 
signifies that the miRNA has perfect diagnostic ability. The p-value accompanying the 
area under the curve tests the null hypothesis that the area under the curve is 0.5.  
The optimal operating point on the ROC curve occurs where the slope of the ROC is 
equal to: 
�
𝐴𝐴𝐴𝐴𝑓𝑓𝑓𝑓𝑃𝑃(𝐷𝐷−)
𝐴𝐴𝐴𝐴𝑓𝑓𝑓𝑓𝑃𝑃(𝐷𝐷+)� 
Where P(D+) is the prior/pre-test probability of disease (i.e. prevalence of disease in 
the population) 
 = average cost associated with false positive diagnosis. 
 = average cost associated with false negative diagnosis. 
The ‘cost’ can be a financial cost or a health cost. 
In many cases, we do not have accurate estimates of the additional health or financial 
costs and we take  
                                                                                          �𝐴𝐴𝐴𝐴𝑓𝑓𝑓𝑓
𝐴𝐴𝐴𝐴𝑓𝑓𝑓𝑓
� = 1 
 
Hence the cut-off point is taken to be where the slope on the ROC curve equals 
       𝑃𝑃(𝐷𝐷−)
𝑃𝑃(𝐷𝐷+) 
Pre-test probability is the probability that the patients have the disease and for all the 
investigation it was set to 0.6 as approximately 60% of the patients had aGVHD or 
were deceased at the point of analysis. The cost ratio was set to default one. The cut-
off values and the area under the curves (AUC) were all calculated using statistical 
software SigmaPlot 12.5. 
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2.14.3   Homogeneity of variance 
 
Variance is a measure of the spread of continuous data from the mean. Levene’s test 
assumes that the difference between groups is equal and was performed to assess the 
homogeneity of variance in the different cohorts for model fitting. A difference of 
greater than 0.05 was indicative of equal variance.   
2.14.4   Model building 
 
There are several known clinical risk factors that may influence the outcome (aGVHD, 
relapse, non-relapse mortality) of allo-HSCT such as patient’s age at the time of 
transplant, donor-patient relationship, patient and donor gender, graft source 
(BM/PBSC) and the underlying disease. However, when building models, all the clinical 
risk factors cannot be included as it can result in the variance of the predictions. 
Therefore, variables that show the least association with outcome are eliminated and 
not included in the model building method. In relevant Chapters, frequency tables are 
presented which show the number and percentage of patients per specific group. 
Univariate Fisher’s exact test was conducted to determine the difference in 
proportions when time was not included in the analysis. For OS and relapse where 
time was a factor, univariate Kaplan-Meier and Cox regression analysis were 
performed to test for proportions. Continuous variables such as patient’s age, 
Cyclosporine A dose and time to onset of aGVHD are all presented as median and 
range. Survival analysis was performed using the Kaplan-Meier log-rank test and 
multivariate Cox regression analysis.  
Graft-versus-host disease outcome is measured on an ordered categorical scale 
ranging from 0-IV (0: without aGVHD, I: mild aGVHD, II: moderate aGVHD and III: 
severe aGVHD). Thus, the outcome cannot be assumed to have a normal distribution.  
Additionally, basic statistical approaches only identify the main effects or difference 
between variables and not the most complex interactions involved with regards to a 
particular outcome. In such instances, advanced statistical model building methods are 
considered such as the generalised linear models (GLMs) that can result in more 
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precise analysis of the data (Brown and Prescott, 1999). GLMs allow both the main and 
interaction effects to be investigated in the covariates with regards to the outcome. 
Main effect is statistically defined as an effect of an independent variable on the 
outcome  (Hinton, 2014)  while and interaction is a measure of two or more 
independent variables on the dependent outcome (Hinton, 2014). In this scenario, the 
main effect was the effect of the individual miRNA expressions or significant clinical 
risk factors on aGVHD outcome and the  interaction was a measure of the effect of one 
independent miRNA expression levels as it differed at every condition in comparison to 
the other independent miRNA expression levels (Hinton, 2014). 
There are various classifications of GLMs using different link functions and based on 
ANOVA or regression depending on whether the outcome variable is a scale, count, 
ordinal, binary or a mixture as this indicates the distribution of the outcome variable. 
Thus, in order to predict aGVHD outcome from a list of covariates, GLMs were built 
using the binary and/or ordinal logistic regressions. The equation for the binary or 
ordinal regression models that was used for determining aGVHD grade (outcome) is as 
follows;  
aGVHD grade (cumulative logit function)= β0+ β1 (miRNA expression1) + β2 (miRNA 
expression2) + β3 (miRNA expression1 x miRNA expression2). β0= intercept coefficient 
and β1-3= the coefficient of each miRNA expression. SPSS version 21.0 was used to run 
the GLMs.  
2.15   Ingenuity Pathway Analysis 
 
2.15.1   Data source 
 
Total RNA extracted from normal skin biopsies (n=12), pre-transplant (n=12) and 
aGVHD onset skin biopsies (n=17) with a range of different histopathological and 
clinical grades (0-III) were used to synthesize universal cDNA and then amplified using 
custom made Taqman Low Density Arrays (TLDA) (Life Technologies) to screen for 
candidate GVHD genes (Norden et al., (unpublished) and patent (Publication Number: 
WO2012080359 A3) (Dickinson et al., 2012)). Skin biopsies from normal individuals 
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were used as control. The initial three custom-made TLDA were used to test for 282 
genes. Genes with ≤ 25 fold change in expression (n=38) were further assessed in the 
validation cohort. The final list contained 18 genes that were incorporated into the 
pathway mining analysis using Ingenuity Pathway Analysis (IPA) software (ANP32A, 
C1qTNF7, CARD11, CEACAM4, CXCL9, HCLS1, HTRA1, LGALS7, LST1, MSR1, PIK3AP1, 
PSTPIP1, PTGER2, PTPN7, TAP1, TGM2, TREM2 and UBD). These genes were 
considered as focus genes throughout the analyses. 
2.15.2   Analyses criteria 
 
The IPA software provides several types of analyses that can be used for pathway 
mining. Since gene lists were used for this pathway mining analysis, the core analysis 
was performed. Genes were individually searched and identified from the Ingenuity 
Knowledge Base. The report also included endogenous chemicals. The filter for species 
was set for humans only, and the confidence options present in IPA was set for highly 
predicted and/or experimentally observed data only. The Benjamini-Hochberg method 
which derives the corrected p-value was used to determine the significance of the 
biological functions and/or diseases in relation to the focus genes (n=18). 
 
2.15.3   Annotation of focus genes 
 
The data set comprising the 18 focus genes was used to derive Entrez gene names and 
their locations and types from the Ingenuity Knowledge Base.   
2.15.4   Functional analyses of data sets and networks 
 
Functional analysis was divided into three main categories; Diseases and Disorders, 
Molecular and Cellular Functions and Physiological System Development and Function. 
Each category included an annotation of the top five significant functions and the focus 
genes involved, respectively.  
2.15.5   Canonical pathway analyses 
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The significance of the relationship between the data set and the canonical pathway 
was measured in ratios and p-values. IPA calculates the ratio by dividing the number of 
genes into a given pathway that meet the particular selected or automatic cut-off and 
the total number of genes in that canonical pathway. The right-tailed Fisher’s exact 
test was used to calculate the p-value, which determined the probability that the 
relationship between the focus genes and the canonical pathway was explained by 
chance alone.   
A comprehensive list of the molecular and relationships used in the generation of 
networks and canonical pathways are presented in figure 2.16. 
 
Figure 2.16 The legend shows the main symbols and lines used in the generation 
of networks and canonical pathways (adopted from www.ingenuity.com/).  
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 Chapter 3. Pathway Mining of Candidate Genes 
Associated with Graft-Versus-Host Disease  
 
 
 
 
 
“When you make the finding yourself - even if you're the last person on Earth to see 
the light - you'll never forget it.” 
-Carl Sagan 
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 3.1 Introduction       
 
Experiments to identify gene expression signatures associated with a specific disease 
state are now routinely performed. Such profiling experiments utilize microarray, 
barcoding (Nanostring) or RT-qPCR technologies. These high-throughput technologies 
generate a wealth of data that need to be analysed both quantitatively (i.e. expression 
levels) and functionally (i.e. biological functions, pathways). Thus, pathway-mining can 
be employed to decipher the potential biological roles and downstream impacts of the 
genomic and proteomic data generated through these experiments (Huang da et al., 
2009). Pathway analysis also depicts the overall picture of all the genes experimentally 
investigated in relation to one another, as well as in relation to other relevant 
molecules.  
Furthermore, the gene signatures identified using each of the different techniques may 
not overlap, due to several reasons such as technical and technology based variations, 
small sample size, and sample heterogeneity especially when using samples from 
transplant and/or cancer patients. To reduce the challenges of analysing results from 
several gene expression arrays a meta-analysis based method is employed. This 
approach permits the combination of gene expression results from several studies in 
order to identify a signature pattern. There are numerous meta-analysis methods 
available and used in the literature (Rhodes et al., 2004; Shen et al., 2004; Choi et al., 
2007). One method uses the statistical p-value derived from various investigations for 
a particular gene to discriminate diseased from healthy tissues (Rhodes et al., 2004). 
Others have used Bayesian methods whereby probabilities are determined to 
distinguish cancer cell from that of normal (Shen et al., 2004; Wang et al., 2004).  
Analysing array results based on their biological associations in established, as well as 
predicted pathways is the new upcoming meta-analysis method. Pathway-based 
approaches can use both the p-values obtained from gene expression arrays or 
selectively utilize the signature list to identify specific pathways. Currently, there are 
several bioinformatics resources available for pathway-mining and pathway-based 
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meta-analysis such as DAVID (the database for annotation, visualization and integrated 
discovery) (Huang da et al., 2007), GoMiner (Zeeberg et al., 2005), GoToolBox (Martin 
et al., 2004) and more recently, Ingenuity Pathway Analysis (IPA) software (QIAGEN 
Redwood City, USA) (Systems, 2012). The pathways generated can lead to the 
identification of new therapeutic targets. Indeed, Arasappan et al., (2011) have shown 
that meta-signatures can clearly distinguish patients with systemic lupus 
erythematosus (SLE) from that of the controls. The investigation utilized gene 
expression results from five independent microarray experiments performed on 
PBMCs derived from SLE and normal controls (Arasappan et al., 2011) and was 
analysed using IPA.  
3.1.1 Specific study aims 
In this present study Ingenuity Pathway software was used to perform pathway mining 
to enrich for common biological functions among the signature gene list, the 
associated pathway and any other biological molecules involved in the process. The 
signature list comprised of genes that had been shown to be differentially expressed 
with regards to aGVHD incidence. The signature  gene list was identified by Norden et 
al., (unpublished) and a patent has been filed (Publication Number: WO2012080359 
A3) (Dickinson et al., 2012).  
Therefore, the aims of this investigation were as follows; 
1. To utilize the existing GVHD signature gene list to identify relevant pathways and 
networks involved in this disease process 
2. To identify potential genes/proteins and miRNAs that may target the signature 
GVHD list and, therefore, represent new potential therapeutic targets. 
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3.2 Results 
 
Norden et al., (unpublished) conducted TLDA on skin biopsies collected at query onset 
(GVHD assessed as per clinical disease symptoms prior to histopathological analysis 
report) aGVHD time-points, to screen for candidate genes associated with aGVHD. 
Eighteen genes that were significantly differentially expressed between normal 
controls and aGVHD skin biopsies of various grades (0-IV) were further validated using 
RT-qPCR. The final dataset comprised of the 18 genes and was uploaded into the 
Ingenuity Pathway Analysis software.  
The core analysis was performed identifying both direct and indirect relationships. 
Direct relationships (interactions) were defined as one molecule or transcription factor 
directly binding and impacting the expression level of a gene. In direct relationships 
were defined as those interactions where no direct binding was reported yet it was 
mediated via other molecules and influenced the expression level of the gene. 
Molecules from the dataset that were associated with haematological, dermatological 
or immunological functions or diseases were considered for the analysis. The 
Benjamini-Hochberg method was the preferred method, as prior information on the 
significance of the associations was absent. Also, this unsupervised approach reduced 
the introduction of bias in the study, as it allowed the software to generate networks 
based on the inbuilt algorithms and curated literature. Molecules from the data set 
that met the filter criteria and that were associated with a canonical pathway in 
Ingenuity Knowledge Base were considered for analysis. The significance of the 
association between the dataset and the canonical pathway was measured by ratios 
and p-values. 
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3.2.1 Annotation of the focus genes 
 
The dataset was mapped to the Ingenuity Knowledge Base. The Entrez gene name, 
location and type were determined for each of the 18 focus genes.  A summary of the 
annotations is presented in Table 3.1. 
Symbol Entrez Gene Name Location Type(s)
ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A Nucleus other
C1QTNF7 C1q and tumor necrosis factor related protein 7 Extracellular Space other
CARD11 caspase recruitment domain family, member 11 Cytoplasm kinase
CEACAM4 carcinoembryonic antigen-related cell  adhesion molecule 4 Plasma Membrane other
CXCL9 chemokine (C-X-C motif) l igand 9 Extracellular Space cytokine
HCLS1 hematopoietic cell-specific Lyn substrate 1 Nucleus transcription regulator
HTRA1 HtrA serine peptidase 1 Extracellular Space peptidase
LGALS7/
LGALS7B
LST1 leukocyte specific transcript 1 Plasma Membrane other
MSR1 macrophage scavenger receptor 1 Plasma Membrane transmembrane receptor
PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 Cytoplasm other
PSTPIP1 proline-serine-threonine phosphatase interacting protein 1 Cytoplasm other
PTGER2 prostaglandin E receptor 2 (subtype EP2) Plasma Membrane G-protein coupled receptor
PTPN7 protein tyrosine phosphatase, non-receptor type 7 Cytoplasm phosphatase
TAP1 transporter 1, ATP-binding cassette, sub-family B Cytoplasm transporter
TGM2 transglutaminase 2 Cytoplasm enzyme
TREM2 triggering receptor expressed on myeloid cells 2 Plasma Membrane transmembrane receptor
UBD ubiquitin D Nucleus other
lectin, galactoside-binding, soluble, 7 Extracellular Space other
 
Table 3.1. Annotation results of the 18 focus genes. The location and type of proteins 
are mentioned in the table.
 
3.2.2 Network analysis of the focus genes 
 
The focus genes (18 signature genes) were used to deduce molecular networks based 
on algorithms that take into account the connection of the genes according to 
information available in Ingenuity Knowledge Base (curated database). Network 
analysis predicted five networks in which the focus genes could have potential 
involvement. Direct and indirect interactions were determined de novo using the 
network analysis, and these were based upon the input genes. All direct interactions 
indicated that the two genes were directly in contact i.e. direct binding of a molecule 
or transcription factor and the gene. On the other hand, indirect interactions showed 
the impact of one molecule on another as a result of a signalling cascade.  
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Ten of the 18 focus genes were involved in Network 1 (Figure 3.1). NFkB complex was 
indirectly associated with all the focus genes in Network 1 (UBD, HTRA1, LGALS7/ 
LGALS7B, PIK3AP1, PTGER2, MSR1, CXCL9, CARD11 and PSTIP1). Four of the focus 
genes (ANP32A, TAP1, TREM2 and PTPN7) were present in Network 2 (Figure 3.2). 
Networks 3, 4 and five each had only one of the focus genes involved (Figure 3.3 (a), 
(b) and (c)). In Network 3, C1qTNF7 and NR3C1 (nuclear receptor subfamily 3, group C, 
member 1) were shown to interact, and both genes are known to play roles in cancer, 
cellular assembly and organization. NR3C1 is known as the glucocorticoid receptor. 
CEBPA (CCAAT/enhancer binding protein (C/EBP), alpha) is a transcription regulator 
located in the nucleus and directly acts on LST1.  CEBPA and LST1 are involved in cell 
cycle, cellular growth and proliferation as well as connective tissue development and 
function. Network 5 showed the involvement of LYN (v-yes-1 Yamaguchi sarcoma viral 
related oncogene homolog) and SYK (spleen tyrosine kinase), F2 (coagulation factor II) 
and HCLS1. LYN and SYK both belong to the kinase family and are located in the 
cytoplasm. HCLS1 is a transcription regular located in the nucleus. F2 is a peptidase 
found in the extracellular space. All the four genes play a role in energy production, 
molecular transport and nucleic acid metabolism. Interestingly, CEACAM4 was the only 
gene that was not involved in any network. All the interactions mentioned in the 
Networks are in humans and indirect unless otherwise stated. 
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Figure 3.1  Network 1 shows the most significant interactions of the 18 genes 
with the NFκB pathway suggesting their role in inflammation. The network illustrates 
the relationship of ten focus genes (purple) with other genes (white) and the NFκB 
complex. As part of this network, the ten focus genes play a role in inflammatory 
responses, cell-to-cell signalling and inflammatory diseases. Solid lines represent direct 
interactions while dashed lines; indirect interactions. For a comprehensive list of 
symbols see Chapter 2, Section 2.15.5. 
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Figure 3.2 Network 2 shows the most significant interactions of the 18 genes 
with the tumour suppressor TP53. This network illustrates the involvement of four of 
the focus genes in relation to other genes and miRNAs that function in cell cycle, DNA 
replication, recombination, and repair as well as cellular growth and proliferation. Solid 
lines represent direct interactions while dashed lines; indirect interactions. For a 
comprehensive list of symbols see Chapter 2, Section 2.15.5. 
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        Network 3 (a)           Network 4 (b)                              Network 5 (c)  
Figure 3.3 Network 3, 4 and 5 are graphical representations of the molecular 
relationship between a focus gene and other identified molecule in the Ingenuity 
Knowledge Base. (a) Network 3. This network shows that C1qTNF7 expression is 
indirectly affected by the activation of NR3C1. (b) Network 4. CEBPA directly interacts 
with LST1. (c) Network 5. HCLS1 is indirectly affected by F2 while directly acted on by 
LYN and SYK. The three limited networks identified using the Ingenuity Knowledge 
Base are the most comprehensive for each of the genes; C1qTNF7, LST1 and HCLS1 
(accessed date: December 2011). Solid lines represent direct interactions while dashed 
lines; indirect interactions. For a comprehensive list of symbols see Chapter 2, Section 
2.15.5. 
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3.2.3 Functional analyses of the focus genes 
 
Functional analyses were divided into three main categories; Diseases and Disorders 
(Table 3.2), Molecular and Cellular Functions (Table 3.3) and Physiological System 
Development and Function (Table 3.4). Each category included annotation of the top 
five significant features and the focus genes involved, respectively. The top five 
diseases and disorders were; infectious disease, cancer, connective tissue & genetic 
disorders and inflammatory diseases. Likewise, the top molecular and cellular 
processes were; cellular growth and proliferation, cell morphology, cell to cell 
signalling and interaction, cellular development and biochemical processes.  
Performing functional analyses on the focus data set revealed the involvement of the 
genes in 301 processes. Eight genes were identified to affect arthritis disease (CXCL9, 
HCLS1, HTRA1, LST1, PIK3AP1, PSTPIP1, PTGER2 and TAP1) and nine genes to affect 
autoimmune disease (CARD11, CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, PTGER2, TAP1 
and TGM2). A summary of the focus genes involved with relevance to GVHD processes 
is presented in Table 3.5.  
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Category Functions Genes
1.     infection by bacteria CXCL9,MSR1,UBD
2.     leprosy MSR1,UBD
1.     formation of mammary tumor MSR1
2.     B-cell  non-Hodgkin's disease CARD11,LGALS7/LGALS7B
3.     hydatidiform mole PTGER2
4.     metastatic colorectal cancer HCLS1,HTRA1
5.     diffuse large B-cell  lymphoma CARD11
1.     arthritis CXCL9,HCLS1,HTRA1,LST1PIK3AP1,PSTPIP1, 
TAP1
3.     ankylosing spondylitis CXCL9
1.     asthma, nasal polyps, and aspirin intolerance PTGER2
2.     polycystic l ipomembraneous osteodysplasia TREM2
3.     exudative age-related macular degeneration HTRA1
4.     chronic small and large plaque psoriasis CXCL9
5.     exfoliation syndrome TGM2
6.     maturity-onset diabetes of the young TGM2
7.     ankylosing spondylitis CXCL9
8.     tuberculoid leprosy UBD
9.     progressive supranuclear palsy TGM2
10. osteoporosis PTGER2
1.     familial recurrent arthritis PSTPIP1
2.     asthma, nasal polyps, and aspirin intolerance PTGER2
3.     inflammatory disorder C1QTNF7,CXCL9,HCLS1,HTRA1,LST1,PIK3AP1,
PSTPIP1,PTGER2,TAP1
5.     dermatomyositis CXCL9
CXCL9,HCLS1,HTRA1,LST1, PIK3AP1,TAP1
CXCL9,HCLS1,HTRA1,LST1,PIK3AP1,TAP1
Infectious 
Disease
Cancer
Connective 
Tissue Disorders 2.     rheumatoid arthritis
4.     rheumatoid arthritis
Genetic 
Disorder
Inflammatory 
Disease
 
Table 3.2 Involvements of the 18 focus genes in top diseases and disorders. 
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Category Functions Annotation Genes
1.      proliferation of peripheral blood leukocytes CARD11,LST1
2.      growth of neuroblastoma cells LGALS7/LGALS7B
3.      proliferation and co-stimulation of peripheral T lymphocyte CARD11
4.      proliferation of mesangial cells CXCL9
5.      proliferation of skin cancer cell  l ines PTGER2
6.      colony formation of colon cancer cell  l ines LGALS7/LGALS7B
7.      proliferation of fibroblast cell  l ines TGM2
1.     branching of actin fi laments HCLS1
2.     multinucleation of colon cancer cell  l ines UBD
3.     polarization of hematopoietic progenitor cells CXCL9
4.     morphology and cell  spreading of embryonic cell  l ines MSR1
5.     morphology and cell  spreading of kidney cell  l ines MSR1
6.     morphology and cell  spreading of epithelial cell  l ines MSR1
7.     reorganization of actin cytoskeleton CXCL9
8.     autophagy of brain cancer cell  l ines PTGER2
1.     attachment of keratinocyte cancer cell  l ines PTGER2
2.     activation of smooth muscle cell  l ines TGM2
3.     activation of smooth muscle cells TGM2
4.     activation of embryonic cell  l ines TGM2
5.     activation of epithelial cell  l ines TGM2
6.     phagocytosis of monocyte-derived macrophages TGM2
7.     activation of kidney cell  l ines TGM2
8.     adhesion of hematopoietic progenitor cells CXCL9
9.     adhesion of leukocyte cell  l ines TGM2
10. binding of melanoma cell  l ines CXCL9
11. co-stimulation of T lymphocytes CARD11
12. phagocytosis of leukemia cell  l ines TGM2
13. adhesion of blood cells CXCL9,TGM2
14. binding  amd adhesion of embryonic cell  l ines MSR1
15. binding and adhesion of epithelial cell  l ines MSR1
16. binding and adhesion of kidney cell  l ines MSR1
1.     branching of actin fi laments HCLS1
2.     growth of neuroblastoma cells LGALS7/LGALS7B
3.     differentiation of myeloid dendritic cells UBD
4.     differentiation of neuroblastoma cell  l ines TGM2
1.     conjugation, modification and trans-amidation of histamine TGM2
2.     deposition, transport and efflux of cholesterol MSR1
3.     synthesis of leukotriene B4 PTGER2
4.     fatty acid metabolism MSR1,PTGER2
Cellular Growth and 
Proliferation
Cell Morphology
Cell-To-Cell Signalling 
& Interaction
Cellular Development
Small Molecule 
Biochemistry
 
Table 3.3 Function of focus genes in molecular and cellular processes.
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Category Functions Annotation Genes
1.     proliferation of peripheral blood leukocytes CARD11,LST1
2.     polarization of hematopoietic progenitor cells CXCL9
3.     cell  movement of T lymphocytes CXCL9,TGM2
4.     aggregation, adhesion and chemotaxis of hematopoietic progenitor cells CXCL9
5.     differentiation of myeloid dendritic cells UBD
6.     phagocytosis of monocyte-derived macrophages TGM2
7.     adhesion of leukocyte cell  l ines TGM2
8.     co-stimulation and proliferation of T lymphocytes CARD11
9.     chemotaxis of eosinophils CXCL9
1.     attachment of keratinocyte cancer cell  l ines PTGER2
2.     aggregation and adhesion of hematopoietic progenitor cells CXCL9
3.     development of dendrites LST1
4.     adhesion of leukocyte cell  l ines TGM2
5.     adhesion of embryonic, epithelial and kidney cell  l ines MSR1
6.     proliferation of fibroblast cell  l ines TGM2
Tumor Morphology 1.     formation of mammary tumor MSR1
1.     re-epithelialization of wound LGALS7/LGALS7B
2.     activation of epithelial cell  l ines TGM2
3.     cell  spreading, morphology, binding and adhesion  of epithelial cell  l ines MSR1
Haematological System Development 
and Function
Tissue Development
Hair and Skin Development and 
Function
 
Table 3.4 Physiological System Development and Function. 
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Function Annotation Genes
increases activation of leukocytes CARD11, CXCL9, TREM2
increases apoptosis of tumor cell  l ines HCLS1, LGALS7/LGALS7B, MSR1, TGM2
affects arthritis CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, PSTPIP1, PTGER2, TAP1
affects autoimmune disease CARD11, CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, PTGER2, TAP1, 
TGM2
increases cell  death of tumor cells CXCL9, HCLS1, LGALS7/LGALS7B, MSR1, TGM2
affects dermatological disorder ANP32A, CARD11, CXCL9, MSR1, UBD
affects differentiation of cells CARD11, LGALS7/LGALS7B, PTGER2, TGM2, UBD
affects digestive system disorder C1QTNF7, CARD11, CXCL9, HTRA1, LST1, TAP1, TGM2, UBD
affects hematological disorder CARD11, CXCL9, HCLS1, LGALS7/LGALS7B, MSR1, PTGER2, 
TGM2
affects immune response CARD11, MSR1, PIK3AP1, PTGER2, TGM2, TREM2
affects inflammatory disorder C1QTNF7, CARD11, CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, 
PSTPIP1, PTGER2, TAP1, TGM2
affects leukocyte migration CXCL9, MSR1, TGM2, TREM2
affects metastasis HCLS1, HTRA1, PTGER2
affects migration of cells CXCL9, MSR1, PTGER2, TGM2, TREM2
affects non-Hodgkin's disease CARD11, CXCL9, LGALS7/LGALS7B
affects proliferation of cells CARD11, LGALS7/LGALS7B, MSR1, PIK3AP1, PTGER2, TGM2
affects quantity of leukocytes CARD11, PIK3AP1, PTGER2, TAP1
affects response of cells CARD11, CXCL9, MSR1, TGM2, TREM2
affects rheumatoid arthritis CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, TAP1
affects skeletal and muscular disorder CXCL9, HCLS1, HTRA1, LST1, PIK3AP1, PSTPIP1, PTGER2, TAP1, 
TGM2  
Table 3.5 Functional annotation of focus genes. Functional analysis of the 18 
focus genes identified the diseases and processes in which the genes may have an 
impact on. 
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3.2.4 Canonical pathway analyses 
 
Canonical pathway analyses identified the metabolic and signalling pathways that were 
most significant to the focus genes. The top five canonical pathways were T cell 
receptor, NFkB and interferon signalling, and DC maturation (Table 3.6 and Figure 3.4). 
Six of the focus genes were either directly or indirectly associated with IFN-γ (TAP1, 
CXCL9, LST1, LILRA5, IL1R2 and UBD) (Figure 3.5). 
Canonical Pathway Gene Networks
T Cell  Receptor Signall ing & NFκB Signall ing CARD11 1
T Cell  Receptor Signall ing PTPN7 2
Interferon Signall ing TAP1 2
Dendritic Cell  Maturation TREM2 2  
Table 3.6 Canonical Pathways. The relevant canonical pathways were selected 
and the involvement of the 18 focus genes in these pathways determined. The 
networks in which the focus genes are involved in are indicated in the table. The 
Networks are numbered as mentioned in Section 3.3.2. 
 
Figure 3.4 Canonical pathways relevant to GVHD. T Cell Receptor and Interferon 
Signalling were the main pathways associated with GVHD with the maximum number 
of the focus genes present in these pathways.  The four selected canonical pathways 
are displayed along the x-axis. The height of the bars represents the number of genes 
associated with that specific canonical pathway. IPA calculated the ratios by dividing 
the number of genes in a pathway that met the automatic cut-off and the total 
number of genes in that canonical pathway. Then the software used the right-tailed 
Fisher’s exact test to calculate the p-values. 
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 Figure3.5  Interferon-γ indirectly acts on six of the focus genes. 
Focus genes are highlighted in blue (TAP1, CXCL9, LST1, LILRA5, IL1R2 
and UBD). TNF and IFN-γ    directly interact as well as with the focus 
genes in this pathway. LST1 was also found to be influenced by IFN-γ 
and was therefore added to the pathway. This finding is depicted with 
the dashed purple line from IFN-γ to LST1. For a comprehensive list of 
symbols see Chapter 2, Section 2.15.5. 
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3.2.5 More than 1000 microRNAs target the 18 genes 
 
MicroRNA prediction for the 18 genes was performed using the miRWalk database 
(Dweep et al., 2011). MicroRNAs that were identified by at least three databases 
(miRanda, miRDB, miRWalk, RNA22 and Targetscan) were considered as predicted 
targets. In total 1500 miRNAs were predicted to target the 18 genes. Table 3.7 shows a 
summary of the predicted miRNAs that may each regulate the 18 genes. MiR-34a was 
the most interesting miRNA as its role in aGVHD has been recently reported in the 
literature (Wang et al., 2013). However, the study had focused on gastrointestinal 
biopsies and not skin biopsies.  
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 Table 3.7 Summary of predictive miRNAs that may target the 18 genes.The most 
interesting miRNA (miR-34a) is highlighted in yellow due to its recent reported 
association with gastrointestinal aGVHD (Wang et al., 2013).  
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3.3 Discussion 
 
The candidate gene list was derived from an investigation by Norden et al 
(unpublished) using Taqman Low Density Arrays. Total RNA extracted from clinical 
aGVHD skin biopsies (grades 0-IV) and normal controls were used in this profiling 
experiment. The highly differentially expressed genes were selected, validated by RT-
qPCR and the signature gene list (n=18) used for this pathway-mining study. Ingenuity 
Pathway Analysis was used to determine the pathways and networks in which the 
significant 18 focus genes were involved, either through direct or indirect association. 
This investigation also aimed to identify additional molecules that may be associated 
with the existing 18 focus genes or pathways. These new molecules could potentially 
be studied further as new leads in understanding the pathobiology of GVHD. The 18 
focus genes were analysed using the core IPA analysis, which permits the study of the 
dataset in a biological context (processes, diseases and disorders). In silico pathway 
analysis approaches, such as IPA, allow researchers to predict the biological 
mechanisms underlying their genomic experiments.   
The pathway analysis demonstrated that the 18 genes were involved in five networks.  
Network 1 analysis showed that IL13 protein could indirectly act on HTRA1 mRNA 
expression, as a result of which HTRA1 mRNA expression is reduced in human 
monocytes (Scotton et al., 2005). On the other hand, IL-13 increases the expression of 
TGM2 mRNA (Scotton et al., 2005). IFN-γ increases UBD mRNA expression while IL1RA 
protein indirectly decreases UBD mRNA expression (Hurgin et al., 2007). In 
keratinocytes, LGALS7 mRNA is reduced by human IgG complexes which exhibit 
pemphigus vulgaris (Nguyen et al., 2004). In cytotoxic T-lymphocyte cultures, IL12B 
enhances the expression of PIK3AP1 mRNA (Chowdhury et al.). ERK1/2 proteins are 
regulated by PTGER2 (Donnini et al., 2007). It has been demonstrated in human 
derived macrophages that ADIPOQ protein reduces the expression of MSR1 mRNA 
(Ouchi et al., 2001). When macrophages are LPS treated, ADIPOQ decreases CXCL9 
expression (Okamoto et al., 2008). PSTPIP protein enhances the localization of FASLG 
to the intracellular space (Baum et al., 2005). In Jurkat cells, CARD11 increases NFκβ 
complexes (Ishiguro et al., 2006). Interestingly, both HTRA1 and LGAL7 have been 
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shown to be significantly reduced (Norden et al, unpublished) in aGVHD skin which 
overlaps with the finding of IPA in Network 1.  
Network 2 involved four focus genes; TAP1, PTPN7, ANP32A and TREM2. 
Investigations have shown that p53 directly acts on TAP1 and is essential for its mRNA 
expression (Daoud et al., 2003) while SMARCA4 protein is indirectly involved in PTPN7 
and TREM2 expression (Hendricks et al., 2004). There is direct relationship between 
TAP1 and p53; whereby binding of p53 to it, enhances TAP1 expression levels.  
SMARCA4 is a transcription factor with a role as a tumour suppressor. Studies have 
shown that both ANP32A and SMARCA4 expression is regulated by miR-21 which is 
responsible for tumour growth (Schramedei et al., 2011). No change in the expression 
of ANP32A was observed in the experimental validation (Norden et al, unpublished), 
but higher levels were found in an aGVHD rat skin explant model (Novota et al., 2011). 
This may indicate that Anp32a expression is regulated via a different mechanism in 
humans and rats and there might be a differential level of miR-21 and/Smarca4 
expression in the rat skin explant model. In the validation cohort, TAP1 expression was 
up-regulated in aGVHD human skin as well as the rat skin explant model (Norden et al, 
unpublished). Thus, it might be biologically reasonable to investigate p53 mRNA and 
protein expression in the same skin biopsies and correlate the expression with TAP1 
levels. P53 is an established regulator of apoptosis (Fridman and Lowe, 2003) and 
understanding its interaction with TAP1 may explain the increased levels of apoptosis 
seen in cutaneous aGVHD.  
According to Network 3, NR3C1 protein indirectly impacts C1qTNF7 mRNA expression 
(Lu et al., 2007). NR3C1 is the glucocorticoid receptor gene and plays a role in 
inflammatory responses and cellular proliferation (Ray and Prefontaine, 1994). 
According to the findings of IPA, in Network 3, NR3C1 indirectly interacts with 
C1qTNF7 which is a gene with very limited associated literature available on it. In allo-
HSCT glucocorticoids are administered as first line GVHD therapy. In the validation 
study, low levels of C1qTNF7 mRNA expression were observed in both aGVHD skin 
(Norden et al, unpublished) and the rat skin explant model. Thus, the interaction found 
in Network 3 might provide additional insight in how C1qTNF7 is regulated and 
functions in aGVHD.  
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Network 4 showed that CEBPA protein directly enhances LST1 mRNA expression (Tavor 
et al., 2003). CEBPA is a gene that is associated with familial AML (Smith et al., 2004). 
CEBPA has been shown to be significantly up-regulated in the PBMC of aGVHD 
patients. In the rat skin explant model Lst1 was up-regulated, while in human 
cutaneous aGVHD its levels were down-regulated (Norden et al, unpublished). CEBPA 
has tissue specific expression with high levels being present in peripheral blood 
(Antonson and Xanthopoulos, 1995).  There is 92% similarity between the rat and 
human CEBPA protein sequence (Antonson and Xanthopoulos, 1995). The IPA network 
finding thus shows that it would be insightful to also investigate CEBPA levels in the 
same skin biopsies and to test for interactions as well as correlations.   
Network 5 showed the involvement of HCLS1. F2 protein indirectly acts on HCLS1 and 
increases its mRNA expression while SYK and LYN protein directly act on HCLS1 to 
enhance its expression (Brunati et al., 2005). Experimentally, HCLS1 levels were 
unaltered in aGVHD human skin while they were up-regulated in the rat skin explant 
model (Norden et al, unpublished). In fact, HCLS1 has a binding site in its promoter for 
CEBPA, which was identified in Network 5 to interact with LST1 (van Rossum et al., 
2005). It is therefore possible that CEBPA, HCLS1 and LST1 interact in GVHR. A 
preliminary aGVHD investigation in peripheral blood has shown that LST1 and CEBPA 
are over-expressed prior to aGVHD onset that may indicate the initiation of an 
inflammatory response (Buzzeo et al., 2008). However, the results of the investigation 
must be cautiously interpreted as their cohort comprised of AML patients who had 
undergone allo-HSCT procedure. As mentioned earlier, CEBPA may be mutated and 
also is present in familial AML (Smith et al., 2004). 
Moreover, six of the focus genes were either directly or indirectly associated with IFN-
γ (TAP1, CXCL9, LST1, LILRA5, IL1R2 and UBD) and this has also been demonstrated 
experimentally by Norden et al (unpublished). The genes also interacted with TNF-α 
which has established roles in aGVHD onset in particular during Phase 1 when target 
organs namely the skin and gut are damaged due to the conditioning regimen. TNF-α is 
released during the effector stage (Phase 3) and leads to organ damage in aGVHD. This 
may suggests that the IFN-γ inducible genes in this study are secreted after donor T cell 
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activation when both IFN- γ and TNF-α are present exacerbating organ damage during 
the effector phase (Figure 3.6).  
 
Figure 3.6 IFN-γ inducible genes may be expressed at the effector phase of 
aGVHD (adopted from (Hill and Ferrara, 2000)). TAP1, CXCL9, LST1, LILRA5 and UBD 
have been shown both via pathway mining analysis and experimentally (Norden et al, 
unpublished) to be induced by IFN-γ. IPA analysis has also shown that the genes 
interact both directly and indirectly with TNF-α. This may suggest their involvement in 
the effector phase of cutaneous aGVHD.  
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 T cell receptor, NFκB and IFN signalling as well as dendritic cell maturation were 
identified as one of the four canonical pathways using IPA. Each pathway involved one 
of the focus genes. CARD11, PTPN7, TAP1 and TREM2 were part of each pathway. The 
same genes were also part of two of the networks identified in this analysis, primarily 
Network 2 and 1. All the pathways have been shown to be involved in GVHD 
pathogenesis. The common findings between the network and canonical pathway 
analysis may suggest that the above mentioned genes could be more likely involved in 
aGVHD. 
Interestingly, more than 1000 miRNAs were predicted to target the 18 genes. This is in 
support of the well-known fact that a single miRNA can target more than 200 genes 
and 50% of the genes are controlled by these short nucleotides (Bartel, 2009). 
Surprisingly, miR-34a that has reported associations with gastrointestinal aGVHD 
(Wang et al., 2013) was also identified to target four of the 18 genes (ANP32A, 
C1qTNF7, HTRA1, and TGM2).  
Overall, all the 18 genes were identified to be involved in immune-related and/or 
autoimmune diseases and disorders. It is well known that GVHD is an immune-
mediated reaction. The 18 focus genes were identified using skin biopsies and IPA 
identified the role of some of these genes in tissue, hair and skin development which 
may suggest the tissue-specificity of the genes. A caveat of pathway analysis is that 
pathways generated are based on statistical probability rather than the actual 
biological involvement of the genes. Thus, the additional genes identified in a pathway 
and the interactions depicted in the networks are only suggestive of potential roles 
and need to be verified experimentally to validate them. 
Moreover, the genes in this study were evaluated in total RNA from the whole skin 
biopsy, which contains a heterogeneous population of cell types (keratinocytes, 
epithelial cells, fibroblasts, T cells etc.). Thus, the deregulation observed 
experimentally could have been as a result of the contribution of all the various cell 
types, yet the pathway analysis was able to identify skin specific functions. The focus 
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genes were also highly involved in haematological system development and function, 
which again reflects the contribution of all the different cell types in the skin.  
A limitation of using IPA or other in silico pathway analysis software is that the analysis 
is based on literature that has been curated in the database, rather than the whole 
field. This limitation can be overcome by a thorough search of the literature and 
careful examination of the pathways and networks created using IPA. In this 
investigation, LST1 was not identified to be impacted by IFN-γ. However, Norden et al 
(unpublished), identified literature on LST1 and the impact of IFN-γ on this gene. 
Therefore, LST1 was included in the canonical pathway (Figure 3.4) showing the 
indirect influence of IFN-γ on this focus gene.  
Similarly, a limitation of this investigation was that the genes for pathway analysis 
were pre-selected and thus, the fold change results were not analysed using the 
software. This method of analysis might have introduced bias and therefore eliminated 
genes that may have had additional potential roles to play in related pathways and 
networks.  
In conclusion, the present pathway analysis using IPA corroborates the role of the 18 
focus genes in inflammation and autoimmune disorders as well as roles in T- and 
dendritic cells. There is an extensive literature on the function of both T and DCs in the 
pathobiology of GVHD. More importantly, the findings of the miRNA prediction search 
provided additional clues for the selection of the most significant miRNAs in the next 
skin study (Chapter 4) that was based on the identification of a signature list of miRNAs 
associated with aGVHD incidence and other allo-HSCT outcomes. 
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 Chapter 4. MicroRNA Expression in Clinical Skin 
Biopsies of Allogeneic Stem Cell Transplantation 
Patients 
 
 
 
 
 
“Do not go where the path may lead, go instead where there is no path and leave a 
trail.” 
-Ralph Waldo Emerson 
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4.1 Introduction  
 
Skin is the largest organ of the human body and the most frequently affected aGVHD 
target organ. In brief, the skin is divided into three primary layers: the epidermis 
(outer-most), the dermis (centre) and the hypodermis (inner-most). The epidermis is 
mainly made up of proliferative keratinocytes while the dermis is composed of 
fibroblasts. The basement membrane separates the epidermis from the dermis. The 
hypodermis comprises of adipose cells. Melanocytes and APCs are also present in the 
epidermis (Mancini et al., 2014). The immune compartment of the skin constitutes; 
DCs, macrophages and T cells. It has been established that the number of T cells and 
DCs in the skin are more than present in the circulation, which highlights their function 
in immunosurveillance (Clark et al., 2006).  
4.1.1 Cutaneous aGVHD 
 
The overall clinical aGVHD is still classified into four grades (I-IV) as per the 1994 NIH 
consensus conference (Przepiorka et al., 1995).  Skin is staged based on how severely it 
is affected by the disease as well as the presence of any blistering or epidermolysis 
(Przepiorka et al., 1995).  The staging of skin is based on Glucksberg criteria 
(Glucksberg H, 1974). Conversely, the skin histopathological grading system used even 
today was established in 1974, by Lerner et al., (Lerner et al., 1974). Skin aGVHD is 
histopathologically graded based on the degree of vacuolization observed in the ‘basal 
layer of the epidermis and skin appendages such as the hair (Ziemer, 2013). 
Lymphocytic inflammatory cell infiltrates are also considered as well as the percentage 
of apoptotic cells comprising of keratinocytes and lymphocytes. Apoptotic 
lymphocytes are referred to as satellite necrotic cells (Ziemer, 2013). Table 4.1 shows 
the histological changes that are considered for grading cutaneous aGVHD in patients. 
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Cutaneous aGVHD grading Histological changes
Grade I Focal or diffuse vacuolar change
Grade II Grade I histological changes + dyskeratotic keratinocytes
Grade III Grade II histological changes + subepidermal cleft formation
Grade IV Complete loss of the epidermis and separation from the dermis
 
 
Table 4.1 Histological criteria used for grading cutaneous aGVHD  
Cutaneous aGVHD manifests as a result of a sequence of events that is divided into 
three phases (Figure 4.1). Phase I of cutaneous aGVHD involves the activation of 
resting Langerhans cells (LCs) that are myeloid DCs present in the epidermis. Depletion 
of host LCs in murine models has been shown to prevent cutaneous aGVHD, and also 
they have been found to persist in the tissue post-engraftment (Merad et al., 2004). 
This activation is due to the release of cytokines as a consequence of damage to host 
tissues during chemotherapy regimen and/irradiation therapy. Apoptosis of 
keratinocytes also leads to the release of danger signals in the skin. HLA class I and II 
molecules are also overexpressed during this period. Phase II of cutaneous aGVHD 
occurs post allo-HSCT when the activated donor T cells recognize the antigens 
presented by activated host DCs. In this phase, premature keratinocytes undergo 
apoptosis due to the ‘cytokine storm’, this exacerbates histological skin damage.   
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Figure 4.1 Pathogenesis of cutaneous aGVHD. The three phases that are involved 
in cutaneous aGVHD are depicted where in; phase I, danger signals are released due to 
the damage caused to the host skin tissue,  phase II, post allo-HSCT, cytokines are 
released and host DCs are activated which coincides with phase III and further 
monocyte-macrophage differentiation. In this phase, premature keratinocytes undergo 
apoptosis; donor T cells mediated cytokine storm results in further damage to the host 
tissue. Skin homeostasis and morphology are disturbed, and histological changes are 
clearly evident (Hofmeister et al., 2004).  
 
As mentioned in Chapter 1, aGVHD is commonly treated with corticosteroids. Initial 
first-line therapy for mild cutaneous aGVHD is topical steroids. Calcineurin inhibitors 
such as Cyclosporine A are also administered as part of GVHD prophylaxis. In addition 
to the above medications, moderate-severe cutaneous aGVHD can also be treated 
with phototherapy or ECP (Ziemer, 2013).  
4.1.2 MicroRNAs identified as biomarkers of aGVHD 
 
Currently, biomarkers that can be used in the clinic to stratify patients to improve 
response to treatments, diagnose or predict aGVHD or patient survival outcome are 
absent. Recently, the role of several miRNAs have been investigated in aGVHD as these 
very short regulatory molecules have been shown to have significant functions in 
numerous autoimmune diseases [rheumatoid arthritis (Leah, 2011), psoriasis (Sonkoly 
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et al., 2007), and systemic lupus erythematosus (Wang et al., 2012)] as well as cancers 
[lymphoma (Lawrie et al., 2007), oral (Park et al., 2009) and colorectal (Bandres et al., 
2006)]. MiR-146a has been shown to be down-regulated in severe aGVHD murine 
models, and its target Traf6 was elevated, leading to the activation of NFκB pathway 
(Stickel et al., 2014). The crucial role of miR-155, which has established functions in 
immune system control, has been highlighted in the development of aGVHD 
(Ranganathan et al., 2012). Elevated levels of miR-155 were expressed in the gut of 
severe aGVHD patients compared to normal controls (Ranganathan et al., 2012). 
Likewise, the function of miR-34a (Wang et al., 2013) and miR-100 have also been 
reported with regards to aGVHD. MiR-34a was expressed at higher levels in the gut of 
patients with aGVHD grades II-IV compared to pre-transplant biopsies and patients 
with aGVHD grades 0-I (Wang et al., 2013). The authors hypothesized that gut damage 
was a consequence of up-regulated miR-34a, which resulted in apoptosis of epithelial 
gut cells (Wang et al., 2013). Similarly, miR-100 expression was increased in the gut of 
mice without aGVHD, therefore suggesting a protective function (Leonhardt et al., 
2013). More recently, a predictive signature list of miRNAs for aGVHD have been 
detected in the plasma of allo-HSCT patients (Xiao et al., 2013). The authors showed 
that miRNAs (miR-423, -199a-3p, -93*, and -377) in the plasma could discriminate 
patients who would develop aGVHD from those who would not (non-aGVHD group). 
The miRNAs were also associated with reduced OS as well as aGVHD severity (Xiao et 
al., 2013).  No functional experiments were performed in their study thus the role of 
their signature miRNA in GVHD is yet to be determined.  
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4.1.3   Specific study aims 
 
Therefore, experiments in this Chapter aimed to identify the key miRNAs that may be 
involved in the onset and development of aGVHD as well as be used to predict patient 
survival and/disease-free state outcomes. As mentioned previously, skin is one of the 
major target organs affected by aGVHD. Firstly, the global profiling of miRNAs was 
performed in skin biopsies taken at the time of aGVHD onset from allo-HSCT patients. 
In this investigation, we used skin biopsies from patients who underwent plastic 
surgery (two females) and healthy volunteers (two males) as normal controls. Female 
controls were used when all the cases in the initial discovery cohort were males to see 
if there was any sex-dependent miRNA expression patterns. Moreover, the initial 
discovery cohort did comprise of two additional cases that were female but had to be 
excluded from the study due to their clinical profiles (post-DLI aGVHD and late aGVHD 
onset). Secondly, a validation cohort comprising of both clinical allo-HSCT (n=17) 
biopsies and normal controls (n=6) was also used to identify any false-positives either 
due to technical reasons or as a result of cohort heterogeneity and small sample size in 
the discovery set.  The validation set identified miRNAs that retained their significantly 
different expression levels across the groups. The main aims of this study were as 
follows; 
1. To identify a list of miRNAs that may have significant potential in diagnosing 
aGVHD severity. 
2. To validate the significance of the signature list of miRNAs in clinical skin 
biopsies, with the overall goal of using the identified miRNAs as diagnostic 
markers. 
3. To predict OS, relapse and NRM using miRNA expression levels in the skin 
4. To develop a model showing the interaction between the validated miRNAs 
with regards to allo-HSCT outcome (GVHD, OS, relapse)  
 
114 
 
4.2 Results 
 
4.2.1 Global MicroRNA Expression Profile of Cutaneous Biopsies 
4.2.1.1 Study cohort 
 
Global miRNA expression profiling was performed on clinical skin biopsies obtained 
from allo-HSCT patients (n=5) with various overall clinical and skin histopathological 
aGVHD grades. The overall clinical aGVHD grade was determined in the clinic, taking 
into account the sum of stages for the three different target organs (skin, gut and liver) 
as mentioned in Chapter 1, Section 1.1.5. Clinical aGVHD was evaluated based on the 
NIH consensus. Skin histopathological aGVHD grade was determined by two 
independent histopathologists who were blinded to the origin of the samples and used 
Glucksberg criteria (Glucksberg H, 1974). Skin biopsies were collected upon routine 
examination in the clinic at the time of aGVHD onset (Figure 4.2). Skin biopsies were 
also obtained from healthy (n=2 males) and plastic surgery volunteers (n=2 females) 
and used as normal controls. Thus, profiling was performed on a total of nine biopsies. 
The exclusion criteria included any patient who had been biopsied post-DLI/ had 
cyclosporine withdrawal/ had received steroids and/or had developed late aGVHD. The 
patients with classic aGVHD (allo-HSCT to onset ≤100 days) were only included in the 
comprehensive profiling analysis. 
The characteristics of the five patients used in this investigation are provided in Table 
4.2. The group comprised of five male patients with heterogeneous underlying 
diseases and median age 61 (range: 19-66) who had undergone allo-HSCT (2010-2012). 
This heterogeneity was regarded as representative of the allo-HSCT clinic. All the 
patients had received PBSC as the graft. Four patients had reduced conditioning 
regimens (Fludarabine and Melphalan) while one had myeloablative treatment (total 
body irradiation and cyclophosphamide). All five patients were in complete remission 
at the time of transplantation. Median aGVHD onset was 33 days (range: 18-79) post 
allo-HSCT. All had MUDs except for the youngest patient (19 years old) in this cohort 
who had a sibling donor and had undergone myeloablative conditioning. Four patients 
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developed cGVHD 100 days after transplantation, and one patient had died before 
assessment. None of the patients in this group relapsed.  
 
 
Figure 4.2 Diagram is showing the time of clinical skin biopsy collection from 
patient’s post- allo-HSCT. Clinical biopsies were collected from patients at the time of 
query aGVHD onset. Patients with classic aGVHD onset were only included in this 
investigation. Therefore, the period for biopsy collection was any day post allo-HSCT 
up to 100 days. D0 was the day that the patients received grafts.  
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Patient Characteristics A1292 A2224 A2274 A1300 A2137
Diagnosis NHL MDS ALL CLL AML
Patient Age 63 58 19 61 66
Transplant Type MUD MUD SIB MUD MUD
Source PBSC PBSC PBSC PBSC PBSC
Protocol Flu Mel Flu Mel TBI Cy Flu Mel Flu Mel 
Campath 60 90 30 60 60
Reduced Intensity Conditioning Yes Yes No Yes Yes
Status at Transplant CR1 CR1 CR1 CR CR2
CMV Patient - + + + -
CMV Donor - - + + +
Patient Sex M M M M M
Donor Sex M F F M M
Skin Histopathological aGVHD grade 2 3 2 1 1
No. of Days from Tx (aGVHD Onset) 23 18 79 76 33
Overall  Clinical aGVHD Grade 2 4 2 0 2
Chronic GVHD N/A YES YES YES YES
Relapse No No No No No  
 
Table 4.2 Patient characteristics (n=5) for the global miRNA profiling analysis 
using skin biopsies taken from allo-HSCT patients. Exiqon miRCURY LNATM Universal 
Reverse Transcription miRNA Human Panel I and II were used for the global profiling 
analysis. Abbreviations:- AML: Acute Myeloid Leukemia, MDS: Myelodysplastic 
Syndrome, CLL: Chronic Lymphocytic Leukemia, NHL: Non-Hodgkins Lymphoma, ALL: 
Acute Lymphocytic Leukemia, SIB: Sibling transplant, MUD: Matched Unrelated Donor, 
PBSC: Peripheral Blood Stem Cells, Flu: Fludarabine, Mel: Melphalan, Alem: 
Alemtuzumab, CR1: Complete Remission 1, CR2: Complete Remission 2, CR: Complete 
Remission, CMV: Cytomegalovirus, M: Male, F: Female, +: Positive, -: Negative, CMV: 
N/A: Not applicable as patient deceased before assessment.  
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4.2.1.2 Data analyses 
 
Data were initially analysed based on the overall clinical aGVHD grades, as results from 
gene expression studies by Norden et al. (unpublished) had shown a significant 
correlation between these grades and gene expression. Thus, the initial signature list 
of miRNAs was selected based on the profiling results using the overall clinical aGVHD 
grades. Since the overall clinical aGVHD grade is the summation of the different stages 
of the target organs, as mentioned in Chapter 1, Section 1.2.3.1, the data was also 
analysed based on the skin histopathological aGVHD grade. All validation results 
presented have been analysed using both grades. Figure 4.3 shows the study design 
for this Chapter. 
 
Unsupervised hierarchical clustering analysis was performed using RStudio™ 
Version 0.98.501 (RStudio, Inc., U.S.A). An unsupervised approach allows data to be 
analysed without prior assumptions, therefore reducing bias. The global profiling 
results were analysed using one-way ANOVA with Bonferroni multiple-comparison 
correction on SPSS version 21 (IBM, SPSS Inc, USA). The differential expression of 
miRNAs in skin biopsies between all groups (normal controls, pre-transplant, grades 0-I 
and grades II-III/IV) for the validation of the signature miRNA list was determined using 
Kruskal-Wallis one-way analysis of variance with Dunn’s post-hoc test on GraphPad 
Prism 5 (GraphPad Software, Inc, USA). Significance was set at p > 0.05. Jonckheere–
Terpstra test (SPSS version 21) was also performed for the miRNAs in the signature list 
to test for trends in the expression levels for aGVHD severity. Generalised Linear 
models (Ordinal logistic regression) were run to find the main effects and interactions 
between miRNAs in the signature list SPSS version 21 (IBM, SPSS Inc, USA). Rotational 
3D scatterplots were generated using JMP®, Version 11 (SAS Institute Inc., Cary, NC, 
1989-2007). 
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Figure 4.3 Chapter 4 study design. Global miRNA profiling was performed initially 
and then miRNA expressions were analysed based on the overall clinical and the skin 
histopathological aGVHD grades. A miRNA signature list was then derived based on the 
significant differences between the diseased skin biopsies and controls which included 
biopsies from normal individuals and plastic surgery patients. The signature list was 
validated by RT-qPCR and results were again analysed based on the two grading 
systems mentioned above for the aGVHD outcome study. MicroRNA expression results 
from the signature list were also used for relationship (interaction) analysis and 
survival outcome predictions.  
 
 
 
 
 
 
Global miRNA profiling results 
 
 
Overall clinical aGVHD grade 
 
Skin histopathological aGVHD grade  
 
MicroNA signature list  
 
Validation by RT-qPCR  
Allo-HSCT outcome analysis 
(aGVHD, OS, relapse) 
 
 
Normal controls 
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4.2.1.3 Grading system for determination of miRNA signature list 
 
Global miRNA profiling was performed, using the Exiqon miRCURY LNA qPCR human 
panels I and II. The aim was to identify a potential set of miRNAs significantly 
associated with aGVHD onset and severity. The expressions of 739 miRNAs present on 
human panels I and II were studied in total RNA extracted from skin biopsies of 
patients with various aGVHD grades (n=5) and also in normal skin biopsies (n=4) that 
were used as controls. Of the 739 miRNAs assessed, 186 were detectable in all the 
samples in this cohort. For statistical calculations, 245 miRNAs with expressions in at 
least three skin biopsies per group were included (Cq <35). The mean of the 186 
detected miRNAs (Cq <31) was used to normalize individual assay expression. As 
mentioned earlier, multiple analyses were performed on the global profiling data to 
select the signature list for further validation by RT-qPCR. Two analyses were 
performed to determine the differentially expressed miRNAs; (1) using overall clinical 
aGVHD grades and (2) using skin histopathological grades. Interestingly, miR-34a-5p 
and miR-142-3p were identified as differentially expressed using either approach.   
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4.2.1.4 Overall clinical aGVHD grade does not correlate with 
histopathological grade 
 
The overall clinical aGVHD and histopathological grade of the skin were also used to 
determine the correlation between the two grading systems (Figure 4.4, A). Results 
corroborated with the literature, and no significant correlation was observed (rs=0.50, 
p=0.083). Similarly, correlation between grading of the same skin biopsy by two 
independent histopathologists was evaluated (Figure 4.4., B). Results showed a 
significant positive correlation between the two histopathologists (rs=0.77, p=0.000). 
Therefore, the consensus skin histopathological grade was used for further 
investigations.  
 
 
 
 
 
Figure 4.4 Correlation of aGVHD grades in clinical skin biopsies from allo-HSCT 
patients. (A) No significant correlation between the overall clinical aGVHD grade of the 
patient and the histopathological grade of the skin biopsy (B) Significant correlation 
between the grading of the same skin biopsy by two independent histopathologists 
(p=0.000). The p-values (p) were calculated by Spearman correlation. Simple linear 
regression is shown by the line of best fit. rs: Spearman’s rho. 
B A 
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4.2.1.5 Distinct microRNA expression clusters exist between post allo-
HSCT and normal skin biopsies  
 
MicroRNAs (rows) and skin biopsies (columns) with similar expression values were 
grouped by performing the hierarchical clustering. As mentioned earlier, an 
unsupervised approach was employed to perform the hierarchical clustering, as it is 
assumption-free and aids in identifying under-expressed miRNAs. The top 50 miRNAs 
that were expressed in all the skin biopsies (n=9), including the normal controls with 
the highest standard deviation were selected for the analysis. MicroRNA expression in 
skin biopsies collected from post allo-HSCT patients (n=5) and normal controls (n=4) 
was used to plot the dendrogram (Figure 4.5) and heat-map (Figure 4.6). The 
dengrogram shows a clear segregation of the skin biopsies into two distinct clusters; 
the normal in one branch and the allo-HSCT group in the other. Interestingly, miRNA 
expression profiles within the normal cluster were highly dissimilar, as shown by the 
height of the branches. This is unlike the miRNA expression profile in the post allo-
HSCT cluster which was highly similar. The heat-map shows three distinct expression 
regions. Highly up-regulated miRNAs cluster in the first-top section and the down-
regulated miRNAs in the lower section of the heat map. MiR-720 was expressed 
consistently high in all the nine skin biopsies. MiR-34a-5p expression was distinctly 
different between normal and allo-HSCT group. MiR-451-5p is expressed highly in 
erythrocytes and its levels were highly variable in all the skin biopsies.  
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Figure 4.5 Dendrogram shows two distinct clusters, one consisting of the post 
allo-HSCT skin biopsies and the other normal controls.  The post allo-HSCT patients 
had a distinct expression profile separating them from that of normal skin biopsies. 
The height on the y-axis shows the distance that represents dissimilarity between the 
observations. The x-axis shows the nodes that represent the individual 
patients/healthy volunteers. RStudio™ was used to plot the dendrogram.  
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Figure 4.6 Heat map showed three distinct miRNA expression levels. 
Unsupervised hierarchical clustering was performed using the expression levels from 
all the 186 detectable miRNAs in the total investigation cohort (n=9). The top 50 
miRNAs that were expressed in all 9 samples. The dendrogram on the left shows that 
there are three distinct miRNA clusters based on the expression values in each row. 
The horizontal scale of the dendrogram shows the distance that represents 
dissimilarity between the clusters. There is dissimilarity between two of the miRNA 
clusters [overexpressed (green) to intermediate (light purple) and under-expressed 
(dark purple)]. The dendrogram on the top shows the clustering of the samples as in 
Figure 4.5. Normalized log2 values were used for this analysis. The average linkage 
method was used for the unsupervised hierarchical clustering of the normalized 
expression results. The histogram represents under-expressed (dark purple) to over-
expressed (green) miRNAs in all samples. Fold change range is from -5 to 10. Each row 
is representative of one miRNA and each column represents one sample.  
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4.2.2 Comparisons Using Overall Clinical aGVHD Grades 
4.2.2.1 MicroRNA signature list identified using overall clinical aGVHD 
grades 
 
Clinical skin biopsies were categorised based on their overall clinical aGVHD grades. 
There was only one patient without aGVHD (grade 0), three with aGVHD grades II and 
one with aGVHD grade IV. Thus, the miRNA expression levels in four of the patients 
(grades II-IV) and normal controls (n=4) were used to perform one-way ANOVA to 
identify a signature list of miRNAs for further validation by RT-qPCR. Fourteen miRNAs 
were identified as differentially expressed between normal and aGVHD grades II-IV 
(Table 4.3). Out of these 14 miRNAs, the expression of only four miRNAs (miR-142-3p, 
miR-142-5p, miR-155-5p and miR-34a-5p) met the Bonferroni correction p-value 
(p≤0.0002). The four miRNAs were over-expressed in the allo-HSCT skin biopsies in 
comparison to the expression in normal skin biopsies. This corrected p-value was 
calculated in order to rule out false positives. 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 MicroRNAs p-value
aGVHD grades II-IV           
(Mean expression)
Normal              
(Mean expression)
hsa-miR-142-3p 0.00002 5.60 2.95
hsa-miR-142-5p 0.00005 0.57 -2.41
hsa-miR-155-5p 0.00013 1.66 -2.19
hsa-miR-34a-5p 0.00016 3.67 1.97
hsa-miR-21-3p 0.0003 -1.10 -4.29
hsa-miR-21-5p 0.00043 6.20 3.69
hsa-miR-181c-5p 0.00052 -4.91 -3.67
hsa-miR-503-5p 0.00056 -1.19 -5.49
hsa-let-7c-5p 0.00061 1.49 2.41
hsa-miR-223-5p 0.00073 4.92 2.03
hsa-miR-23b-3p 0.00082 4.69 5.32
hsa-miR-146b-5p 0.00094 -0.73 -3.11
hsa-miR-125b-5p 0.00146 4.92 6.13
hsa-miR-365a-3p 0.00166 2.03 2.83  
Table 4.3 Fourteen miRNAs were identified as differentially expressed between 
skin biopsies from allo-HSCT patients with overall clinical aGVHD grades II-IV 
compared to normal controls. MiR-142-3p, miR-142-5p, miR-155-5p and miR-34a-5p 
were the only miRNAs that met the Bonferroni corrected p-value. All the four miRNAs 
were over-expressed in the allo-HSCT skin biopsies in comparison to the expression in 
normal biopsies. One way-ANOVA was performed to determine the significant 
difference. Bonferroni corrected p-value was calculated (p≤0.0002). Mean expression 
value per group was calculated using the miRNA expression levels of all the samples in 
that group.MicroRNA p-values that met the Bonferroni correction value are 
underlined, in bold. 
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4.2.3 Comparisons Using Skin Histopathological aGVHD Grades 
4.2.3.1 MicroRNA signature list was determined using the skin 
histopathological aGVHD grades 
 
The skin biopsies were also categorized on the basis of cutaneous histopathological 
grades. The initial one-way ANOVA with two groups (Grades I-III vs Normal) showed 
that only miR-142-3p and its other strand, miR-142-5p, met the Bonferroni corrected 
p-value (p≤0.0002) (Table 4.4). Both miRNAs were over-expressed in the allo-HSCT skin 
biopsies.  
MicroRNAs p-value
aGVHD grades II-IV           
(Mean expression)
Normal                    
(Mean expression)
hsa-miR-142-3p 0.00005 5.48 2.95
hsa-miR-142-5p 0.00020 0.47 -2.41
hsa-miR-34a-5p 0.00073 3.49 1.98
hsa-miR-21-3p 0.00114 -1.27 -4.29
hsa-miR-223-5p 0.00141 4.874 2.0325
hsa-miR-21-5p 0.00189 6.08 3.70
hsa-miR-146b-5p 0.00250 -0.77 -3.11
hsa-miR-328-5p 0.00411 -2.36 -1.37
hsa-miR-155-5p 0.00418 1.238 -2.1875
hsa-miR-664-5p 0.00484 -3.19 -2.37
hsa-miR-503-5p 0.00513 -1.74 -5.49
hsa-let-7c-5p 0.00659 1.59 2.41  
Table 4.4 Twelve microRNAs were differentially expressed between skin 
biopsies from allo-HSCT patients with skin histopathological aGVHD grades I-III and 
normal controls. MiR-142-3p and its other strand, miR-142-5p were the only miRNAs 
that met the Bonferroni correct p-value. Both miRNAs were over-expressed in the allo-
HSCT skin biopsies in comparison to the normal skin. One way-ANOVA was performed 
to determine the significanct difference. Bonferroni multiple testing corrected p=value 
was calculated (p≤0.0002). Mean expression value per group was calculated using the 
miRNA expression levels of all the samples in that group. MicroRNA p-values that met 
the Bonferroni correction value are underlined, in bold 
 
Skin histopathological grading allowed the segregation of the five skin biopsies into 
two groups (Grade I (n=2) and Grades II-III (n=3)). Therefore, multiple comparisons 
were possible (Grade I vs Grade II-III vs Normal). None of the miRNAs met the 
Bonferroni post-hoc adjusted p-value (p≤0.0002) in any of the comparison groups 
(Table 4.5). Since, the miRNAs and the samples were independent it was justifiable to 
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MicroRNA p-value MicroRNA p-value MicroRNA p-value
miR-142-3p 0.0004 miR-142-3p 0.0001 miR-34a-5p 0.151
miR-142-5p 0.001 miR-142-5p 0.0003 miR-503-5p 0.213
miR-21-3p 0.008 miR-34a-5p 0.001 miR-664-5p 0.3072
miR-223-5p 0.009 miR-21-3p 0.002 miR-23b-3p 0.389
miR-21-5p 0.0092 miR-223-5p 0.0021 miR-142-3p 0.41
miR-146b-5p 0.0093 miR-21-5p 0.0031 miR-328-5p 0.4566
miR-34a-5p 0.017 miR-328-5p 0.0046 miR-365-3p 0.82
miR-125b-5p 0.0236 miR-146b-5p 0.0048 let-7c-5p 1
miR-155-5p 0.03 miR-664-5p 0.0051 miR-21-3p 1
let-7c-5p 0.053 miR-155-5p 0.0056 miR-155-5p 1
miR-328-5p 0.0619 miR-503-5p 0.006 miR-21-5p 1
miR-181c-5p 0.0726 let-7c-5p 0.008 miR-142-5p 1
miR-503-5p 0.083 miR-125b-5p 0.0124 miR-181c-5p 1
miR-664-5p 0.1049 miR-23b-3p 0.019 miR-146b-5p 1
miR-23b-3p 0.38 miR-181c-5p 0.031 miR-223-5p 1
miR-365-3p 0.428 miR-365-3p 0.046 miR-125b-5p 1
Normal vs Grade I Normal vs Grades II-III Grade I vs Grades II-III
not use the Bonferroni post-hoc and set significance value at p≤0.05. Ten miRNAs were 
observed as significantly differentially expressed between normal and aGVHD Grade I 
skin biopsies (miR-142-3p/-5p, miR-21-3p/-5p, miR-223-5p, miR-146b-5p, mir-34a-5p, 
miR-125b-5p, miR-155-5p and let-7c-5p). Likewise, nine miRNAs were also significantly 
differentially expressed between Normal and aGVHD Grades II-III (miR-142-3p/-5p, 
miR-34a-5p, miR-21-3p/-5p, miR-223-5p, miR-328-5p, miR-146b-5p and miR-664-5p). 
However, none of the miRNAs were differentially expressed between aGVHD grade I 
and Grades II-III. Venn diagrams were generated to identify the common as well as the 
unique miRNAs between the three groups (Figure 4.7). Six miRNAs (MiR-181c-5p, miR-
23b-3p, miR-328-5p, miR-365a-3p, miR-503-5p and miR-664-5p) were unique to the 
comparison between normal and aGVHD Grades II-III while none were only unique to 
the normal and aGVHD Grades I.  
 
Table 4.5 MicroRNAs differentially expressed between skin biopsies from allo-
HSCT patients with grades I, grades II-III and normal controls. Histopathological 
grades were used for the grouping of one way-ANOVA. 
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Figure 4.7 Venn diagram showed the differentially expressed miRNAs between 
normal controls vs Grade I and Grades II-III. Six miRNAs were unique to the 
comparison between normal and aGVHD Grades II-III. None of the miRNAs were 
unique to the normal vs aGVHD grade I only. The skin biopsies were all categorised 
based on the skin histopathological aGVHD grade. Ten miRNAs (let-7c-5p, miR-125b-
5p, miR-142-3p, miR-142-5p, miR-146b-5p, miR-155-5p, miR-21-3p, miR-21-5p, miR-
223-5p and miR-34a-5p) were common between normal versus Grades I-III. The Venn 
diagram was generated using the miRNAs that had p≤0.05 from the comparison in 
table 4.5. The available online software was used to generate the Venn diagrams 
(http://www.bioinformatics.lu/venn.php). 
 
Eight miRNAs (MiR-503-5p, miR-21-3p, miR-34a-5p, let-7c-5p, miR-142-3p, miR-365a-
3p, miR-23b-3p and miR-24-3p) were selected for further validation by RT-qPCR, based 
on their differential expression levels between normal and aGVHD groups when either 
the overall clinical aGVHD or skin histopathological grades were used for 
categorisation and analysis. Normalized mean miRNA expression levels across all the 
three groups when skin histopahological grades were used are presented in Table 4.6. 
From the calculated fold-changes it was noted that miR-34a-5p, miR-503-5p, miR-21-
3p and miR-142-3p expression were up-regulated in all the skin biopsies post allo-
HSCT, independent of the aGVHD grade when compared to the normal controls. 
Similarly, Let-7c-5p fold-change was lower in the post allo-HSCT skin biopsies in 
comparison to the normal controls. Interestingly, miR-503-5p expression was more 
highly expressed in the aGVHD grades II-III when compared to grade I (Figure 4.8). The 
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expression levels of miR-24-3p and miR-365a-3p were approximately constant in all 
the nine skin biopsies, regardless of aGVHD or normal status.  
Grade I Grades II-III Normal
miR-34a-5p 3.08 3.76 1.97
miR-503-5p -2.9 -0.97 -5.49
let-7c-5p 1.72 1.5 2.41
miR-142-3p 5.2 5.67 2.94
miR-365a-3p 2.38 2.04 2.83
miR-23b-3p 5 4.67 5.31
miR-24-3p 6.58 6.35 6.76
miR-21-3p -1.6 -1.05 -4.29
MicroRNAs
Mean expression (LOG2RQ)
 
Table 4.6 Normalized mean miRNA expression values across skin biopsies with 
skin histopathological Grades I, II-III and normal controls. MicroRNA expression levels 
were all log2 transformed. Mean expression per group (Grade I, Grade II-III and 
Normal) was calculated using the log2 values of all the samples in that group.  
 
 
Figure 4.8 MicroRNAs were differentially expressed across skin biopsies with skin 
histopathological grades I, II-III and normal controls. MicroRNA expression results 
were all log2 transformed.  Each bar represents mean with SEM. 
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4.2.3.2 Five of the miRNAs selected for further validation were 
predicted to target the 18 genes 
 
As mentioned in Chapter 1, there are numerous miRNA online databases that aid the 
prediction of miRNAs target genes and vice versa. The online database miRwalk 
(Dweep et al., 2011) can retrieve both validated and predicted miRNA and gene targets 
from multiple databases (miRanda, miRDB, miRWalk, RNA22 and Targetscan). Since 
each of the databases are created based on their unique algorithms and seed 
sequence matching (between the miRNA and its targets), retrieval from multiple 
databases can increase the prediction accuracy. Thus, miRwalk was used to predict 
miRNAs that could target the 18 genes analysed in Chapter 3 (ANP32A, C1qTNF7, 
CARD11, CEACAM4, CXCL9, HCLS1, HTRA1, LGALS7, LST1, MSR1, PIK3AP1, PSTPIP1, 
PTGER2, PTPN7, TAP1, TGM2, TREM2 and UBD). MicroRNAs predicted by at least three 
databases were selected. The list was further refined by only selecting miRNAs that 
were in the signature miRNA list. These miRNAs were then used to generate a Venn 
diagram to identify common and unique genes from the list. Results showed that 
MSR1 and TGM2 were predicted to be targeted by at least three of the miRNAs in the 
further validation study (Figure 4.9). Interestingly, miR-200b was also predicted to 
target four of the patented genes (MSR1, CXCL9, C1QTNF7 and PTGER2).  
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 Figure 4.9 Five miRNAs from the validation list were predicted to target the 18 
genes (patent genes). The online database miRwalk (Dweep et al., 2011) was used to 
perform the prediction analysis of miRNA target genes. The Venn diagram shows the 
number of common and unique genes that are predicted as targets per miRNA. The 
table on the right shows the miRNA genes. The Venn diagram was generated using an 
online program (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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4.2.3.3 Twelve microRNAs were selected for further validation 
 
In summary, 12 miRNAs were selected for further validation by RT-qPCR. Eight miRNAs 
(miR-142-3p, miR-34a-5p, miR-503-5p, let-7c-5p, miR-21-3p, miR-365a-3p, miR-23b-3p 
and miR-24-3p) were selected based on their significant differential expression across 
the three groups (normal vs grade I vs grade II-III/IV) taking into consideration the two 
separate analyses performed using the two grades (overall clinical and skin 
histopathological grades). Two additional miRNAs (miR-2110 and miR-493-3p) were 
also included, because expression was only detected in the skin biopsies with overall 
clinical aGVHD grades II-IV and not in normal controls. A further miRNA, miR-200b-3p 
was also selected because of its known expression in epidermal homeostasis (Banerjee 
et al., 2011). In the present experiment, miR-200b-3p expression was observed in the 
normal controls and only one aGVHD grade II skin biopsy. Therefore, it was considered 
biologically interesting to assess the expression of miR-2110, miR-493-3p and miR-
200b-3p in order to evaluate whether these results were true positives or a technical 
error. Since miR-34a-5p expression was significantly over-expressed it was deemed 
biologically valuable to investigate its other strand miR-34a-3p in the same skin 
biopsies. MiR-155-5p and miR-155-3p were also investigated separately by Norden et 
al (unpublished data). MiR-21-5p and miR-125b-5p were not selected for further 
validation as they had been investigated previously (unpublished data) and no 
significant differential expression was observed between patients with and without 
aGVHD. 
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4.2.4 Real-Time PCR based microRNA arrays and individual RT-qPCR 
assays agreed with each other  
 
Concordance between the RT-qPCR array and the individual RT-qPCR assays was 
evaluated using Bland-Altman method to measure agreement and Spearman’s rho (rs) 
to assess correlation (Figure 4.10). In brief, for the qPCR array, normalization was 
carried out using the mean of the 186 detectable miRNAs while for the RT-qPCR 
results, the geometric mean of miR-103-3p and SNORD48 were used (see Chapter 2, 
Section 2.6.2). For Bland-Altman analysis the two methods agreed if the bias between 
them was equal to or less than one as this equated to less than one RT-qPCR cycle 
difference. For correlation, significance was set at p<0.05 and trend to significant set at 
p<0.10. Only eight of the 12 miRNAs that were selected on the basis of their 
differential expression levels were included in this method comparison analysis. The 
additional four miRNAs were not assessed as either their expression was Cq≤35 or 
absent from the array. MiR-24-3p expression was not included as its levels were 
detected using Taqman and not LNA chemistry.  
In this analysis, results showed that the two RT-qPCR based methods agreed with each 
other for seven miRNAs (miR-503-5p, miR-23b-3p, 34a-5p/-3p, miR-142-3p, miR-365a-
3p and let-7c-5p). The bias for miR-21-3p expression was greater than one so there 
was no statistical agreement between the two methods for this miRNA (Figure 4.10, E). 
The expression of only one miRNA (miR-142-3p) significantly correlated between the 
two RT-qPCR methods (Figure 4.10, F). The lack of correlation between the two 
methods showed that the detection methods are independent of each other.  
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Figure 4.10 Bland-Altman plots for the two RT-qPCR based methods. (A) miR-503-
5p, (B) miR-23b-3p, (C) let-7c-5p (D) miR-34a-5p, (E) miR-365-3p, (F) miR-21-3p, (G) 
miR-142-3p and (H) miR-34a-3p, expressions. The expression of seven miRNAs agreed 
between the two methods (plots: A, B, C, D, E, G and H). Correlation was only observed 
for miR-142-3p (plot G). Bias is the mean difference. Dashed lines show the 95% lower 
and upper limits of agreement. SD: Standard deviation. Correlation was assessed by 
Spearman rho (rs). Significance (p) was set at p<0.05 and trend to significant set at 
p<0.10. All results were log2 transformed.  
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4.2.5 Validation of the Signature MicroRNA List  
 
4.2.5.1 Study cohort 
 
Skin biopsies were collected from patients (n=17) post-allo-HSCT during 2010-2012. 
These biopsies were taken before patients had received DLI and/or steroids (Figure 
4.11). The biopsies were taken when the patients were free of viral infections and/or 
other underlying skin diseases such as psoriasis and eczema. In addition, in this 
validation study skin biopsies were also collected from patients prior to undergoing the 
allo-HSCT procedure. These skin biopsies were collected ideally seven days pre-
transplant before the initiation of the conditioning regimen.  
Patient characteristics for all the 17 patients used in this investigation are provided in 
Table 4.7. The cohort comprised of three females and 14 males. The median age was 
47 years (range: 19-65). Only one patient had bone marrow infusion while the rest 
(n=16) had PBSC for graft infusion. Three patients had undergone total body 
irradiation. The patients with classic aGVHD were only included in the validation 
cohort. Median aGVHD onset was 23 days (range: 13-98) post allo-HSCT. When 
patients were categorized based on their overall clinical aGVHD grades, 41.2% had 
aGVHD grades 0-I (n=7) while 58.8% had been diagnosed with aGVHD grades II-IV 
(n=10). For histopathological aGVHD grading, the skin parameters are only considered 
as mentioned in Chapter 1. Thus, in this cohort 58.8% were diagnosed with grades 0-I 
skin histopathological aGVHD grade in contrast to 41.2% with grades II-III. In this 
cohort, 52.9% had developed cGVHD (no cGVHD: 23.5% and unassessed: 23.5%). In all, 
29.4% of the patients had relapsed and 47.1% had died post allo-HSCT.  
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Figure 4.11 Diagram showing the time of clinical skin biopsy collection from 
patient post allo-HSCT. Clinical biopsies were collected from patients at the time of 
query aGVHD onset. Patients with classic aGVHD onset were only included in this 
investigation. Therefore, the time period for biopsy collection was any day from the 
day of graft infusion up to 100 days post allo-HSCT. Skin biopsies were also collected 
from the patients at approximately seven days pre-transplant (Pre-Tx). D0 is the day 
that the patients had graft infusion. 
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No. % No. %
1.000
Female 2 67 1 33
Male 8 57 6 43
Female 3 60 2 40
Male 7 64 4 36
BM 1 100 0 0
PBSC 9 56 7 44
ALL 1 50 1 50
AML 1 33 2 67
MDS 3 75 1 25
MF 0 0 1 100
NHL 3 60 2 40
CLL 1 100 0 0
MM 1 100 0 0
Myeloablative 1 33 2 67
RIC 9 64 5 36
Cy TBI Alem 1 33 2 67
Flu Bus Alem 1 33 2 67
Flu Mel Alem 8 73 3 27
30 mg 3 60 2 40
60 mg 6 60 4 40
90 mg 1 50 1 50
SIB 2 50 2 50
MUD 8 62 5 39
Negative 3 50 3 50
Positive 6 60 4 40
Negative 6 60 4 40
Positive 3 50 3 50
None 8 67 4 33
One 2 40 3 60
None 3 50 3 50
One 3 43 4 57
Two 4 100 0 0
Alive 7 78 2 22
Dead 3 38 5 63
No 6 55 5 46
Yes 4 80 1 20
CR 1 100 0 0
CR1 2 33 4 67
CR2 4 80 1 20
PR 1 33 2 67
Survival status 0.153
Relapse status 0.588
Disease status at 
Transplant 0.394
Donor CMV status 1.000
HLA class I 
compatibility 0.593
HLA class II 
compatibility 0.219
Campath 1.000
Relationship 1.000
Patient CMV 
status 1.000
Regimen 0.537
Protocol 0.481
Donor gender 1.000
Graft soruce 1.000
Underlying 
Disease
0.907
Patient age (median years)
Patient gender 1.000
47 (19-65)
Cohort Characteristics Difference (p-value)
0-I II-III
aGVHD Histopathological Grades      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7 Patient characteristics for the validation of the miRNA signature list. 
Histopathological aGVHD grades were used for this grouping. Fisher’s exact test was 
used to estimate the difference in frequencies between the aGVHD groups. 
Abbreviations:- BM: Bone marrow, PBSC: Peripheral blood stem cells, ALL: Acute 
lymphocytic leukaemia, AML: Acute myeloid leukaemia, CLL: Chronic lymphocytic 
leukaemia, MDS: Myelodysplastic syndrome, MM: Multiple myeloma, MPS: Multiple 
proliferative syndrome, NHL: Non-Hodgkin’s lymphoma, RIC: Reduced intensity 
conditioning, Flu: Fludarabine, Mel: Melphalan, Bus: Busulfan, Cy: Cytrabine, TBI: Total 
body irradiation, Alem: Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, CR 
(1-3) Complete remission, PR: Progression, SIB: Sibling, MUD: Matched unrelated 
donor. 
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4.2.5.2 Data analyses 
 
From the miRNA profiling investigation by RT-qPCR array, 12 miRNAs (miR-503-5p, let-
7c, miR-365a-3p, miR-23b, miR-21-3p, miR-24-3p, miR-34a-5p/-3p, miR-142-3p, miR-
493-5p, miR-200b-3p, and miR-2110) that were differentially expressed between the 
aGVHD skin biopsies and normal controls were selected for further validation. 
Normfinder was used to determine the most suitable miRNA for normalization of the 
validation data. MiR-103-3p was identified as the most suitable endogenous control. 
SNORD48 was also selected as the second endogenous control, as results from 
previous studies (unpublished data) had shown that this small nucleolar RNA has a 
stable expression profile across all skin specimens. Therefore, the geometric mean of 
the two endogenous controls was calculated for normalization of the expression 
results (see Chapter 2, Section 2.6.2). Taqman miRNA expression assays were used for 
the validation of miR-493, miR-200b, miR-24 and miR-2110 and Exiqon LNA miRNA 
assays for miR-503-5p, let-7c-5p, miR-365a-3p, miR-23b-3p, miR-21-3p, miR-142-3p, 
miR-34a-5p/-3p (see Chapter 2, Section 2.4.2, for explanation on the different 
chemistries between Taqman and LNA). These two different chemistries were used 
because the dissociation curves showed non-specific binding of the LNA primers for 
miR-493-3p and miR-24-3p as explained in Chapter 2 (Section 2.5.2). 
4.2.5.3 Five miRNAs were significantly differentially expressed 
between pre- and post allo-HSCT skin biopsies independent of 
aGVHD grading system 
 
The validation cohort was analysed separately using the overall clinical aGVHD grades 
(n=16) and the skin histopathological grade (n=17). One of the skin biopsies had no 
overall clinical aGVHD grade and was eliminated when the grouping was based on the 
clinical grade, hence n=16 for this group. Results showed that five miRNAs (let-7c-5p, 
miR-503-5p, and miR-365a-3p and miR-34a-5p /-3p) were significantly differentially 
expressed across all the four groups. The expression level of miR-365a-3p could be 
reduced as a consequence of the transplant procedure, regardless of the grading 
system. However, seven of the miRNAs (miR-493-3p, miR-142-3p, miR-21-3p, miR-24-
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3p, miR-2110, miR-200b-3p and miR-23b-3p) did not retain their significance in this 
validation study (results presented in Appendix I, Figure 1).  
 
4.2.5.4 Let-7c-5p, miR-503-5p and miR-365a-3p were differentially 
expressed in the skin biopsies post allo-HSCT 
 
Let-7c-5p, miR-503-5p and miR-365a-3p were all measured in the validation cohort 
using both the overall clinical aGVHD grades and the skin histopathological grade 
(Figure 4.12). Overall, let-7c-5p was differentially expressed across the different groups 
(Overall clinical aGVHD grade: p=0.013, Skin histopathological grade: p=0.037). There 
was also a significant down-regulation in the pre-transplant biopsies in comparison to 
the normal controls (p<0.05). Significant differential expression between pre-
transplant biopsies and aGVHD grades II-IV was only observed when the overall clinical 
aGVHD grades were used for analysis (p<0.05) (Figure 4.12, A and B). Similarly, miR-
503-5p showed significant variation among normal controls, pre-transplant and post-
allo-HSCT patients (Overall clinical aGVHD grade: p=0.042, Skin histopathological 
grade: p=0.021) (Figure 4.12, C and D). However, miR-503-5p expression was only up-
regulated in aGVHD patients in comparison to the pre-transplant group (p=0.021) 
when the skin histopathological grades were used for analysis (Figure 4.12, D). 
Interestingly, miR-365a-3p was differentially expressed across all patient and normal 
group (Overall clinical aGVHD grade: p=0.016, Skin histopathological grade: p=0.015, 
Figure 4.12, E and F). When the overall clinical aGVHD grades were used, significant 
down-regulation of miR-365a-3p was observed between patients assessed with aGVHD 
grades II-IV in comparison to those pre-transplant (p<0.05) (Figure 4.12, E). However, 
when the skin histopathological grades were used for analysis, miR-365a-3p was down-
regulated in grade 0-I in comparison to the pre-transplant cohort (p<0.05) (Figure 4.12, 
F).  
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Figure 4.12 Let-7c-5p, miR-503-5p and miR-365a-3p validated in skin biopsies. 
MicroRNA expression results for (A, B) let-7c-5p, (C, D) miR-503-5p and (E, F) miR-
365a-3p were used to perform analyses on the basis of overall clinical aGVHD grade 
(n=16) and the skin histopathological grade (n=17). Compared to pre-transplantation, 
significant overexpression was observed in let-7c-5p and miR-503-5p in the post allo-
HSCT skin biopsies independent of the grading system used. MiR-365a-3p expression 
was down-regulated in post allo-HSCT skin biopsies compared to pre-transplantation. 
Kruskal-Wallis analysis of variance was used to determine the significance set at p≤0.05 
(*). Scatter-plots show the mean and SEM. Each row shows the expression for a 
specific miRNA across all the skin biopsies. Each column shows the grading system 
used to perform the categorization of the skin biopsies. Normal: normal controls, Pre-
Tx: Pre-transplant. 
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4.2.5.5 MiR-34a-5p was over-expressed post allo-HSCT and its 
expression positively correlated with miR-34a-3p expression in 
the skin biopsies 
 
Expression of miR-34a-5p was also investigated in the validation cohort (n=17). 
Interestingly, miR-34a-5p was differentially expressed across all groups in the cohort 
(overall clinical aGVHD grade: p=0.0006, skin histopathological grade: p=0.0005). Data 
analyses using overall clinical aGVHD and histopathological grades demonstrated that 
miR-34a-5p was significantly up-regulated post allo-HSCT regardless of aGVHD grade 
(p<0.01) (Figure 4.13).  
Since recent literature on miRNA expression highlights that the passenger strand may 
not be degraded but may function independently; expression of miR-34a-3p was also 
investigated in the same cohort. Results showed that miR-34-3p was expressed and 
not completely degraded in the skin biopsies. However, the mean miR-34a-5p 
expression (mean Cq= 27.898) was higher than miR-34a-3p (mean Cq= 32.362). It was 
also evident that miR-34a-3p expression was significantly varied across all groups in 
the cohort (overall clinical aGVHD grade: p=0.007, skin histopathological grade: 
p=0.013). Based on the overall clinical aGVHD grade, miR-34a-3p was significantly up-
regulated in the cohort with 0-I aGVHD in comparison to both normal and pre-
transplant skin biopsies (p<0.05) (Figure 4.13, C). No significant differential expression 
of miR-34a-3p was observed when the skin histopathological grades were used for 
analysis (Figure 4.13, D).  
Therefore, correlation in miRNA expression was evaluated between miR-34a-5p and 
miR-34a-3p (Figure 4.13, E). Results demonstrated that the expression of miR-34a-5p 
and miR-34a-3p was significantly positively correlated in skin biopsies in this cohort 
(rs=0.496, p=0.006).  
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Figure 4.13 MiR-34a-5p expression was significantly up-regulated post allo-HSCT 
in skin biopsies and its expression positively correlated with miR-34a-3p expression. 
There was a direct positive correlation between miR-34a-3p and miR-34a-5p 
expression. Scatter plots show (A, B) miR-34a-5p and (C, D) miR-34a-3p expression 
with error bars for SEM. Expression of both miRNAs was studied by RT-qPCR. Kruskal-
Wallis analysis of variance was used to determine the significance set at p<0.05. 
Normal: normal controls, Pre-Tx: Pre-transplant. (E) Spearman correlation was used to 
determine the correlation between the two miR-34a strands. Spearman’s rho: rs. Solid 
line represents regression. Significance was set at p≤0.05 (*) and p≤0.01 (**).  
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4.2.5.6 MiR-34a-5p showed the most significant trend with regards to 
aGVHD severity 
 
Jonchkeere-Terpstra test was performed to assess for statistically significant trends. 
The cohort was arranged in an ordered pattern (pre-Tx, grade I, grade II). The patient 
with skin histopathological aGVHD grade III was eliminated from this analysis as for 
Jonchkeere test, the number of variables per group should be approximately the same. 
Results demonstrated that miR-34a-5p had the highest statistically significant trend 
towards over-expression from pre to grade II aGVHD (Table 4.8). 
Jonckheere’s trend test
P-value
miR-34a-5p 0.001
miR-503-5p 0.005
miR-142-3p 0.024
miR-21-3p 0.024
miR-34a-3p 0.029
miR-24-3p 0.029
let-7c-5p 0.034
miR-493-3p 0.04
miR-365a-3p 0.062
miR-200b-3p 0.082
miR-2110 0.528
miR-23b-3p 0.61
MicroRNAs
 
 
Table 4.8 Eight miRNAs exhibited a significant trend in expression levels. 
Significant values are underlined and shown in bold. 
 
 
4.2.6 Comparisons between MicroRNA Expression Levels, the Number of 
Necrotic Cells and Inflammatory Cell Infiltrates 
 
The number of inflammatory cell infiltrates and necrotic cells were semi-quantitated in 
the clinical skin biopsies (n=17) by two independent histopathologists. Necrotic cells 
were defined as dead cells with a degenerative nucleus and altered cytoplasm. 
Inflammatory cell infiltrates (lymphoid cells) were also counted and the mean of five 
fields of view per biopsy was calculated and used for this analysis. 
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 4.2.6.1 The number of necrotic cells positively correlated with skin 
histopathological aGVHD grade  
 
There was no statistically significant correlation between the number of inflammatory 
cell infiltrates and the skin histopathological aGVHD grade (rs=0.33, p=0.190) (Figure 
4.14, A). However, there was significant positive correlation between the number of 
necrotic cells and the skin histopathological grade (rs=0.66, p=0.004) (Figure 4.14, B).  
Results also showed borderline positive correlation (rs=0.48, p=0.052) between the 
number of cell infiltrates and necrotic cells (Figure 4.14, C). 
 
  
 
 
 
Figure 4.14 Skin histopathological aGVHD grade correlated positively with the 
number of necrotic cells. (A) Skin histopathological grade versus the number of 
inflammatory cell infiltrates, (B) Skin histopathological grade versus the number of 
necrotic cells and (C) Direct positive correlation between the number of necrotic cells 
and inflammatory cell infiltrates. The cells were counted per field at 400X 
magnification. The y-axis shows the mean of inflammatory cell infiltrates counted for 
five fields per biopsy. Spearman correlation was the test used, and significance was set 
at p<0.05.  Spearman’s rho: rs. 
 
Acknowledgments: Prof Anne Janin and Dr Philippe Ratajczak performed the semi-
quantitative analyses.  
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4.2.6.2 Three microRNA expression levels negatively correlated with 
the number of inflammatory cell infiltrates  
 
Correlation statistics was performed to evaluate whether the miRNA expression levels 
were dependent on the number of inflammatory cell infiltrates and necrotic cells in the 
skin. The correlation was not statistically significant between any of 12 miRNAs in the 
validation cohort and the number of necrotic cells counted in the skin biopsies. 
However, miR-200b-3p (rs=-0.53, p=0.011), miR24-3p (rs=-0.60, p=0.011) and miR-23b-
3p (rs=-0.53, p=0.031) expressions negatively correlated with the number of 
inflammatory infiltrating cells in the skin biopsies (n=17) (Figure 4.15).  
 
 
 
 
         
Figure 4.15 Statistically significant negative correlations existed between miRNA 
expression levels and the number of inflammatory cells infiltrating the skin biopsies. 
(A) miR-200b-3p, (B) miR-24-3p and (C) miR-23b-3p expression versus inflammatory 
cell infiltrates. The cells were counted per field at 400X magnification. The y-axis shows 
the mean of inflammatory cell infiltrates counted for five fields per biopsy. Spearman 
correlation was the test used, and significance was set at p<0.05. Spearman’s rho: rs. 
 
 
 
 
 
 
 
A B C 
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4.2.7 Association between MicroRNA Expressions with Overall Survival  
 
The aim of this Section was to evaluate whether the addition of miRNA expression 
levels could be predictive of other post allo-HSCT outcomes such as OS and relapse. 
There is limited research present on the role of miRNAs in predicting allo- HSCT 
survival outcomes and most of the existing knowledge relates to cancers and solid 
organ transplantations (Fan et al., 2013; Han et al., 2013; Zhu and Xu, 2014). In a meta-
analysis study comprising of 25 independent investigations, it has been shown that 
higher levels of miR-21 was predictive of poor OS and disease-free survival (DFS) in 
cancer (Zhu and Xu, 2014). Likewise, it has been shown that down-regulation of miR-
20a expression in hepatocellular carcinoma patients was predictive of poor OS (Fan et 
al., 2013). In hepatocellular carcinoma patients who had undergone solid organ liver 
transplantation, higher miR-155 expression levels were associated with reduced 
survival (Han et al., 2013). With the current research showing the association between 
miRNA expression level and allo-HSCT outcome, similar analyses were performed in 
this Section for survival. 
4.2.7.1 Study cohort  
 
The patient cohort (n=17) comprised of nine alive and eight deceased patients. The 
follow-up period was 19 months for all the patients. The cohort included patients that 
survived more than 4 months.  . There was only one patient who had bone marrow 
infusion and had died. In all, 56% of patients infused with PBSC were alive while 44% 
were dead. Patients with skin histopathological aGVHD grades II-III had a high 
mortality percentage, 71%. This was in contrast to patients with grades 0-I of which 
70% were still alive at the time of last follow-up. All ALL and MM patients had died, but 
this result must be interpreted with caution as the cohort size is small, and the 
underlying diseases are very heterogenous in this study. In all, 60% of patients who 
had disease relapse had died. Interestingly, all the female patients were alive in this 
cohort, in comparison to 35% of the males. Table 4.9 shows a frequency table with all 
the patient characteristics and OS grouping (alive/dead). 
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4.2.7.2 Data analyses 
Variable selection for both clinical risk factors and miRNAs was performed using 
univariate analysis; either Kaplan-Meier log-rank test or Cox regression. Variables 
associated with outcome were entered in the multivariate analysis but only the 
significant variables were retained in the equation.
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No. % No. %
No aGVHD (Grade 0-I) 7 70 3 30
Yes aGVHD (Grades II-III) 2 29 5 71
Female 3 100 0 0
Male 6 43 8 57
Female 3 60 2 40
Male 5 45 6 55
BM 0 0 1 100
PBSC 9 56 7 44
ALL 0 0 2 100
AML 2 67 1 33
MDS 2 50 2 50
MF 1 100 0 0
NHL 3 60 2 40
CLL 1 100 0 0
MM 0 0 1 100
Myeloblative 1 33 2 67
RIC 8 57 6 43
Cy TBI 1 33 2 67
Flu Bu 1 33 2 67
Flu Mel 7 64 4 36
30 mg 2 40 3 60
60 mg 6 60 4 40
90 mg 1 50 1 50
SIB 7 54 6 46
MUD 2 50 2 50
Negative 2 33 4 67
Positive 6 60 4 40
Negative 5 50 5 50
Positive 3 50 3 50
None 8 67 4 33
One 1 20 4 80
None 4 67 2 33
One 3 43 4 57
Two 2 50 2 50
No 7 64 4 36
Yes 2 40 3 60
CR 1 100 0 0
CR1 2 33 4 67
CR2 3 60 2 40
PR 1 33 2 67
Graft source
Underlying Disease
Dead (%) (n=8)Alive (%) (n=9)
Cohort Characteristics (n=17)
Histopathological 
aGVHD grade
Patient gender
Donor gender
HLA Class I 
mistmatches
Disease status at 
Transplant
Regimen
Protocol
Campath
Relationship
Patient CMV status
Donor CMV status
HLA Class II 
mismatches
Relapse status
 
Table 4.9 Patient characteristics for the overall survival analysis. Abbreviations:- 
BM: Bone marrow, PBSC: Peripheral blood stem cells, ALL: Acute lymphocytic 
leukaemia, AML: Acute myeloid leukaemia, CLL: Chronic lymphocytic leukaemia, MDS: 
Myelodysplastic syndrome, MM: Multiple myeloma, MPS: Multiple proliferative 
syndrome, NHL: Non-Hodgkin’s lymphoma, RIC: Reduced intensity conditioning, Flu: 
Fludarabine, Mel: Melphalan, Bus: Busulfan, Cy: Cytrabine, TBI: Total body irradiation, 
Alem: Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, CR (1-3) Complete 
remission, PR: Progression, SIB: Sibling, MUD: Matched unrelated donor. 
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4.2.7.3 Lower miR-503-5p and miR-34a-3p expressions are associated 
with improved overall survival 
 
Clinical risk factors as well as miRNA expression levels from Section 4.4 were used to 
perform survival analysis. The expression of miR-34a-3p was also included as it 
positively correlated with its -5p strand. Since miRNA expressions were on a 
continuous scale, for OS, it was considered necessary to determine a decision 
threshold (cut-off) for each miRNA via ROC curve analysis.  This enabled a threshold to 
be determined where the majority of patients above this value had a specific outcome 
and the majority of patients below this value had the alternative outcome (McNeil et 
al., 1975). Thus, patients were dichotomised as having low or high miRNA expression 
levels (Table 4.10). For each value of specific miRNA sensitivity (True positivity) and 
specificity (false positivity) estimates were determined and these were used to plot the 
ROC curve. An area under the curve (A) of 0.5 signified that the miRNA had no 
diagnostic ability; an area under the curve of 1 signified that the miRNA had perfect 
diagnostic ability. The p-value accompanying the area under the curve tested the null 
hypothesis that the area under the curve was 0.5 (see Chapter 2, Section 2.14.2; for 
further details on ROC curve analysis). The ROC curve does not take into account the 
available time element. Thus, for improved cut-off accuracy, Kaplan-Meier analysis 
could have been employed incorporating the time factor. Subsequently, a survival 
curve would have been plotted for each of several divisions of the specific miRNA’s full 
continuum; a dichotomy could hence have been established by observing how the 
survival curves naturally clustered together. However, such a Kaplan-Meier analysis is 
dependent on a very large sample size due to the large number of divisions required; 
in this study n=17 and hence the analysis was not possible.  
The expression values of all the 12 miRNAs (miR-503-5p, let-7c-5p, miR-365a-3p, miR-
34a-5p, miR-34a-3p, miR-142-3p, miR-21-3p, miR-24-3p, miR-2110, miR-200b-3p, miR-
493-3p and miR-23b-3p) were used to perform the survival analysis. The ROC curve 
showed that the expression levels of miR-503-5p (A=0.833, p=0.021) and miR-34a-3p 
(A=0.931, p=0.003) were diagnostically significant in predicting the dead and alive 
patients (Table 4.10, Figure 4.16, A and C).  
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 MicroRNAs Cut-off value Sensitivity Specificity AUC (95% CI) P-value for AUC
miR-503-5p >-7.79 0.75 0.89 0.83(0.63-1.03) 0.021
miR-34a-3p >-6.04 0.88 0.89 0.93(0.81-1.05) 0.003
miR-34a-5p <-1.13 0.88 0.33 0.57(0.28-0.86) 0.63
miR-23b-3p >0.21 1.00 0.22 0.51(0.23-0.80) 0.923
miR-21-3p >5.51 0.63 0.67 0.56(0.26-0.85) 0.7
miR-142-3p >-1.78 1.00 0.33 0.74(0.49-0.98) 0.102
let-7c-5p >-3.11 0.88 0.22 0.54(0.26-0.83) 0.773
miR-365a-3p >-2.47 0.88 0.56 0.65(0.37-0.93) 0.29
miR-493-3p >-8.54 0.88 0.22 0.57(0.26-0.85) 0.7
miR-200b-3p <2.45 0.88 0.33 0.51(0.23-0.80) 0.923
miR-24-3p >2.26 1.00 0.11 0.53(0.24-0.82) 0.847
miR-2110 <-7.55 1.00 0.22 0.60(0.32-0.87) 0.501  
Table 4.10 ROC curve analysis of miRNA expression with overall survival. Log-
transformed miRNA expression values were used to derive the cut-off value for 
dichotomising the expression as low or high. Significant values are underlined and 
shown in bold. <: lower values signify patient more likely to die; higher values signify 
patient more likely to live. >: higher values signify patient more likely to die; lower 
values signify patient more likely to live. Significant values are underlined and shown in 
bold. 
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To reinforce the ROC’s dichotomy, the Kaplan-Meier log-rank-test (incorporating the 
time element) was then performed to compare the resulting two different levels (low 
and high) of miRNA expression with regards to OS. Only two miRNA dichotomies 
proved significantly associated with survival (Table 4.11):  miR-503-5p (log-rank test, p 
= 0.003) and miR-34a-3p (log-rank test, p = 0.004) (Figure 4.16, B and D). 
 
Log-Rank P-value
(Alive n=9, Dead n=8)
miR-503-5p 0.003
miR-34a-3p 0.004
miR-34a-5p 0.777
miR-23b-3p 0.218
miR-21-3p 0.213
miR-142-3p 0.114
let-7c-5p 0.731
miR-365a-3p 0.109
miR-493-3p 0.502
miR-200b-3p 0.448
miR-24-3p 0.404
miR-2110 0.218
MicroRNAs
 
                                                              
Table 4.11 Univariate Kaplan-Meier analysis of miRNA expression with overall 
survival. Significant values are underlined and shown in bold. 
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Figure 4.16 ROC and Kaplan-Meier survival analysis for miR-503-5p and miR-34a-
3p expression.  The cut-off value determined from the ROC test was used to 
dichotomise the miRNA expression for the log-rank test. (A) The dichotomy for miR-
503-5p at the time in which aGVHD was clinically assessed significantly (p=0.021) 
discriminated the patients that went on to survive (n=9) from those who died (n=8).   
(B) The clear separation of the Kaplan-Meier curves showed that the dichotomy for 
miR-503-5p expression could be used to predict OS post-HSCT (p=0.003). (C) The 
dichotomy for miR-34a-3p at the time in which aGVHD was clinically assessed 
significantly (p=0.003) discriminated the patients that went on to survive (n=9) from 
those who died (n=8). (D) The clear separation of the Kaplan-Meier curves showed that 
the dichotomy for miR-34a-3p expression could be used to predict OS post-HSCT 
(p=0.004). Dashed lines (---) = high miRNA expression and solid black line (—) = low 
miRNA expression levels. 
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The chi-square statistic was employed to establish if the dichotomy used for each 
miRNA was sufficient to differentiate between patients who were dead and patients 
who were alive (Table 4.12). Overall there were eight dead (events) and nine alive 
(censored) cases. Exact p-values for the chi-square test were used to ensure accuracy 
regardless of the size, distribution, sparseness, or balance of the data. These results 
agreed with those of the log rank tests from the Kaplan-Meier analysis: miR-503-5p (p 
=0.003) miR-34a-3p (p=0.004). Low miRNA expression level was shown to be indicative 
of higher cumulative survival probability for both miR-503-5p and miR-34a-3p. 
Total No. Dead Fisher’s Exact 
N N N Percent alive p-value
Low expression 10 2 8 80.0%
High expression 7 6 1 14.3%
Low expression 9 1 8 88.9%
High expression 8 7 1 12.5%
Low expression 14 7 7 50.0%
High expression 3 1 2 66.7%
Low expression 2 0 2 100.0%
High expression 15 8 7 46.7%
Low expression 9 3 6 66.7%
High expression 8 5 3 37.5%
Low expression 3 0 3 100.0%
High expression 14 8 6 42.9%
Low expression 3 1 2 66.7%
High expression 14 7 7 50.0%
Low expression 6 1 5 83.3%
High expression 11 7 4 36.4%
Low expression 3 1 2 66.7%
High expression 14 7 7 50.0%
Low expression 13 7 6 46.2%
High expression 4 1 3 75.0%
Low expression 1 0 1 100.0%
High expression 16 8 8 50.0%
Low expression 15 8 7 46.7%
High expression 2 0 2 100.0%
miR-2110 0.471
miR-493-3p 1.000
miR-200b-3p 0.577
miR-24-3p 1.000
miR-142-3p 0.206
let-7c-5p 1.000
miR-365a-3p 0.131
miR-34a-5p 1.000
miR-23b-3p 0.471
miR-21-3p 0.347
MicroRNAs Expression levela
No.Alive
miR-503-5p 0.015
miR-34a-3p 0.003
 
Table 4.12 Case processing summaries for all the 12 validated miRNAs showing 
the number of events and censored cases per group. All patients had the same follow-
up period of 19 months. a grey shade: level containing larger proportion of patients 
who died. Significant values are underlined and shown in bold. 
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4.2.7.4 Association of clinical risk factors with overall survival 
 
To increase the accuracy of the multivariate model, variable selection was performed 
for both the clinical risk factors and miRNAs. The association of the clinical risk factors 
with OS was first assessed by either Kaplan-Meier log-rank test or univariate Cox 
regression with appropriate coding for categorical variables.  Risk factors that had p-
values less than 0.2 were selected for inclusion in the Cox regression variable selection 
procedure. Kaplan-Meier survival analysis was performed to assess the association of 
donor type, source, conditioning regimen, patient gender, donor gender, patient CMV 
status and donor CMV status with OS (Table 4.13). Patient gender (p=0.114) and CMV 
status (p=0.110) were chosen as candidate variables for subsequent variable selection 
in multivariate Cox regression modelling as their log-rank p-values were less than 0.2.  
 
Clinical Risk Factors Log-Rank P-value
Donor type 0.767
Source 0.546
Conditioning regimen 0.678
Donor gender 0.56
Patient gender 0.114
Donor CMV status 0.67
Patient CMV status 0.11  
Table 4.13 Univariate Kaplan-Meier analysis of clinical risk factors with survival. 
Factor with p≤0.2 were considered significant for inclusion in the multivariate analysis. 
Significant values are underlined and shown in bold. 
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The significance of the following clinical risk factors with OS were assessed by 
performing univariate Cox regression; Diagnosis (ALL, AML, MDS, MF, CLL, MM and 
NHL) patient age, type of protocol (Cy TBI/ Flu Bu/ Flu Mel), dosage of alemtuzumab 
(30/ 60/ 90), status at transplant (CR/ CR1/ CR2/ PR), HLA Class I and HLA Class II 
mismatches, skin histopathological aGVHD status (with/ without aGVHD). Mismatches 
in HLA Class I (p=0.171) and skin histopathological aGVHD grade (p=0.096) were the 
only variables selected for entry into the multivariate model (Table 4.14). Univariate 
Cox regression analysis was also performed for all the 12 miRNAs to select the 
significant ones for the final multivariate analysis (Table 4.14). The analysis showed 
that miR-503-5p (p=0.008), miR-34a-3p (p=0.015) and miR-142-3p (p=0.099) were 
significantly (p≤0.2) associated with OS and were therefore included in the multivariate 
Cox regression model. 
Factors P-value
Diagnosis 0.809
Patient age 0.729
Alemtuzuman dosage 0.678
Status at transplant 0.533
HLA Class I mismatches 0.171
HLA Class II mismatches 0.603
Skin histopathological aGVHD grade 0.096
miR-503-5p 0.008
miR-34a-3p 0.015
miR-34a-5p 0.694
miR-23b-3p 0.918
miR-21-3p 1.000
miR-142-3p 0.099
let-7c-5p 0.884
miR-365a-3p 0.748
miR-493-3p 0.586
miR-200b-3p 0.918
miR-24-3p 0.610
miR-2110 0.385  
Table 4.14 Univariate Cox regression analysis of clinical risk factors and miRNAs 
with survival. Factors with p≤0.2 were considered significant for inclusion in the 
multivariate analysis. Significant values are underlined and shown in bold. 
156 
 
Subsequently, multivariate Cox regression analysis was performed to estimate the 
predictive value of miRNA expression with OS post-HSCT. Data from a total of 17 
patients was used for modelling; eight patients had died (event) and nine were alive 
(censored). There was no missing data in this analysis. The following were entered into 
the stepwise forward LR, multivariate Cox regression analysis: clinical risk factors 
(Patient gender and CMV status, mismatches in HLA Class I and skin histopathological 
aGVHD grade) and selected miRNAs (miR-503-5p, miR-34a-3p and miR-142-3p).  
Interestingly, miR-503-5p [p=0.042, HR= 1.73 (95% CI: 1.02-2.94)] and miR-34a-3p 
[p=0.036, HR= 4.88 (95% CI: 1.11-21.53)] were the only variables that were entered in 
the Cox regression equation (Table 4.15). When both miR-503-5p and miR-34a-3p 
were entered into the equation, the significance and hazard ratio (HR) of miR-503-5p 
declined. MiR-503-5p alone was highly significant in predicting the patients that were 
at risk of death [p=0.011, HR=1.95 (95% CI: 1.16-3.26)]. The results showed that the 
hazard of dying increased (miR-503-5p: HR=1.73, miR-34a-3p: HR=4.88) with every unit 
increase in miR-503-5p and miR-34a-3p expression (Table 4.15). Thus, both the Kaplan-
Meir log-rank test and the Cox regression model showed that low miR-503-5p and miR-
34a-3p was associated with longer OS in this cohort.  
 
Hazard Ratio (95% CI) P-value
Step 1 miR-503-5p 1.95 (1.16-3.26) 0.011
miR-503-5p 1.73 (1.02-2.94) 0.042
miR-34a-3p 4.88 (1.11-21.53) 0.036
Step 2
Variables in the equations
 
Table 4.15 MiR-503-5p and miR-34a-3p were significant in predicting overall 
survival 
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4.2.8 Association of MicroRNA Expression with Relapse 
 
4.2.8.1 Study cohort  
 
The same patient cohort (n=17) was grouped into; no relapse and relapsed. The 
patient characteristic in each group is mentioned in Table 4.16. In all, 40% of the 
patients with skin histopathological aGVHD grades 0-I relapsed while only 16.7% 
patients with aGVHD grades II-III relapsed. Percentage of relapse was higher in female 
(66.7%) patients when compared to males (23.1%). The two patients who had been 
treated with 90 mg Campath (Alemtuzumab) did not relapse. The percentage of 
relapse in patients undergoing MUD or HLA-matched sibling transplants was almost 
equal. There was 50% relapse in allo-HSCT procedures where there were two 
mistmaches in HLA class II in patient-donor pair.  
 
4.2.8.2 Data analyses 
 
As in the previous Section 4.6.2, univariate analysis was performed to identify clinical 
risk factors and miRNAs associated individually with relapse for inclusion in the 
multivariate Cox regression analysis. There was no missing data in these analyses. 
Evidently, patients with PR status at transplant had relapsed. Patient gender (p=0.192), 
CMV status (p=0.185) and graft source (p=0.070) were also selected as candidate 
variables for the subsequent variable selection in the multivariate Cox regression 
modelling as their log-rank p-values were less than 0.2 (Table 4.16).  The univariate Cox 
regression analysis showed that Status at transplant (p=0.201) and mismatches in HLA 
class II (p=0.198) were significant variables associated with relapse and were thus 
included for entry in the multivariate Cox regression model (Table 4.16).  
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No. % No. %
0.564†
No aGVHD (Grade 0-I) 6 60 4 40
Yes aGVHD (Grades II-III) 5 83 1 17
Female 1 33 2 67
Male 10 77 3 23
Female 4 80 1 20
Male 6 60 4 40
BM 0 0 1 100
PBSC 11 73 4 27
ALL 1 50 1 50
AML 2 67 1 33
MDS 2 50 2 50
MF 1 100 0 0
NHL 3 75 1 25
CLL 1 100 0 0
MM 1 100 0 0
Myeloblative 2 67 1 33
RIC 9 69 4 31
Cy TBI 2 67 1 33
Flu Bu 1 33 2 67
Flu Mel 8 80 2 20
30 mg 2 50 2 50
60 mg 7 70 3 30
90 mg 2 100 0 0
SIB 9 69 4 31
MUD 2 67 1 33
Negative 3 60 2 40
Positive 8 80 2 20
Negative 6 67 3 33
Positive 4 67 2 33
None 8 73 3 27
One 3 60 2 40
None 4 80 1 20
One 5 71 2 29
Two 2 50 2 50
CR 1 100 0 0
CR1 5 83 1 17
CR2 3 60 2 40
PR 1 50 1 50
Relapse (%) (n=5)
Patient age 47 (19-65)
P-value
0.185*
0.315†
0.264†
0.588*
0.192*
Regimen
No relapse (%) (n=11)
0.201†
0.568†
0.198†
0.535*
0.437†
HLA Class II 
mismatches
Disease status 
at Transplant
0.969*
0.07*
0.862*
0.718*
Protocol
Campath
Relationship
Patient CMV 
status
Donor CMV 
status
HLA Class I 
mistmatches
Cohort Characteristics (n=17)
Histopathologic
al aGVHD grade
Patient gender
Donor gender
Graft source
Underlying 
Disease
 
Table 4.16 Patient characteristics for patients with no relapse and relapse. 
Abbreviations: - *Univariate Kaplan-Meier log-rank test and †univariate Cox regression 
for variable selection. BM: Bone marrow, PBSC: Peripheral blood stem cells, ALL: Acute 
lymphocytic leukaemia, AML: Acute myeloid leukaemia, CLL: Chronic lymphocytic 
leukaemia, MDS: Myelodysplastic syndrome, MM: Multiple myeloma, MPS: Multiple 
proliferative syndrome, NHL: Non-Hodgkin’s lymphoma, RIC: Reduced intensity 
conditioning, Flu: Fludarabine, Mel: Melphalan, Bus: Busulfan, Cy: Cytarabine, TBI: 
Total body irradiation, Alem: Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, 
CR (1-3) Complete remission, PR: Progression, SIB: Sibling, MUD: Matched unrelated 
donor 
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4.2.8.3 Let-7c-5p expression may have a protective role against 
relapse 
 
As in the previous Section 4.6.2, univariate Cox regression analyses were also 
performed for all the 12 miRNAs to select the ones significantly associated with relapse 
(Table 4.17). The analysis showed that miR-34a-3p (p=0.060), miR-23b-3p (p=0.061), 
let-7c-5p (p=0.000) and miR-2110 (p=0.050) were significantly (p≤0.2) associated with 
relapse and were therefore included in the multivariate Cox regression model. 
Clinical Risk Factors P-value
miR-503-5p 0.811
miR-34a-3p 0.060
miR-34a-5p 0.737
miR-23b-3p 0.061
miR-21-3p 0.864
miR-142-3p 0.656
let-7c-5p 0.000
miR-365a-3p 0.343
miR-493-3p 0.382
miR-200b-3p 0.822
miR-24-3p 0.310
miR-2110 0.050  
Table 4.17 Univariate Cox regression analysis of miRNAs with relapse. Significant 
values are underlined and shown in bold. 
Multivariate Cox regression analysis was performed to estimate the predictive value of 
miRNA expression with relapse. The following were entered into the stepwise forward 
LR, multivariate Cox regression analysis: clinical risk factors (Patient gender and CMV 
status, graft source, status at transplant and mismatches in HLA Class II) and selected 
miRNAs (miR-34a-3p, miR-23b-3p, let-7c-5p and miR-2110).  
The multivariate Cox regression analysis showed that let-7c-5p [p=0.051, HR= 0.01 
(95% CI: 0.00- 1.03)] was the only variable entered in the Cox regression equation. This 
indicated that for every unit increase in let-7c-5p expression the patient risk of relapse 
declined by 0.01. Thus, let-7c-5p expression had a protective effect against relapse. 
Interestingly, quasi-complete separation was also identified for let-7c-5p expression 
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between the relapse and non-relapse group of patients. Only one patient with low let-
7c-5p expression did not relapse, and this has been shown clearly in Table 4.18.  
 
Relapse
(Yes=1, No=0)
-3.65 2 1
-3.2 8 1
-3.14 3 1
-3.1 5 1
-2.8 12 0
-2.44 10 1
-2.09 13 0
-2.09 19 0
-1.91 4 0
-1.89 12 0
-1.73 7 0
-1.55 13 0
-1.51 4 0
-1.48 7 0
-1.44 12 0
-1.12 12 0
-1.07 7 0
let-7c-5p expression Event free Survival (months)
 
Table 4.18  Quasi-complete separation for let-7c-5p expression (log2 fold change). 
The box indicates the only patient that did not relapse but had low let-7c-5p 
expression. 
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4.2.9 Model for MicroRNA Expression Levels 
 
4.2.9.1 Significant interaction between miR-503-5p and miR-34a-3p 
 
Almost all biological processes are dependent on interactions between different 
molecules. Interactions between all the 12 miRNAs were also assessed in this research. 
Ordinal logistic regression analysis was performed encompassing both the main effect 
and interaction of all the validated miRNAs in a step-wise manner. The skin 
histopathological aGVHD grade was selected as the response outcome. Results showed 
that there was a statistically significant interaction between miR-503-5p and miR-34a-
3p expression (p=0.016) with miR-503-5p had the most significant main effect 
(p=0.011) and miR-34a-3p was the moderator (p=0.020) in this interaction (See 
Chapter 2, Section 2.14.4; for detailed explanation on main effect and interactions). 
There existed a conditional relationship between miR-503-5p and miR-34a-3p such 
that when high levels of miR-34a-3p were expressed, higher levels of miR-503-5p were  
more clearly associated with severity of skin histopathological aGVHD grade (Figure 
4.17, A). However, the relationship between miR-503-5p and skin histopathological 
aGVHD severity was less clear when low levels of miR-34a-3p were expressed and this 
needs further investigation to elucidate either the clinical or biological reason for this 
change in trend (Figure 4.17, B). To further understand the conditional interaction 
between miR-503-5p and miR-34a-3p, rotational 3D scatterplots were generated 
(Figure 4.18). Since miR-503-5p and miR-34a-3p were significantly associated with OS; 
non-parametric density contours based on the patient survival status were also added 
to the scatterplots to aid visualisation. The plots demonstrated the conditional 
interaction between miR-503-5p and miR-34a-3p expression visually. 
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Figure 4.17 MiR-503-5p expression is associated with aGVHD severity. (A) miR-
503-5p expression was associated with skin histopathological aGVHD severity when 
high levels of miR-34a-3p were expressed. (B) MiR-503-5p expression was not clearly 
associated with skin aGVHD severity when low miR-34a-3p levels were expressed.  
A B 
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Figure 4.18 Rotational 3D scatterplots demonstrating miR-503-5p and miR-34a-3p 
conditional interaction. (A) Higher miR-503-5p expression was associated with skin 
histopathological aGVHD severity (B) lower miR-34a-3p expression was also associated 
with skin aGVHD severity and (C) Distinct separation between the dead and alive 
patients based on their miRNA expression levels in particular with low miR-34a-3p 
expression showing improved OS. The plot shows three axes: miR-34a-3p, miR-503-5p 
and cutaneous histopathological aGVHD grades. Red=dead, blue= alive patients. Each 
dot represents a patient. Non-parametric density contours were drawn based on the 
patient survival status (dead or alive). The arrow shows the expression scale from high 
to low.  
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4.3 Discussion 
 
Currently, more than 1900 miRNAs (Kozomara and Griffiths-Jones, 2011) have been 
identified in humans, and it is well known that a single miRNA can target more than 
200 mRNAs (Bartel, 2004b). The critical role of miRNA in disease pathology and 
development has been highlighted in numerous studies to-date (Lu et al., 2005). 
MicroRNAs are cell-specific, stable and therefore ideal biomarkers (Culpin et al., 2013). 
This study aimed to identify a signature list of miRNAs that could discriminate mild 
(Grade I) from moderate/severe (Grade II-III) aGVHD. Global miRNA profiling by RT-
qPCR was carried out, 12 miRNAs that were either differentially expressed across the 
groups (miR-142-3p, miR-34a-5p, miR-503-5p, let-7c-5p, miR-21-3p, miR-365a-3p, miR-
23b-3p and miR-24-3p) or could have an important role in disease biology (miR-493-
3p, miR-2110 and miR-200b-3p) were selected and then individually validated by RT-
qPCR in normal controls, pre- and post-transplantation skin biopsies. MiR-34a-3p 
expression was also investigated as its expression correlated with miR-34a-5p, and it 
was biologically interesting to further investigate its association with allo-HSCT in 
particular aGVHD.  
Global miRNA profiling by RT-qPCR was considered the most appropriate technique for 
this investigation as the quantity of total RNA extracted (concentration<100 ng/µl) 
from skin biopsies was below the acceptable concentration for both microarrays (100 
ng/µl) and Nanostring (100 ng) profiling technologies. As the total RNA concentrations 
were low, prior to profiling every sample was quality control checked by RT-qPCR to 
detect for any PCR inhibitors. All samples had RIN>7.0 that was indicative of purity and 
gel analysis showed no degradation.  
Allogeneic HSCT is a complicated process with a high mortality rate, and GVHD is one 
of its major complications. Acute GVHD is assessed by considering the onset of 
characteristic clinical symptoms in any of the target organs (skin, liver and gut) as 
outlined in Chapter 1. Histopathological changes are also examined in skin and gut to 
rule out infections or adverse drug reactions. Skin is the first and most frequently 
affected GVHD target organ when compared to the gut and liver. Liver is the most 
difficult target organ to study as liver biopsies are rarely taken due to the invasiveness 
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of the procedure that can increase the risk of internal bleeding. On the other hand, gut 
biopsies are more common than liver and are performed if the patient is suspected of 
gastrointestinal aGVHD with characteristic clinical symptoms as classified by 
Glucksberg (Przepiorka et al., 1995). However, at the Newcastle Transplantation 
centre, gut biopsies are rarely taken from the patients. GVHD gut involvement is 
mainly assessed based on the patient’s clinical symptoms. Thus, the skin was the ideal 
target organ to investigate both pathophysiologically and also due to its accessibility. 
As mentioned earlier, skin biopsies are more often taken from the patients than gut, 
yet treatment usually starts prior to skin histopathological grading. This is due to the 
fact that clinical symptoms do not frequently correlate with the skin histopathological 
aGVHD grade and therefore, treatments are based on the severity of clinical symptoms 
(percentage coverage of skin rash) rather than histological changes. All the patients in 
this study had been administered Cyclosporine A as standard GVHD prophylaxis but 
not steroids.  
Since clinical aGVHD grades are necessary with regards to patient treatment, in this 
investigation all results were analyzed by grouping patients based on the overall 
clinical aGVHD grade and also on the skin histopathological grade for comparison. As 
such, the overall clinical aGVHD grade and the skin histopathological grade did not 
correlate as demonstrated extensively in the literature and also again confirmed in this 
study (Zhou et al., 2000).  
Several recent investigations have highlighted the impact of aging on the expression 
levels of specific miRNAs such as miR-151-5p, miT-181a-5p and miR-1248 (Noren 
Hooten et al., 2013). However, none of these miRNAs were significantly differentially 
expressed between the 0-I aGVHD and II-III aGVHD histopathological grades. All the 
patients in this cohort were older than 50 years except the single patient in the 
profiling experiment (19 years old). Therefore, the patients investigated were an older 
population hence the differential expression observed was independent of age.  
Unsupervised hierarchical clustering of the global miRNA expression levels showed 
that there were two distinct clusters among the skin biopsies. One cluster comprised 
of only the allo-HSCT patients while the other, the normal controls. There were also 
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three distinguishable microRNA clusters on the basis of their expression levels; over-
expressed, intermediate and under-expressed miRNAs. In fact, majority of the miRNAs 
in the clusters were under-expressed.  The clustering analyses supported the 
hypothesis that normal controls and allo-HSCT patients have different miRNA 
expression patterns.  
 
Discriminatory analyses were then performed to identify which miRNAs were 
deregulated in allo-HSCT patients with an emphasis on aGVHD.  Twelve miRNAs were 
determined for further validation. The investigation showed that five miRNAs (let-7c-
5p, miR-503-5p, miR-365a-3p and miR-34a-5p/-3p) were significantly differentially 
expressed between pre- and post allo-HSCT skin biopsies independent of aGVHD 
grading system (overall clinical or skin histopathological aGVHD grade). The findings 
suggested that miRNAs could be deregulated as a result of both, the allo-HSCT 
procedure and aGVHD disease onset. Additionally, a positive correlation was observed 
between miR-34a guide (-5p) and passenger (-3p) strands. 
 
The next hypothesis to test was whether miRNA expression patterns reflected aGVHD 
severity. Extreme aGVHD cases are rare in the Newcastle Transplantation facility due 
to the controlled conditioning and prophylaxis treatments administered to patients. 
Almost every patient in this centre is administered alemtuzumab (Campath) which is 
an antibody against CD25 lymphocytes. Thus, all the patients undergo T-cell depletion, 
this is one of the reasons for the limited number of severe aGVHD patients. In this 
study, only one patient had an overall clinical aGVHD grade IV with skin 
histopathological grade III. The remaining patients had either been assessed with 
aGVHD grade I (mild) or II (moderate). Therefore, finding a set of miRNAs that could 
clearly discriminate the severe aGVHD patients with grades III-IV from those with 
grades I was not feasible experimentally. Statically, it was possible to test for trends 
that showed miRNA deregulation could be characteristic of aGVHD severity.  
 
It is well known that inflammatory lymphocyte infiltrates and necrosis are the immune 
system hallmarks of cutaneous aGVHD. Keratinocyte apoptosis is also one of the main 
distinguishing factors. It has been shown in a single centre; homogeneous underlying 
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disease population (Fanconami anemia) that increased apoptosis was related with 
aGVHD severity. Not surprisingly, miR-34a-5p showed the most significant trend 
towards over-expression with regards to aGVHD severity. The authors also showed 
that it was miR-34a expression that was linked to higher epithelial apoptosis.  
 
In contrast to the study mentioned above, it was thought appropriate to test the 
relationship between the number of necrotic cells, inflammatory cells infiltrates, 
cutaneous aGVHD severity and miRNAs. There was no direct positive correlation 
between any of the miRNAs and the number of cell infiltrates or necrotic cells. But, 
there was direct negative correlations between miR-24a (interfollicular keratinocyte 
differentiation), miR-200b (fibroblast proliferation) and 23b (keratinocyte 
differentiation), all of which have been shown to exhibit extensive roles in skin 
morphology (Hildebrand et al., 2011; Amelio et al., 2013; Li et al., 2014a). MiR-24 is a 
polycistronic miRNA and is localized on two chromosomes 9 (mir-23b, mir- 27a and 
mir-24-1) and 19 (mir-23a, mir-27a and mir-24-2) (Amelio et al., 2013; Kozomara and 
Griffiths-Jones, 2014). However, its mature passenger strand miR-24-3p has the same 
sequence when produced from either of the clusters. This finding further supports the 
hypothesis that miR-24-3p and miR-23b are reflecting the inflammatory skin status 
through the imbalance in keratinocyte differentiation or apoptosis. To confirm this 
hypothesis, it might be interesting to detect keratinocyte apoptosis. Interestingly, the 
number of necrotic cells positively correlated with skin histopathological aGVHD grade 
which might be as a consequence of the conditioning and prophylaxis treatments as 
well as GVH reaction. There was also borderline significant positive correlation 
between the number of necrotic and inflammatory cell infiltrates. Infiltration of 
lymphocytes is indicative of inflammation or infection; however, none of the patients 
had infection at the time of biopsy collection. This could be due to the lymphocytes 
infiltrating the skin tissue post allo-HSCT during the GVH reaction and undergoing 
apoptosis.   
 
Three of the miRNAs in the validation cohort are polycistronic with more than one 
miRNA being encoded by the same gene. Let-7c-5p is both part of the let-7c family and 
let-7c-mir-99a cluster, and its gene localized to chromosome 21(Griffiths-Jones et al., 
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2006; Kozomara and Griffiths-Jones, 2014). MiR-503 is also a polycistronic (mir-424, 
mir-503, mir-542, 450a-1/2, 450b) miRNA and derived from the mir-424-503 precursor 
miRNA. The gene for the miR-424-503 cluster is located on chromosome X (Griffiths-
Jones et al., 2006; Kozomara and Griffiths-Jones, 2014). Chromosome 16 encodes the 
gene for miR-365a which is again a polycistronic miRNA (mir-365a and mir-193b) 
(Griffiths-Jones et al., 2006; Kozomara and Griffiths-Jones, 2014). MiR-34a was the only 
monocistronic miRNA and a member of the miR-34 family and its gene located on 
chromosome 1 (Griffiths-Jones et al., 2006; Kozomara and Griffiths-Jones, 2014). 
This study has shown that let-7c-5p expression increases after transplantation. But it 
was surprising to find out that its levels were approximately the same as that of 
normal controls in skin biopsies with histopathological grades II-III. Survival analysis 
also showed that let-7c-5p expression was protective against relapse. To better 
understand its role in transplantation, the patient characteristics was studied, and it 
was found that only one out of six patients with skin histopathological grade II-III had 
relapsed. Thus, let-7c-5p might be a marker for GVT effect rather than GVHD both 
because of its normal levels in moderate-severe aGVHD patients and also it protective 
role against relapse. Studies have shown that let-7c-5p is highly expressed in CD4+T 
cells in healthy individuals (Swaminathan et al., 2011). Results in the normal controls 
were, therefore, in concordance with this study, despite studying let-7c-5p expression 
in the whole skin rather than a subset of cells. Swaminathan et al., (2011) have shown 
that the expression of IL-10 protein could be modulated by let-7c-5p. IL-10 is an anti-
inflammatory cytokine that has been extensively studied in GVHD (Lin et al., 2005). At 
this stage, it could be postulated that let-7c-5p might play a role in immunoregulation 
rather than GVHD.   
In this study, miR-503-5p was also overexpressed in the skin with histopathological 
aGVHD grades II-III in comparison to pre-transplant biopsies. Interestingly, its 
expression levels had a direct impact on OS, with lower expression of this miRNA 
improving survival. MiR-503 has been shown to regulate CD40 gene expression 
negatively when malignant human monocyte-derived cells (U937 cells) were irradiated 
(Cheng et al., 2012). The function of CD40-CD40 ligand (CD40L) pathway has been 
investigated in GVHD models (Durie et al., 1994). T and NK cells are activated when 
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CD40 and CD40L ligate as this results in the release of established pro-inflammatory 
cytokines such as IFN-γ, IL-2 and IL-12 (Briones et al., 2011). Studies have shown that 
anti-CD40L antibodies can decrease GVHD severity (Durie et al., 1994). Activated CD4+ 
T-cells express CD40L that can be targeted by anti-CD40L antibodies. These antibodies 
block CD4+ T-cells, thus making them tolerant to host antigens and result in lower 
GVHD(Blazar et al., 1998). Moreover, CD40 is also expressed in human keratinocytes in 
the skin (Denfeld et al., 1996). Since, miR-503 and miR-424 are polycistronic they have 
very similar seed sequences. As a result, they have been shown to target the same 
genes and also be involved in the monocyte to macrophage differentiation in an AML 
cell line study (Forrest et al., 2010). In a GVHD related study, the investigators showed 
that miR-424 levels are higher in cord blood CD4+ and CD8+ cells when compared to 
adult peripheral blood cells (Takahashi et al., 2012). The authors also showed that miR-
424 was over-expressed in adult blood CD14+ monocytes when compared to CD4+ and 
CD8+ T cells (Takahashi et al., 2012). It is known that during inflammation monocytes 
are recruited to the affected site and differentiate to either macrophages and/or DCs 
(as reviewed by (Ginhoux and Jung, 2014)). Several mechanisms of action could be 
proposed for miR-503-5p and its role in allo-HSCT and GVHD. Firstly, it could be 
overexpressed to target CD40 gene expression and thus inhibit T cell activation. 
Secondly, miR-503-5p expression levels might be up-regulated as more monocytes are 
recruited from the blood to host skin tissue.  
Likewise, miR-365a-3p was under-expressed post-transplantation. Xu et al (2010) have 
shown that miR-365a-3p is a negative regulator of IL-6, which is a cytokine involved in 
the control of immune responses (Akira et al., 1990; Xu et al., 2011). Studies have 
demonstrated that IL-6 levels are elevated at the time of aGVHD onset in the sera of 
patients (Symington et al., 1992). Skin fibroblasts have also been shown to express IL-6 
under inflammatory conditions (Koch et al., 1993). It may be possible that because 
miR-365a-3p decline post-transplant, IL-6 levels increase in the aGVHD patients. 
MiR-34a-5p was significantly differentially expressed between pre-transplant and 
Grade 0-I as well as Grade II-III skin biopsies (p<0.01). However, no significant 
difference was observed between mild and moderate aGVHD independent of the 
aGVHD grading system (overall clinical or skin histopathological) used for the analyses. 
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Results suggested that miR-34a-5p was up-regulated as a result of the allo-HSCT as 
well as inflammation due to GVHD. MiR-34a-5p was selected as the most suitable 
candidate for further investigation in order to determine its function in allo-HSCT and 
skin GVHD as; (1) results from the validation study of miR-34a-5p were promising in 
this cohort, (2) it was determined by miRwalk miRNA target prediction databases to 
target the GVHD associated genes previously identified by Norden et al (unpublished 
data) and (3) it is reported in the literature to be involved in GVHD severity of the gut 
(Wang et al., 2013).  
The penultimate hypothesis was that the miRNA expression in post allo-HSCT patients 
is associated with survival outcome. Therefore, to test it, validated miRNA expression 
levels from all the 12 miRNAs were included as variables in predicting post allo-HSCT 
outcomes (OS and relapse) in addition to the clinical risk factors that were identified as 
significant from univariate analysis.  
The relationship between graft source (PBSC/BM) has been studied previously with 
reports indicating higher aGVHD risk for patients who had received PBSC with no 
improvement on survival outcome (Eapen et al., 2007). Currently, PBSC is the most 
common graft source, and this was reflected in the patient cohorts evaluated in the 
skin survival study. In this study also there was no association between graft source 
and allo-HSCT outcome in particular since the majority had received PBSC. Historically, 
patient age has been associated with poor survival outcome (Lowenberg et al., 1999) 
but with the changes in the transplant protocol more elderly patients are transplanted. 
In this study, the median age was greater than 45 years that by default scored the 
patients as high risk. Therefore, the age range of the EBMT risk score was not 
applicable in this cohort.  
The comprehensive survival study supported the hypothesis as it showed that low 
expression levels of miR-503-5p and miR-34a-3p was indicative of improved OS 
outcome. Additionally let-7c-5p was associated with relapse and its expression had a 
protective effect. Quasi-complete separation was also observed in the expression 
levels of let-7c-5p that re-iterated its association with relapse. Competing risks analysis 
is performed to determine the probability of failure for a particular cause (event) in the 
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presence of other causes at a specific time-point post-HSCT. It was not feasible to 
perform competing risk analysis due to the few cases present per group.  
To test the final hypothesis that miRNAs' interactions exist under pathophysiological 
conditions, all the miRNA expression levels were analyzed with advanced statistical 
tests (ordinal logistic regression, GLM). The finding that a significant interaction was 
present between miR-503-5p and miR-34a-3p and that it was distinctly evident when 
survival status was added onto 3D plots for visualization further supported the last 
hypothesis. 
Studies have reported global profiling of miRNAs in plasma of patients with various 
aGVHD grades. The signature list of miRNAs identified in the study by Xiao et al (Xiao et 
al., 2013) in the plasma of allo-HSCT patients do not correspond with the list of 
miRNAs differentially expressed in this research (miR-423, miR-199a-3p, miR-93*, and 
miR-377). Numerous investigations have shown that miRNAs are cell and tissue 
specific (Allantaz et al., 2012). Thus, the lack of overlap between the two miRNA 
studies in skin and plasma support the cellular specificity of miRNAs. To my knowledge 
this is the only study that has investigated the expression of miRNA in the skin biopsy 
of aGVHD patients.  
Skin is comprised of several different cellular layers. The uppermost layer is the 
epidermis that protects the body from harmful external attacks. Below is the dermis 
which contains APCs and lymphatic vessels. In this study whole skin biopsies were used 
for miRNA expression analysis (Pasparakis et al., 2014). However, aGVHD mainly 
attacks the epidermal layer of the skin (Hofmeister et al., 2004). Thus, the miRNA 
expressions observed are collective and may decrease the discriminatory specificity of 
the results. In addition, the proportion and types of cells in the epidermis and dermis 
are different. Dispase treatment is required to separate the epidermis from dermis. 
The effect of the dispase treatment on miRNA expression is unknown. Thus, it may be 
essential to assess the miRNA expression levels separately in each of the layers as well 
as the whole skin but to take into consideration the impact of dispase on the miRNA 
levels. 
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Furthermore, some of the patients in this cohort had sex-mismatched allo-HSCTs. The 
current finding of this study is not able to demonstrate whether miRNA expressions in 
the skin cells are recipient or donor origin. This issue may be partially addressed by a 
follow-up study showing the chimerism in skin sections and comparing it to miRNA 
expression results. However, the level of chimerism would only represent 
haematopoietic cells and their contribution to the overall miRNA expression.  
In summary, this research has shown that miR-34a-5p, miR-503-5p, let-7c-5p and miR-
365a-3p expression levels may be deregulated as a consequence of the transplant 
procedure (treatment) and the pathogenesis of aGVHD. Further investigation into the 
experimentally validated targets of miR-503-5p, let-7c-5p and miR-365a-3p may shed 
light on their impact at the protein level and their immunoregulatory roles in 
maintaining skin homeostasis. The targets of miR-503-5p, let-7c-5p and miR-365a-3p 
were not studied in this project due to time constraints. Thus, measuring the protein 
targets IL-10, IL-6 and CD40 were out of the scope of this investigation. MiR-34a-5p 
was the most significant miRNA in this investigation and selected for protein target 
investigation to elucidate its pro-apoptotic role in aGVHD, as pointed out in a recent 
literature (Ebner and Selbach, 2014). These preliminary results on allo-HSCT outcome 
based on the expression of miR-503-5p, miR-34a-3p and let-7c-5p are promising.  
Overall, the result from the miRNA expression in the skin study is preliminary and is, 
therefore, only suggestive of their associations with allo-HSCT outcome. The results 
need to be validated in a larger, multicentre cohort to eliminate the impact of peri-
transplant risk factors on the significance of the results. Also, access to cutaneous 
biopsies with severe aGVHD grades can further elucidate the role of the validated 
miRNAs in GVHD.  
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 Chapter 5. The functional role of miR-34a in allogeneic 
haematopoietic stems cell transplantation 
 
 
 
 
 
 
“The journey of a thousand miles begins with one step.” 
-Lao Tzu 
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5.1 Introduction  
 
In Chapter 4, a global miRNA profiling experiment was performed to identify miRNAs 
associated with aGVHD incidence and severity. A signature miRNA list was identified 
and then validated by RT-qPCR. Results showed that miR-34a had the highest 
association with aGVHD severity based on the results of Chapter 4 and thus, was 
selected as the candidate miRNA for further downstream investigations.  
MiR-34a has been extensively studied in numerous diseases and has established roles 
in cancers of the colon, lung, liver, myeloma and leukaemia (as reviewed by (Li et al., 
2014b)). Currently, a phase I clinical trial (NCT01829971) that aims to restore miR-34a 
levels in liver cancer is ongoing. MiR-34a is a member of the highly conserved miR-34 
family which comprises of two other miRNAs; miR-34b and miR-34c. However, miR-34a 
is transcribed from a single gene (monocistronic) encoded on Chromosome 1, whereas 
miR-34b and miR-34c are transcribed from the same gene (polycistronic) on 
Chromosome 11 (Li et al., 2014b) (Figure 1). All three members have the same miRNA 
seed sequence. Thus, they may regulate the same protein targets. The promoter 
regions of both miR-34 genes have a binding site for the tumour suppressor protein 
p53(He et al., 2007). In addition, CpG regions lie upstream of miR-34 genes and 
comprise areas of linear sequences wherein the cytosine and guanine nucleotides are 
separated from one another by just one phosphate molecule. Studies have shown that 
miR-34a is regulated in various ways; (i) genomic deletion (Attiyeh et al., 2005), (ii) 
methylation of the CpG region (Lodygin et al., 2008) and (iii) by transcription factors 
(Raver-Shapira et al., 2007). 
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Figure 5.1 Chromosomal location of miR-34 family (adopted from (Li et al., 
2014b)). MiR-34a is transcribed from its gene on Chromosome 1 while miR-34b/c is 
encoded on Chromosome 11. The genomic loci of all the three members are Exon 2 
(E2). The CpG regions are present prior to Exon 1 (E1) on Chromosome 1 while 
between E1 and E2 on Chromosome 11. Blue represents the miRNA hairpins. The p53 
binding site is denoted by the black line which is upstream of E1.  
 
A well-established transcriptional factor that regulates the miR-34 family is p53 (Raver-
Shapira et al., 2007). This is due to the p53 binding site present upstream of the miR-
34 family genes (Raver-Shapira et al., 2007). Reduced expression of miR-34a is 
commonly reported in cancers (lymphoma, colorectal) (Roy et al., 2012; He et al., 
2013). Both miR-34a and p53 are proapoptotic and therefore may play a crucial role in 
the prevention of cancer (Raver-Shapira et al., 2007; Wiggins et al., 2010). P53 is 
central to the apoptotic pathway as it stops cells in the G1 phase of the cell cycle to 
prevent extension of DNA damage (Yonish-Rouach et al., 1991). P53-mediated 
apoptosis occurs when the DNA damage cannot be repaired (Levine, 1997). It activates 
the miR-34 family, and this contributes to the promotion of apoptosis (Raver-Shapira 
et al., 2007). In addition to activating miRNAs, p53 also plays a central role in the 
miRNA biogenesis pathway. In embryonic fibroblasts loss of Dicer1 (the enzyme 
essential for the production of the mature form of microRNAs), results in the 
development of p53 expression (Mudhasani et al., 2008). P63 that is also a member of 
the p53 family regulates the expression of Dicer1 (Su et al., 2010). P63 is 
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overexpressed in the epithelial cells of the skin and is required for the proliferative 
function of epithelial stem cells (Senoo et al., 2007). In all, p53 is reported to control 
miRNA transcription, processing as well as miRNA target selection, as reviewed by 
(Rokavec et al., 2014). In a study focused on aGVHD, miR-34a was shown to have a 
proapoptotic potential (Wang et al., 2013). Patients with severe aGVHD had 
overexpression of miR-34a that correlated with the number of apoptotic cells counted 
in the patients gut tissues (Wang et al., 2013). Moreover, miR-34a triggers the 
expression of p53 and Sirt1 (Yamakuchi and Lowenstein, 2009). Therefore, the 
convincing results of the afore mentioned  (Wang et al., 2013) study and the over-
expression of miR-34a observed in Chapter 4, prompted further protein investigation 
of p53 by immunohistochemistry. The protein expression was, therefore, investigated 
in the same cohort discussed in Chapter 4, both in the pre- (n=5) and post allo-HSCT 
subjects (n=17). The skin FFPE block for one of the pre-transplant specimens was 
absent, hence sample size was reduced to five. 
As mentioned earlier, p53 activates miR-34a and they both have proapoptotic 
functions. A recent proteomic study had shown that miR-34a suppresses c-MYC 
expression (Ebner and Selbach, 2014), this targeting can also be found by looking at 
the alignment sequence of the MYC gene on microrn.org. Interestingly, c-Myc has 
numerous functions in haematopoiesis such as regulating the HSCs regeneration and 
differentiation (Wilson et al., 2004). c-Myc protein is a transcription factor that is 
constitutively expressed in many tumours (Jackstadt and Hermeking, 2014). c-Myc also 
impacts miRNA biogenesis steps in the nucleus (Jackstadt and Hermeking, 2014). It 
directly binds upstream of the miRNA gene, in the promoter region and regulates the 
transcription of the primary miRNA (Jackstadt and Hermeking, 2014). It can also 
repress miRNA generation via activating genes, such as Lin28, that inhibit the 
enzymatic processing of the miRNA (Chang et al., 2009). Transcription of Drosha can be 
impaired by c-Myc that again impacts on miRNA processing (Wang et al., 2013). 
Interestingly, c-Myc, p53 and miR-34a are all involved in the p53 pathway and the 
epithelial-mesenchymal transition network (Hahn et al., 2013). To better understand 
the role of miR-34a in post allo-HSCT outcome, c-Myc protein expression was also 
investigated via immunohistochemistry.  Figure 5.2 summarizes the interlinked 
regulation mechanisms of p53, miR-34a and c-Myc. In the context of allo-HSCT, p53 
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deficient mice that develop aGVHD have a better overall survival when compared to 
mice with at least one copy of the gene (Yada et al., 2005). In this study, p53 promoted 
the activation of the death cell receptor, Fas that resulted in cellular toxicity and death 
in mice (Yada et al., 2005). 
 
Figure 5.2 MiR-34a interactions with p53 and cMyc (adopted from (Ebner and 
Selbach, 2014)). P53 activates miR-34a expression that targets c-Myc. MiR-34a can also 
activate p53 expression via Sirt1 (Yamakuchi and Lowenstein, 2009). Activation: ↑ and 
inhibition:        .           
 
5.1.1 Study hypothesis 
MicroRNA targets are usually predicted using online databases such as microrna.org 
(Betel et al., 2008) as mentioned in Chapter 1. The mRNA target levels may be 
determined using RT-qPCR and the corresponding protein levels by ELISAs (serum), 
immunocytochemistry (cells) or immunohistochemistry (tissues) depending on the 
target site (Bentwich, 2005).  
In this Chapter, the expression levels of both miR-34a-5p and miR-34a-3p were tested 
for association with p53 and c-Myc protein expression (Figure 5.3, A). MicroRNA 
passenger strands (-3p) also share the same seed sequence as the guide strands (-5p) 
and this may lead to co-regulation of the target mRNAs (Ebner and Selbach, 2014). 
Therefore it was essential when assessing the relationships between miRNAs and 
protein targets, to test for both miR-34a (-5p and -3p) strands. MiR-34a expression 
levels were up-regulated post allo-HSCT and there was a significant trend with regards 
to aGVHD severity (Chapter 4). GVHD is mediated by the triggering of alloreactive T 
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cells and their proliferation that initially occurs in the lymphoid organs and their 
subsequent translocation into tissues such as the skin (Reddy and Ferrara, 2003). It 
was hypothesized that inhibition of miR-34a expression using miRNA inhibition 
approach in an allogeneic MLR may result in lower T cell proliferation and that this 
could be indicative of miR-34a involvement in aGVHD development and severity 
(Figure 5.3, B). Thus, miRNA inhibitors were used to compete with the endogenous 
miRNA in the RISC complex for binding to the 3’ UTR of the mRNA target.  
  
Figure 5.3 Chapter 5 study hypothesis. (A) P53 and c-myc protein expression 
levels are regulated by miR-34a expression. P53 and c-Myc expression levels were 
detected in skin by immunohistochemistry (B) T-cells proliferation is lowered by miR-
34a inhibition. MiRNA inhibitors that competed with miR-34a levels were used for the 
inhibitory experiments. T-cell proliferation was detected by 3H Thymidine assay. 
Activation: ↑ and       inhibition:      .           
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5.1.2 Specific study aims 
 
The aims of this investigation were as follows; 
1. To test whether miR-34a expression correlated with p53 and/or c-Myc protein 
expressions.  
2. To test whether miR-34a expression is involved in alloimmune response.   
3.  To conduct a preliminary investigation into the influence of miR-34a inhibition.  
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5.2 Results 
 
5.2.1 Study cohort 
 
MiR-34a protein targets; c-MYC and p53 were quantified in the aGVHD clinical skin 
biopsies with grades 0-III (n=17), as well as pre-transplant samples (n=5), via 
immunohistochemical methods.  
In brief, for miR-34a inhibition experiments, transfection was initially optimised using a 
miRNA inhibitor hairpin transfection control (C. elegans non-targeting sequence) 
conjugated to a fluorescent tag (Dy547) to monitor levels of transfection efficiency. 
The miRNA inhibitor is complimentary to the endogenous miRNA sequence and 
therefore binds to the strand and prevents its loading onto the RISC complex. 
Electroporation was used for the transfection of PBMCs with the miRNA inhibitors and 
the negative control (for more details, see Chapter 2, Section 2.9.4). 
 
5.2.2 Data analyses 
 
The miR-34a-5p and miR-34a-3p expression values that were determined by RT-qPCR 
in the previous chapter (Chapter 4) were used for the correlation statistics. For details 
on the patient's characteristics, please see Chapter 4, Table 4.7.  
The ‘quick score’ which is a semi-quantitative method was used for assessing the 
percentage of positively stained cells for both p53 and c-Myc proteins and a consensus 
score (average of two assessments) calculated as each section was assessed by two 
independent researchers, who were blinded to the origin of the samples.. The score 
for each biopsy was calculated by considering both the intensity and the proportion of 
cells within that intensity (for more details see Chapter 2, Section 2.12.2). The whole 
section was used for calculating the percentage positivity scores. Since miR-34a 
expression was quantified in both the epidermis and dermis, quick scores were 
calculated (1) for the entire section regardless of the layer and (2) in each layer 
individually.  
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5.2.3 Immunohistochemical analyses of c-Myc and p53 proteins 
5.2.3.1 c-Myc and p53 positive-cells were present in cutaneous 
biopsies of allo-HSCT patients   
 
Immunohistochemical analysis was performed to test whether c-Myc and p53 proteins 
were expressed in cutaneous biopsies from allo-HSCT patients pre- and post-
transplantation. Levels were associated with different skin histopathological aGVHD 
grades. Imaging and analysis of the skin sections showed that the majority of c-Myc-
positive cells particularly those with high c-Myc intensity were present in the basement 
membrane of Grade 0 and Grade I aGVHD biopsies. In Grade II and Grade III, the 
complete epidermis was stained positive for c-Myc and very few negative ones. A 
limited number of cells demonstrated cytoplasmic only staining for c-Myc, while 
majority showed both cytoplasmic and nuclear staining. In general, the percentage of 
cells (positive and negative stained) that were present in the dermis was very low (4%) 
but as aGVHD severity increased from no aGVHD to Grade III, more cells were 
observed to be infiltrating the dermis (Figure 5.4).  
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 Figure 5.4 Skin sections positively stained for c-Myc protein. c-Myc- positive cells 
had variable expression intensities (low, moderate and high). No aGVHD biopsies had 
high intensity c-Myc-positive cells in the basement membrane, while in grades II-III 
aGVHD positivity c-Myc was observed throughout the entire epidermis. Positive-c-Myc 
proteins were also present in the pre-transplantation cutaneous biopsies. The first row 
shows the two pre-transplantation skin sections that were taken from the individuals 
assessed with cutaneous histopathological aGVHD Grade 0 and Grade I (second row), 
respectively. Breast carcinoma tissues were used as negative and positive controls. 
Grade III skin section exhibited the hallmark signs of severe cutaneous aGVHD with the 
initiation of separation between the epidermis and dermis. The number of cells that 
infiltrated the dermis gradually increased from no GVHD (Grade 0) to severe aGVHD 
(grade III). The images were taken at 20X magnification using AxioCamMR3.  
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 Likewise, cells that positively stained for p53 protein were also analysed for observable 
differences between pre- and post allo-HSCT skin biopsies. Visualization of the sections 
showed positive cytoplasmic-nuclear staining for p53 under all histopathological 
conditions (pre-transplantation to Grade III aGVHD). P53-positive cells were localized 
in the epidermis (Figure 5.5). Under normal conditions p53-positive cells are confined 
to the basement membrane (Baran et al., 2005). There was only an occasional cell in 
the dermis that was p53-positive. The majority of p53-positive cells stained with strong 
to moderate intensity.  
 
 
Figure 5.5 Skin sections positively stained for p53 protein. P53-positive cells were 
present in pre-transplantation skin biopsies but were limited in number. Strong 
positive signal was observed with aGVHD severity. The first row shows the two pre-
transplantation skin sections that were taken from the individuals assessed with 
cutaneous histopathological aGVHD Grade 0 and Grade I (second row), respectively. 
Breast carcinoma tissues were used as a negative and positive control. Grade III skin 
section exhibited the hallmark signs of severe cutaneous aGVHD with the initiation of 
separation between the epidermis and dermis. The number of cells that infiltrated the 
dermis gradually increased from no GVHD (Grade 0) to severe aGVHD (grade III). The 
images were taken at 20X magnification using AxioCamMR3. 
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5.2.3.2 P53 positively correlated with miR-34a-5p expression   
 
The quick scores for c-Myc and p53 cell positivity and the miR-34a (-5p and -3p) 
expression levels were used to perform the Spearman correlation statistics. The total 
allo-HSCT cohort was used for the analyses (n=22). As mentioned earlier, the analyses 
were performed by firstly considering the proportion of positive cells in the entire 
section, followed by the dermis alone and finally the epidermis only.  
In all the studies, results showed that there was no statistically significant correlation 
between miR-34a (-5p and -3p) expression levels and the proportion of c-Myc-positive 
cells (rs=0, p>0.05). There was also no trend in the percentage of c-Myc-positive cells 
and this was confirmed by performing Jonckheere’s trend test (p=0.988). 
The dermis had less than 4% p53-positive cells and was, therefore, considered as p-53 
negative. Thus, for p53, the quick score was calculated only based on the epidermis. 
Interestingly, in the entire cohort (n=22) that included pre-transplant subjects, miR-
34a-5p expression alone positively correlated with the percentage of p53-positive cells 
(rs=0.44, p=0.039) in the epidermis (Figure 5.6, A). In post-allo-HSCT skin biopsies only 
(n=17), there was no significant correlation present between p53-positive cells and 
miRNAs. Non-parametric analysis of variance also showed borderline significant 
difference (p<0.5) between the percentage p53-positive cells pre-transplantation and 
skin histopathological grades II-III. Jonckheere’s trend test confirmed the significant 
(p=0.009) trend towards higher p53-positive cells with aGVHD severity post allo-HSCT.  
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Figure 5.6 p53 expressions in the epidermis positively correlated with miR-34-5p 
expression. The proportion of cells positively stained for p53, (A) correlated in the 
epidermis with miR-34a-5p expression in the clinical skin biopsies (n=22), (B) p53-
positive cells were significantly higher in the epidermis of skin biopsies with severe skin 
histopathological aGVHD grades (II-III) in comparison to pre-transplantation. Spearman 
correlation was used to calculate the coefficient of correlation (rho) = rs. . Kruskal-
Wallis analysis of variance was performed to determine the difference between the 
three groups. Significance was set at p<0.05. 
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5.2.4 Silencing the expression of miR-34a in primary peripheral blood 
mononuclear cells 
 
MiR-34a-5p expression results in Chapter 4 demonstrated an increased expression in 
cutaneous clinical biopsies post allo-HSCT in comparison to pre-transplantation. 
Therefore, to investigate the role of miR-34a its expression levels were inhibited in 
cryopreserved PBMCs using commercially available miR-34a-5p and miR-34a-3p 
specific inhibitors. Since miR-34a is expressed in several T cell subsets, PBMCs were the 
ideal source to perform the transfection study as it permitted the impact of inhibition 
to be investigated at a larger magnitude rather than a particular cell subset. In 
addition, current literature has shown that both fresh and cryopreserved PBMCs 
conserve their immune responses when the electroporation is used for transfection 
(Van Camp et al., 2010). 
The experiments in this section aimed to optimise the transfection technique that is 
required for functional confirmation of the findings of this thesis using in vitro 
techniques. For in vitro functional investigations, miRNA transfections were optimised, 
and their knockdown impact on T-cells investigated. The in vitro skin explant model 
was also evaluated, to test whether it could be employed for extended functional 
studies.  
5.2.4.1 PBMCs were viable post-transfection 
 
PBMCs were electroporated using three different voltages (330, 340 and 350 V) for 
transfection with the negative miRNA control. To ascertain that the PBMCs were not 
affected by electroporation, viability was assessed by standard cell counting methods 
(Trypan-blue exclusion) every 24 hours after transfection for up to six days. Cell 
viability was ≥ 89.9% in the transfected PBMCs (Figure 5.7). Pre-B 697 (leukemic cell 
line) was used as the positive transfection control and had a mean viability of 80.4%. 
Post 96 hours their viability had a sharp decline as the cells had reached post-
confluence stage. PBMCs that were not electroporated were also cultured for six days 
as the microenvironment control and had a mean viability of 87.7%.  Results showed 
that PBMCs eletroporated at 330Vs had the highest viability.  
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 Figure 5.7 PBMCs were viable post- transfection. PBMCs were electroporated at 
three different voltages and cultured for six days to determine their percentage 
viability after electroporation and transfection. PBMCs were also cultured alone as a 
microenvironment control, and PreB697 was used as a positive control. The mean 
viability in the six days period is shown in the table and was highest for cells 
electroporated at 330 Vs. 
 
5.2.4.2 PBMCs had the optimal transfection when electroporated at 
350Vs 
 
The optimal voltage for electroporation of the PBMCs was determined based on the 
percentage of cells transfected at three different voltages (330, 340 and 350 Vs). 
Transfection efficiency was determined based on the percentage of cells-positive per 
field of view.  At 330 V and 340V, the transfection efficiencies were 40 and 38.7%, 
respectively. The optimal voltage was assessed as 350 Vs as the transfection efficiency 
was the highest at 60% (Figure 5.8).  
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 Figure 5.8 Optimisation of the electroporation using different voltages. PBMCs 
were transfected using miRNA inhibitor transfection control (500 nM) labelled with 
Pierce Dy547. Three different voltages were used for electroporation. Transfection 
efficiency at each voltage setting (A-C) 40% at 330 V, (D-F) 38.7 % at 340 V and (G-I) 
60% at 350 V. The highest transfection was achieved at 350 Vs. The images were 
acquired using two filters after 24 hrs of transfection. The blue colour showed the 
staining with DAPI and the red colour for Pierce Dy547. The merged images show the 
transfected cells in pink and the blue nuclei. All the images were acquired at 20X 
magnification. The arrows show the representative transfected cells.  
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 5.2.4.3 PBMCs had the highest transfection when 500 nM of miRNA 
inhibitor was used  
 
The optimal concentration of miRNA inhibitor for transfection was also determined by 
using three different set concentrations of the inhibitor control (250, 500 and 750 nM). 
Using 250 nM and 750 nM of inhibitor, the transfection efficiencies were 10 and 30%, 
respectively. The optimal concentration was assessed as 500 nM as the transfection 
efficiency was 45% (Figure 5.9). There were a lot of background when using 700 nM 
that were due to the non-transfection of the inhibitor control.  
 
Figure 5.9 Optimisation of the transfection using different concentrations of the 
inhibitor. Optimal transfection was achieved with 500 nM of miRNA inhibitor control. 
PBMCs were transfected using miRNA inhibitor transfection control (350 V) labelled 
with Pierce Dy547. Three different concentrations were used for transfection; (A-C) 
250 nM, (D-F) 500 nM and (G-I) 750 V. The highest transfection was achieved at 500 
nM. The images were taken using two filters after 24 hrs of transfection. The blue 
colour showed staining with DAPI and the red colour for Pierce Dy547. The merged 
images show the transfected cells in pink and the blue nuclei. All the images were 
taken at 20X magnification. The arrows show the transfected cells.   
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5.2.4.4 Preliminary miR-34a knockdown results 
 
Both miR-34a-5p and miR-34a-3p were inhibited in responder PBMCs using the 
optimised settings: 500 nM concentration of miR inhibitor and 350 V. Cells were 
harvested after 24 hours, RNA extracted and miR-34a levels assessed by RT-qPCR. 
Results showed that miR-34a-5p had a significantly higher level of knockdown  relative 
to that of a non-targeting miRNA-construct, with 17.43%, SEM ± 3.4% (p<0.0001; 
paired t-test) residual miR-34a-5p remaining (Figure 5.10, A). By contrast, using the 
same optimised settings, miR-34a-3p failed to be knocked down significantly with 
71.95% ± 10.92% (SEM) residual miR-34a-3p remaining when compared to that of the 
negative control. These results are preliminary and showed that miR-34a-5p could be 
inhibited significantly in PBMCs using a miRNA-specific inhibitor that competes with 
the endogenous miRNA. However, miR-34a-3p-knockdown in PBMCs requires further 
work to achieve optimal miRNA-reduction for future functional work. 
 
Figure 5.10 MiR-34a-5p was significantly inhibited in primary PBMCs. PBMCs were 
seeded at 1x107 cells/ml and electroporated at 350 V with a miR-inhibitor 
concentration of 500 nM. Both strands of miR-34a (-5p and -3p) were knocked-down 
separately, using strand-specific miRNA inhibitors.  Following a 24 hr incubation, cells 
were harvested, RNA extracted and RT-qPCR performed to assess the miR-34-5p and 
miR-34-3p expression. Data shows mean levels of expression ±S.E.M of miR-34-5p 
(n=5; A) and miR-34-3p (n=2; B) expressed relative to the negative, inhibitor control. 
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5.2.4.5 Preliminary miR-34a-5p functional impact on T cell 
proliferation 
 
To assess the functional ability of responder cells when endogenous miR-34a-5p 
incorporation into the RISC complex was inhibited, mis-matched MLRs (n=2) were 
established and T cell proliferation was measured using the standard 3H-thymidine T 
proliferation assay (Figure 5.11). Briefly, the 3H-thymidine works by incorporating 
radioactive nucleoside thymidine into the DNA of dividing cells during cell division and 
the amount of radioactivity is proportional to the number of proliferating cells. Auto-
MLRs were also set-up as the negative control for the MLRs. PBMCs were transfected 
as described above, using either the miR-34a-5p inhibitor or the non-targeting miRNA, 
and allowed recovery for 24 hours before co-incubation with an irradiated stimulator 
PBMC. After four days incubation, 3H-thymidine was added and 18 hours later, the 96-
well plate was harvested and each well was measured using a scintillation beta-
counter. The preliminary results showed that the miR-34a-5p knockdown in responder 
PBMCs had the potential to reduce T cell proliferation in an allogeneic reaction, when 
compared to PBMCs transfected with a non-targeting miRNA inhibitor. It was not 
possible to calculate an accurate percentage of T cell inhibition as the sample size was 
very small (n=2). 
 
 
 
192 
 
 Figure 5.11 MiR-34a-5p knockdown may result in lower T cell proliferation. T cells 
were tested for their proliferation ability when responder T cells were knocked-down 
in mismatched (n=2) and auto-MLRs, respectively. PBMCs were seeded at 1x107 
cells/ml and electroporated at 350 V with a miR-inhibitor concentration of 500 nM. 
MiR-34a-5p was knocked-down using strand-specific miRNA inhibitor.  
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5.2.4.6 MiR-34a expression was not differential in the in vitro skin 
explant model with regards to GVHR severity 
 
The in vitro human skin explant assay is a very useful research tool for investigating the 
expression of miRNAs, genes and/or the impact of drugs on the allogeneic response 
and the influence on GVHR severity. To test whether miR-34a expression was due to 
the MLR or the severity of the GVH reaction, the levels of both miR-34a strands (-5 and 
-3p) were quantified in time-course in vitro skin explant experiments (n=3-6). Results 
showed that both miR-34a strands were not significantly differentially expressed in the 
skin with GVHR grades II-III. The mean expression level of miR-34a-5p (-2.9) was higher 
when compared to miR-34a-3p (-9.4) levels in the in vitro skin explant assay. The same 
pattern of expression was also observed in the post allo-HSCT skin biopsies (mean 
expression of miR-34a-5p= -1.8 and miR-34a-3p=-6.4). 
 
 
 
 
 
 
Figure 5.12 MiR-34a expressions in the skin explant model. Mis-matched in vitro 
skin explants were set up (n=3-6) for three days. MiR-34a expression was quantified by 
RT-qPCR on skin that was taken from the patient directly (Day 0) and added to the skin 
explant model. Skin biopsies were graded for GVHR by two independent researchers, 
blindly. Skin in medium only (MED) was the experimental control. All Day 1 skin 
biopsies (n=3) had grade I GVHR, and Day 3 (n=6) were assessed as grade 3 GVHR. Both 
(A) miR-34a-5p and (B) miR-34a-3p did not show any deregulation in expression under 
any condition. Kruskal-Wallis ANOVA was performed for all expression analyses.  
 
 
 
A B 
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5.2.4.7 Stimulation with Cyclosporine A had no direct impact on miR-
34a expression levels 
 
Since no difference in miR-34a expression levels were found in the in vitro skin explant 
model between biopsies collected pre-transplantation (Day 0), GVHR grade I (Day I) 
and GVHR grades II-III (Day 3), it was hypothesized that the deregulation observed in 
patient biopsies might be due to Cyclosporine A. This is a GVHD prophylaxis treatment 
and routinely administered to allo-HSCT 1-2 days prior to transplantation and 
continues up to several months post-transplantation. Thus, the effect of Cyclosporine 
A on miR-34a expression levels was assessed by setting up mis-matched MLRs co-
cultured with four different concentrations of Cyclosporine A over 96 hrs time-period. 
Mis-matched MLRs were the experiment and unstimulated auto-MLR acted as a 
control for allogeneic response. The set concentrations were selected based on a 
previous study (Petropoulos and University of Newcastle upon Tyne. Institute of 
Cellular Medicine, 2010) that had shown the inhibitory effect of Cyclosporine A on T 
cells using 10 different Cyclosporine A concentrations (2-1000 ng/ml). This study 
showed that using 50 ng/ml approximately inhibited T cell proliferations by 70% and 
incubation with 200 ng/ml resulted in almost 90% inhibition. To try and increase 
inhibition to 100%, Cyclosporine A concentration of 300 ng/ml was included in this 
test. Allo-HSCT patients have their target Cyclosporine A trough concentration at ~200-
250 ng/ml and therefore this was included as one of the doses in this experiment. 
Unstimulated MLRs were also setup without any Cyclosporine A (0 ng/ml) as a negative 
control. Results showed that there was no statistically significant difference in both 
miR-34a-5p and miR-34a-3p expression level with any Cyclosporine A dose (Figure 
5.13).  
195 
 
  
 
 
 
 
 
Figure 5.13 MiR-34a expression is not influenced by Cyclosporine A. Standard 
MLRs (n=3) were set up co-cultured with different doses of Cyclosporine A (50-300 
ng/μl) for 96 hrs. Mis-matched MLRs were the experiments while auto-MLRs acted as 
the negative controls (A) miR-34a-5p expression was not altered by different 
concentration of Cyclosporine A in the MLR reaction (Kruskal-Wallis p=0.909) and (B) 
miR-34a-3p was also not effected by Cyclosporine A (Kruskal-Wallis p=0.980). Allo-
MLR: mis-matched MLRs. 
A B 
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5.3 Discussion 
 
The epidermal layer of the skin is the primary target site for GVHD-mediated damage 
in particular the basal cells that line the basement membrane.  MiRNA target protein 
detection experiments were performed using immunohistochemistry, to understand 
the impact of miR-34a in allo-HSCT procedure and GVHD. Studies have shown the 
existence of a positive feedback loop between p53 and miR-34a (Yamakuchi and 
Lowenstein, 2009). Likewise, c-Myc expression is regulated by miR-34a expression 
(Ebner and Selbach, 2014).  
Thus, both p53 and c-Myc positive-cells were scored in the skin biopsies of patients 
pre- and post allo-HSCT. This study showed that c-Myc and p53 positive-cells were 
present in cutaneous biopsies of allo-HSCT patients. The proto-oncogene c-Myc is 
involved in numerous processes such as differentiation, apoptosis and cellular 
proliferation (Schuhmacher et al., 1999; Pelengaris et al., 2002). However, in this study 
no significant correlation or association was determined between miR-34a and c-Myc-
positive cells.   
P53 has a very short half-life and for this reason immunohistochemical methods are 
mainly able to detect its stimulated or mutated form only (Hainaut and Hollstein, 
2000). Constitutive expression of p53 is present in most cells (Hainaut and Hollstein, 
2000) and it is usually activated only when there is (1) DNA damage, (3) cellular stress 
due to oncogenic proliferation signals that result in the expression of Myc and (4) 
therapeutics (chemotherapy drugs, irradiation) (Lowe and Lin, 2000; Vogelstein et al., 
2000). There was significant positive correlation between p53-positive cells and miR-
34a-5p expression levels only. This result is in support of the p53 positive feedback 
loop with miR-34a (Yamakuchi and Lowenstein, 2009). P53-positive cells were 
observed even in pre-transplantation skin biopsies, and there was a significant trend in 
the score of positive-cells with aGVHD severity. Taken together, these results may 
suggest that pre-transplant activation of p53 is due to the conditioning regimen, which 
is not sufficient to trigger miR-34a-5p overexpression. In the post allo-HSCT skin p53 is 
over-expressed due to the therapeutics as well as the GVH reaction, which leads to 
higher miR-34a-5p expression and therefore their positive correlation. This may also be 
suggestive of the higher incidence of apoptosis observed in severe aGVHD skin. 
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Moreover, miR-34a is also regulated by p63 that is an additional member of the p53 
family. In the skin, p63 is essential for the proliferation of keratinocytes (Senoo et al., 
2007). A study has shown that miR-34a expression is up-regulated in epidermal cells 
when p63 expression is repressed (Antonini et al., 2010). The same study highlighted 
that in murine skin, there was lower miR-34a expression in the hair follicles in 
comparison to the epidermal layer (Antonini et al., 2010). P63 is targeted by another 
skin related miRNA, miR-203 (Lena et al., 2008). This may suggest a stepwise distinct 
regulatory mechanism in the skin whereby miR-203 and miR-34a expression control 
keratinocyte proliferation (Antonini et al., 2010). However, in the cutaneous miRNA 
study in Chapter 4, miR-203 was not differentially expressed. In addition, excessive 
keratinocyte proliferation is not an attribute of cutaneous aGVHD. This further 
supports that miR-34a-5p overexpression may be due to the activation of p53 
apoptosis pathway rather than p63. 
In the context of allo-HSCT and GVHD, TCR are stimulated during the GVH cycle when 
the HLA mismatches are recognized. This results in partial activation of the T-cells 
(Baxter and Hodgkin, 2002). Recently, it has been shown that overexpression of miR-
34a is related to higher T cell activation by TCR. The positive correlation between miR-
34a expression and TCR stimulation has been linked to diacylglycerol kinase-zeta 
(DAGK- ζ), which is an enzyme responsible for metabolising DAG (Shin et al., 2013). 
Lower DAGK- ζ results in higher T cell activation as the cells become sensitive to TCR 
triggers. It has been demonstrated that miR-34a directly targeted DAGK- ζ mRNA and 
therefore this leads to more un-metabolised DAG, which stimulated TCRs leading to 
enhanced T cell activation (Shin et al., 2013). Phorbol myristate acetate (PMA) is an 
analogue of DAG and has been extensively used for the stimulation and activation of 
TCR. To test whether the miR-34a overexpression is also due to TCR activation in 
addition to the overexpression of p53, it would be interesting to use PMA as the 
stimulator and then measure both miR-34a expressions by RT-qPCR and TCR activation 
(CD25+) by flow cytometry. 
To address the question of whether miR-34a inhibition had an influence on T-cell 
proliferation, preliminary optimisation experiments were performed to silence the 
expression of miR-34a in PBMCs. PBMC viability was checked post transfection and 
showed that the introduction of the inhibitors did not increase cell death. PBMCs were 
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shown to be successfully transfected with 500 nM miR-34a-5p inhibitors using 
electroporation methods set at 350Vs. Preliminary T cell proliferation results also 
looked promising as they showed a trend to lower T cell proliferation when miR-34a-
5p was inhibited. However, additional supplementary tests are required in order to 
enable statistical analysis of the percentage T cell inhibition.  
Moreover, miR-34a expression was also tested in an in vitro skin explant model to test 
for differential expression levels as a result of GVHR severity. The results showed that 
the miR-34a expression was not deregulated in the in vitro skin explant model with 
regards to GVHR severity. This result may be suggestive that the deregulated miR-34a 
expression that was observed in the clinical skin biopsies was not due to the allogeneic 
GVH reaction alone, but due to a cumulative effect of the transplantation procedure, 
the GVH reaction and prophylaxis. In all, it may suggest that in order to use the in vitro 
skin explant model to investigate miRNA functional mechanisms, the assay would need 
to be optimised for the respective applications such that it reflects more accurately the 
in vivo conditions.  
As miRNAs are very sensitive and may be affected by prophylactic therapy, MLRs 
stimulated with different doses of Cyclosporine A were set-up.  Interestingly, miR-34a 
expression was not influenced by the different doses of Cyclosporine A even though 
high doses are indicative of increased T cell inhibition which was hypothesized to result 
in lower miR-34a expression. The influence of drugs on miR-34a expression would 
need to be further studied to better understand the metabolism of action in such 
instances.  
In order to better understand the function of miR-34a with regards to T cells, the 
functional work needs to be further extended. This requires the optimisation of miR-
34a-3p such that higher knocked-down percentages are obtained as well as setting up 
assays where both the strands of miR-34a are inhibited. In addition, the miR-34a 
target, p53 needs to be assessed pre- and post-inhibition of miR-34a-5p using RT-qPCR 
to elucidate the downstream impact of inhibition. Luciferase reporter assays could also 
be incorporated into the study to show the direct targeting of p53 by miR-34a-5p. 
In summary, results of this Chapter have shown that miR-34a-5p expression is 
positively correlated with p53-positive cells and that c-Myc may not be a direct target 
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of miR-34a under allo-HSCT condition. The miRNA inhibition experiments have 
established the optimal conditions required for future transfection studies involving 
miRNA inhibitions for allogeneic experimental conditions.  
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 Chapter 6. Expression of MiRNAs with Specific 
Immune Functions in the Whole Blood of Allo-HSCT 
Patients 
 
 
 
“Science is a way to teach how something gets to be known; what is not known; to 
what extent things are known (for nothing is known absolutely); how to handle doubt 
and uncertainty; what the rules of evidence are; how to think about things so that 
judgements can be made; how to distinguish truth from fraud and from show.” 
-Richard Feynman 
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6.1 Introduction  
 
Body fluids such as serum (Mitchell et al., 2008), plasma (Liu et al., 2012), urine (Wang 
et al., 2010), bone marrow (Dostalova Merkerova et al., 2011) and whole blood (Viprey 
et al., 2012) have extensive miRNA profiles that directly pertain to the type of disease, 
its progression and outcome. Moreover, miRNA investigations have identified miRNA 
signatures for numerous diseases such as breast cancer, lymphomas and rheumatoid 
arthritis as well as more recently for GVHD (murine models) (Ranganathan et al., 2012; 
Xiao et al., 2013; Stickel et al., 2014) (for more detail on miRNA-based GVHD 
biomarkers see Chapter 1). Thus, identifying miRNAs that play a significant role in the 
onset and severity of GVHD can assist the monitoring and prognosis of this potentially 
fatal complication. Additionally, finding a signature list of miRNAs to predict GVHD 
onset can help treatment strategies for improved outcomes and reduce healthcare 
costs. Since miR-146a and miR-155 are both involved in the adaptive and innate 
immune system (Lindsay, 2008; Pauley et al., 2008) it was discerned of great interest 
to assess their dual function in allo-HSCT and in particular, aGVHD. The aim was to 
provide a more meaningful picture of their involvement in this pathophysiologically 
complex disease condition.  In this investigation, miRNA expression levels were 
detected in whole blood collected in PAXgene tubs. Whole blood study can be easily 
extended for clinical applications due to less invasiveness of the procedure and the 
reduced sample processing time. Since miRNAs are present in almost every cell type 
and even in extracellular vesicles, such as, the exosomes, whole blood studies provide 
a more complete picture of the deregulation present under normal and diseased 
conditions.  
6.1.1 Immune specific miRNAs: miR-146a and miR-155 
 
MiR-146 plays a role in the immune system. This miRNA is monocistronic, and two 
copies of its genes are present; miR-146a and miR-146b (Labbaye and Testa, 2012). 
MiR-146a gene is located on chromosome 5 while the gene encoding miR-146b is 
located on chromosome 10 (Griffiths-Jones et al., 2006; Kozomara and Griffiths-Jones, 
2014). MiR-146a and miR-146b only differ by two nucleotides which makes them 
structurally similar. MiR-155 is monocistronic and encoded by the bic gene on 
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chromosome 21 (Griffiths-Jones et al., 2006; Lindsay, 2008; Kozomara and Griffiths-
Jones, 2014). There exists comprehensive literature on both miRNAs, as they have 
been studied extensively in numerous biological processes and diseases. This section 
aims to cover the most relevant literature with an emphasis on the mechanisms of 
action that have been thoroughly investigated to-date. 
6.1.1.1 MiR-146a function and known mechanism of action 
 
MiR-146a is essential for Treg function (Lu et al., 2010). Studies in psoriasis showed 
that the miR-146a indirectly affected the tumor-necrosis factor-alpha (TNF-α) pathway 
(Taganov et al., 2006) leading to disease development. MiR-146a has been 
demonstrated to target several genes: IRAK1, TRAF6, IL8, IL6, and CXCR4 (Taganov et 
al., 2006; Bhaumik et al., 2008; Labbaye et al., 2008). TRAF6 and IRAK1 have been 
reported as the primary targets of miR-146a (Taganov et al., 2006) and regulates their 
expression in a negative feedback-loop via the TLR-4 signaling pathway and NFκB 
activation (Taganov et al., 2006; Taganov et al., 2007) (Figure 6.1). TRAF6 exhibits 
important functions in the development and role of various haematopoietic cells (Choi, 
2005) while IRAK1 plays a role in autoimmunity via miR-146a (Deng et al., 2003). 
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 Figure 6.1 MiR-146a negatively regulates TRAF6 and IRAK via the TLR4 signalling 
pathway and NFκB activation (adopted from (Rusca and Monticelli, 2011) and 
(Taganov et al., 2007)). LPS stimulates TL4 receptor which leads to a subsequent 
activation and expression of adaptor molecules, IRAK1 and TRAF6. This results in the 
activation of the IκB kinase (IKK complex) that promotes phosphorylation of the 
inhibitor of kappa B (IκBα). NFκB is then activated and translocates into the nucleus 
propagating miR-146a gene transcription. The pri-miR-146a then undergoes several 
enzymatic processes both in the nucleus and cytoplasm via its biogenesis pathway. The 
mature miR-146a then binds to the RISC complex that directs it to its targets TRAF6 
and IRAK1. Binding of miR-146a either causes mRNA degradation or translational 
inhibition of both targets depending on the particular inflammatory condition (Rusca 
and Monticelli, 2011). In parallel to this negative feedback regulation, the activation of 
adaptor molecules also leads to the transcription of IFN-inducible genes such as 
CXCL10 and CCL5 (Hirotani et al., 2005). The triggering of the TLR signaling cascade can 
lead to control of inflammation as well as its exacerbation when multiple factors cease 
to function normally. 
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 In addition, IFN regulatory factor 5 (IRF5) and signal transducer and activator of 
transcription 1 (STAT1) are known validated targets of miR-146a (Tang et al., 2009).  
Tang et al., showed that over-expression of miR-146a lowered STAT1 and IRF-5 both at 
the molecular and protein level which further confirmed the two genes as targets of 
miR-146a (Tang et al., 2009). In a murine gene expression study of GVHD, it has been 
shown that the levels of Stat1 were elevated post-transplantation and it may be due to 
lower miR-146a expression (Sugerman et al., 2004). Moreover, it has been shown in 
mice that miR-146a depleted Treg cells have high levels of Stat1 and this results in IFN-
γ mediated autoimmunity (Lu et al., 2010) (Figure 6.2). 
 
 
Figure 6.2 MiR-146a is required to prevent Th1-mediated immune response 
(adopted from (Lu et al., 2010)). Phosphorylation of STAT1 is essential for Th1 effector 
cells to differentiate. The effect of miR-146a presence is shown on the left and its 
absence on the right. In the presence of miR-146a in Treg cells, STAT1 expression is 
regulated, and this prevents Th1 mediated immune response. In the absence of miR-
146a, STAT1 is overexpressed, and this propagates Th1 effector cells to differentiate 
excessively, which leads to inflammation in a Th-1 mediated manner. This deregulation 
results in high secretions of IFN-γ both in the Treg cells as well as from Th1 effector 
cells (Lu et al., 2010).  
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 Further studies have also shown that IL-6 and IL-8 are negatively regulated by the 
expression of miR-146a (Perry et al., 2008; Bhaumik D, 2009). MiR-146a also targets 
chemokine receptor CXCR4 (Labbaye et al., 2008). In all, miR-146a has also been 
implicated in the pathogenesis of other autoimmune diseases (Sonkoly et al., 2008) 
such as RA (Pauley et al., 2008) and SLE (Tang et al., 2009) as well more recently in 
mouse GVHD model (Stickel et al., 2014). Table 6.1 shows a summary of the significant 
roles of miR-146a and its various immune-related functions. Hence, one of the primary 
focus of this investigation was on the expression of miR-146a and four of its validated 
targets (IRAK1, TRAF6, STAT1-α and TRAF6) because of their known functions in both 
the adaptive and innate immune system.  
MiR-146a expression and function Validated targets References
Attenuated TLR4 signaling in monocytes IRAK1, TRAF6 (Taganov et al., 2006)
Contributed to the establishment of endotoxin tolerance in monocytes IRAK1, TRAF6 (Nahid et al., 2009)
Desensitized Langerhans cells to inappropriate TLR signaling (Jurkin et al., 2010)
Controlled megakaryopoiesis CXCR4 (Labbaye et al., 2008)
SNP in pre-miR-146a predisposes to papil lary thyroid carcinoma (Jazdzewski et al., 2008)
In GVHD, regulation of TRAF6 in donor T cells Traf6 (Stickel et al., 2014)
Differential expression in Th1/Th2 cells (Monticell i  et al., 2005)
Impaired Treg function in mice lacking miR-146a Stat1 (Lu et al., 2010)  
Table 6.1 Summary of miR-146a functions and relevant, validated targets 
(adopted from (Rusca and Monticelli, 2011)). 
 
6.1.1.2 MiR-155 functions and known mechanism of action 
 
MiR-155 is required for the normal function of B and T lymphocytes in humans 
(Stauffer et al., 2010). Macrophages and DCs also express miR-155 (O'Connell et al., 
2007). In a small cohort (n=5) it has been shown that it is overexpressed in the gut of 
aGVHD patients while expression is absent in normal gut (Ranganathan et al., 2012). 
MiR-155 is necessary for CD8+ T cell proliferation and its deficiency can lead to the 
overexpression of STAT1, which has anti-proliferative functions in T cells (Tanabe et al., 
2005; Gracias et al., 2013). Myeloid cell development encompasses several regulatory 
mechanisms, one of which is miRNA interactions (Figure 6.3). MiR-155 switches the 
differentiation and activation of the cells during this development cycle. It repress PU.1 
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MiR-155 expression and function Validated targets References
B cell  maturation, homeostasis and hematopoiesis  PU.1, SHIP1 (Thompson et al., 2011)
CD4+ T cell  differentiation SOCS1 (Wu et al., 2012)
Acts as oncogene by targeting pro-apoptotic transcripts (Zhang et al., 2014)
Overexpression in the gut of aGVHD patients (Ranganathan et al., 2012b)
that is a primary myeloid transcription regulator (Vangala et al., 2003). Table 6.2 shows 
a summary of the major roles of miR-155 with various immune-related functions. 
Interestingly, this miRNA also prevents IFN-γ signaling in CD4+T cells by targeting IFN-
γReceptor alpha-chain (Banerjee et al., 2010).  
Table 6.2 Summary of mir-155 functions and relevant, validated targets adopted 
from (Tili et al., 2009)) 
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 Figure 6.3 MiR-155 is involved in myeloid cell development (adopted from 
(O'Connell et al., 2010)). Myeloid cell development is regulated by miRNAs and 
transcription factors such as PU.1. CMPs differentiate to GMP that produces 
monocytes and neutrophils. Monocytes then differentiate to macrophages and/DCs. 
MiR-155 targets SHIP1 and PU.1 thereby influencing the differentiation and activation 
of GMP and DCs. Likewise, it can both activate and repress the NFκB pathway. It also 
targets SOCS1 that represses the TLR activation. MiR-146a has a lower impact in 
myeloid cell development and is mainly involved in regulating inflammatory responses 
via TLR (O'Connell et al., 2010). Abbreviations: - CMP: Common Myeloid Progenitors; 
GMP: Granulocyte-Monocyte Progenitors; SHIP (INPP5D): Inositol polyphosphate-5-
phosphatase; PU.1 (SPI1): Spi-1 proto-oncogene; TLR: Toll-Like Receptors; SOCS1: 
Suppressor of cytokine signaling 1; TAB2: TGF-beta activated kinase 1/MAP3K7 binding 
protein 2. IRAK2: Interleukin-1 receptor-associated kinase 2.  
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6.1.2 Specific study aims 
 
In this investigation, the guide strands (-5p) of both miRNAs were studied; i.e. miR-
146a-5p and miR-155-5p.  
The aims of this study were to; 
1. Assess whether the extensively studied immune related miRNAs; miR-146a and 
miR-155 were associated with aGVHD incidence and severity as well as other 
allo-HSCT outcomes such OS, relapse and NRM.  
2. Determine a model for predicting aGVHD incidence and severity using the 
levels of miR-146a and miR-155 expression. 
3. Investigate the impact of miR-146a on its validated targets (IRAK1, TRAF6, 
STAT1-α and IRF5) as well as miR-155 and its target PU.1 
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6.2 Results 
 
6.2.1 Study cohort 
 
In this study, the expression levels of both miR-146a-5p and miR-155-5p were 
determined in whole blood obtained from allo-HSCT patients at pre-transplant (Day-7) 
and post-transplant (Day+28 and three months). This aim of this study was to evaluate 
whether aGVHD incidence and severity could be predicted from pre and post-
transplant miR-146a-5p and miR-155-5p expression values for patients who at the time 
of testing had no aGVHD but later on went on to develop aGVHD grades II-III.  
In brief, whole blood samples were collected in PAXgene™ Blood RNA tubes; these 
stabilize the total RNA content of the blood including the miRNA population. 
PAXgene™ Blood RNA tubes are ideal for miRNA investigations as they provide the 
miRNA content in whole blood rather than distinct cell populations such as PBMCs 
(Viprey et al., 2012). This is clinically relevant, as endosomes that also contain miRNAs 
and granulocytes are lost when PBMCs are collected but may present valuable disease 
signatures (Viprey et al., 2012). Hence, for prognostic biomarker discoveries whole 
blood samples can be more informative than investigating in only specific cell 
populations. MicroRNA expression levels were quantified by RT-qPCR and results were 
log-transformed, both for the exponential nature of RT-qPCR results as well as for a 
normal distribution. The expression at pre-transplant and Day+28 post-transplant was 
used for building the predictive aGVHD model. Expression at three months was 
interesting as it depicted the overall microRNA expression pattern at the 100 days 
aGVHD cut-off period.  
At three months some of the patients were on prophylactic steroids but most patients 
had their Cyclosporine A administration tapered by then. All patients had received 
Campath (anti-CD52) as part of their conditioning regimen. Clinicians assessed aGVHD 
outcome as per the NIH consensus (Grade 0: without, Grade I: mild, II: moderate and 
III: severe aGVHD). Patients that manifested aGVHD within the 100 days’ time-period 
post-allo-HSCT were included in the analyses. At Day+28 none of the patients were on 
steroids nor had they developed aGVHD. The number of patients per time-point varied 
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as at times it was not feasible to collect blood due to the patient’s clinical conditions. 
In this cohort, all the patients survived until day 100, and none had received DLI before 
the Day+28 whole blood collection. The study cohort comprised of whole blood 
collected from patients at seven days pre-transplantation (n=35), 28 days (n=54) and 
three months (n=34) post-transplantation. The cohort consisted of 48% with aGVHD 
(grade 0) and 52% with an incidence of aGVHD (grades I-III). Ten patients in this cohort 
had developed grade II aGVHD and only one patient had developed grade III aGVHD. 
The cohort consisted of patients who had undergone allo-HSCT (2010-2013) from both 
siblings and matched unrelated donors, primarily those who had undergone a reduced 
intensity conditioning regimen (80%). The follow-up period was 44 months for all the 
patients in this study. The median age of patients was 54.5 years (Range: 19.9-67.6), 
and the majority was over 50 years of age. The median age for the controls (grade 0) 
was 57.2 (Range: 30-67.3) and for the cases (grade I-III) was 51.1 (Range: 19.9-67.3). 
There were only five patients with grade I who were below 30 years old. There were 
only seven cases with ‘female donor-male recipient’ in this study. The predominant 
underlying diseases were AML (28%) and MDS (26%). Cyclosporine A levels at Day+28 
were measured with a median 159 ng/ml (Range: 68-333). Cyclosporine A levels were 
missing for 20 (36%) of the patients in this cohort. Incidence of relapse was 30%, and 
survival rate was 61% in the total cohort. Table 6.4 shows the frequency of patients as 
per the clinical characteristics. 
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6.2.2 Data analyses 
 
A multivariate generalized linear model (GLM: see Chapter 2, for more details) was 
used for the prediction of aGVHD incidence and severity in this investigation. Thus, a 
primary univariate analysis of the patient cohort using Fisher’s exact test was 
performed to identify clinical risk factors associated with aGVHD incidence and 
severity. Clinical risk factors were selected based on the difference between the two 
groups and were entered into the model. Fisher’s exact test was chosen as it ensured 
that the p-value was accurate regardless of the size, distribution, sparseness, or 
balance of the data. Clinical factors are considered for multivariate analysis when p-
values are less than 0.1 or 0.2 but as per the EMBT 2013 statistical guideline the 
significance of the factor must be independently assessed (Iacobelli, 2013). After initial 
univariate analysis, potential predictors with a p-value < 0.2 were selected as 
candidates in the variable selection procedure.  The p=0.2 criterion was chosen to 
reduce the exclusion of relevant factors (18). 
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6.2.3 Associations with aGVHD Incidence and Severity 
 
6.2.3.1 Acute GVHD incidence was significantly predictable using 
miRNA expression levels 
 
To assess for associations between miRNA expression and aGVHD incidence, 
generalised linear model (GLM) were built (see Chapter 2). As mentioned earlier, 
univariate Fisher’s exact test was performed and the following clinical risk factors were 
determined as significant in predicting aGVHD incidence; Patient’s gender (p=0.155), 
underlying disease (p=0.128), transplantation conditioning regimen (p=0.179) protocol 
(p=0.133) and mismatches in HLA class II (p=0.096) (Table 6.3). Chronic GVHD was also 
associated with aGVHD outcome (p=0.011) but it was not included in the model as 
aGVHD develops prior to cGVHD or at the same time during overlap syndrome. There 
was no significant difference with the other clinical risk factors.  
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No. % No. %
0.741
No 11 73 4 27
Yes 8 31 18 69
Female 12 63 7 37
Male 14 40 21 60
Female 8 57 6 43
Male 16 44 20 56
BM 3 50 3 50
PBSC 23 48 25 52
ALL 3 43 4 57
AML 4 27 11 73
CLL 2 100 0 0
CML 1 100 0 0
MDS 9 64 5 36
MM 2 67 1 33
MPS 2 100 0 0
NHL 3 33 6 67
SAL 0 0 1 100
Myeloblative 3 27 8 73
RIC 23 53 20 47
Flu Mel Alem 22 55 18 45
Flu Bus Alem 3 60 2 40
Cy Alem 1 17 5 83
FluAmCyCycloAlem 0 0 3 100
0.795
30 mg 13 52 12 48
60 mg 12 43 16 57
90 mg 1 100 0 0
SIB 11 55 9 45
MUD 15 44 19 56
Negative 11 46 13 54
Positive 15 50 15 50
Negative 17 53 15 47
Positive 9 41 13 59
None 24 47 27 53
One 2 67 1 33
None 17 61 11 39
One 7 41 10 59
Two 2 22 7 78
Alive 16 48 17 52
Dead 10 48 11 52
No 18 47 20 53
Yes 8 50 8 50
CR 2 100 0 0
CR1 11 52 10 48
CR2 4 33 8 67
CR3 2 40 3 60
Unt 4 67 2 33
No aGVHD (Grade 0) (%) (n=26) Yes aGVHD (Grade I-III) (%) (n=28)
0.437
Disease status at 
Transplant
Survival status 1.000
Difference (p-value)
Donor CMV status 0.418
HLA Class I 
mistmatches 0.604
0.497
Relationship 0.574
Patient CMV status 0.791
1.000
HLA Class II 
mismatches 0.096
0.128
Regimen 0.179
Protocol 0.133
159 (68-333)
0.011
Patient gender 0.155
Donor gender 0.533
Graft source 1.000
Cohort Characteristics (n=54)
Patient age (median years) 54.53 (19.85-67.63)
cGVHD
Underlying Disease
Relapse status
Campath
CsA prophylaxis at Day+28 (ng/ml)
 
 
Table 6.3 Frequency of patient characteristics in patients with and without 
incidence of aGVHD grades I-III. Fisher’s exact test was used to estimate the difference 
in frequencies between the two different aGVHD groups. Significant p-values are in 
bold and underlined. Abbreviations:- cGVHD: chronic GVHD, BM: Bone marrow, PBSC: 
Peripheral blood stem cells, ALL: Acute lymphocytic leukaemia, AML: Acute myeloid 
leukaemia, CLL: Chronic lymphocytic leukaemia, CML: Chronic myeloid leukaemia, HD: 
Hodgkin’s Disease, MDS: Myelodysplastic syndrome, MM: Multiple myeloma, MPS: 
Multiple proliferative syndrome, NHL: Non-Hodgkin’s lymphoma, SAL: Secondary Acute 
Leukaemia, RIC: Reduced intensity conditioning, Flu: Fludarabine, Mel: Melphalan, Bus: 
Busulfan, Cy: Cytrabine, Cyclo: Cyclophosphamide, TBI: Total body irradiation, Alem: 
Alemtuzumab, Cyclosporine A: Cyclosporine, CMV: Cytomegalovirus, CR (1-3) 
Complete remission, Unt: Untreated, SIB: Sibling, MUD: Matched unrelated donor.  
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Covariates  p-value
Pre-Tx: miR-146a-5p 0.09
Pre-Tx: miR155-5p 0.77
Day+28: miR-146a-5p 0.91
Day+28: miR-155-5p 0.52
3m: miR146a-5p 0.08
3m: miR-155-5p 0.29
Patient Age at Tx 0.05
CsA concentration at Day+28 0.33
6.2.3.2 Variance was equal and multicollinearity absent across all 
groups 
  
The test of homogeneity of variance was performed to identify if there was any 
variation between the continuous variables in the groups. A difference equal to or 
greater than 0.05 is indicative of equal variance. The test showed that the variance 
between all the groups was equal which indicated that assumptions of Levene’s test 
were satisfied (Table 6.4). Therefore, the scale function in GLM was set to default, i.e. 
one as it was not necessary to adjust the model for variance. The response distribution 
for GVHD outcome (response) was binary and therefore a generalised binary logistic 
regression was run. Multicollinearity was also absent between all the independent 
variables which was indicative by the tolerance values that were all greater than or 
equal to 0.1 (Table 6.5). 
 
 
 
 
 
 
 
 
 
Table 6.4 Test of homogeneity of variances for all the continuous covariates 
used in the generalized linear model 
 
Collinearity Statistics
Tolerance
Pre-Tx: miR-146a-5p 0.7
Pre-Tx: miR155-5p 0.5
Day+28: miR-146a-5p 0.7
Day+28: miR-155-5p 0.5
Patient Sex 0.9
Underlying disease 0.8
Regimen 0.1
Protocol 0.1
HLA class II mismatches 0.9
Independent variables
 
Table 6.5 Test of multicollinearity. (Tolerance value greater than or equal to 0.1 
indicated absence of multicollinearity) 
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6.2.3.3 The interaction between miR-146a-5p and miR-155-5p was 
significant in predicting aGVHD incidence at day+28 post allo-
HSCT  
 
Acute GVHD incidence was predicted in a stepwise manner. The first model comprised 
of miR-146a-5p and miR-155-5p expression both at pre- and at Day+28 post allo-HSCT 
and the clinical risk factors (patient sex, underlying disease, transplant regimen and 
protocol, HLA class II mismatches). The model only included cases without missing 
values. Thus in the first analysis only 35 of the cases were included [pre-transplant 
(n=35) and at Day+28 (n=54)]. Results showed that in this model the clinical risk factors 
and miRNA expression levels at pre- allo-HSCT were not significantly associated with 
aGVHD incidence.  
However, in the same model, the main effect of miR-146a-5p expression and its 
interaction with miR-155-5p at Day+28 were significant in predicting aGVHD incidence. 
An increase in miR-146a-5p expression was associated with a decrease in the odds of 
patients developing aGVHD [odds ratio= 0.023 (95% CI: 0.001-0.588)] which was a 
statically significant main effect (p=0.023). The interaction between miR-146a-5p and 
miR-155-5p expression at Day+28 was also statistically significant, odds ratio=0.516 
(95% CI: 0.292-0.911), p=0.022. The main effect of miR-155-5p had a trend towards 
significance [odds ratio=0.336 (95% CI: 0.104-1.088) p=0.069]. Together, the GLM 
fitted was significantly able to predict the incidence of aGVHD (p=0.043). A confusion 
matrix was created based on the overall adjusted model and showed that 73% of the 
patients were accurately classified as without aGVHD and 86% as with aGVHD 
incidence (Table 6.6).  
 
Table 6.6 Confusion matrix based on the observed aGVHD and predicted aGVHD 
grades. 
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6.2.3.4 Acute GVHD severity was not predictable when using miRNA 
expression levels 
 
Next, the same miRNA expression levels were tested to see if they could also predict 
aGVHD severity. Therefore, the patient cohort (n=54) was dichotomised to those with 
grades 0-I and others who went on to develop aGVHD grades II-III later. The majority of 
the patients had none or grade I aGVHD (79.6%) while only 20.4% had developed 
grades II-III aGVHD post Day+28. As in the previous Section 5.2.2, a univariate Fisher’s 
exact test was performed to select the significant clinical risk factors for inclusion in 
building the GLM (Table 6.7). Graft source, the relationship of donor to patient, donor 
CMV status and mismatches in HLA Class II were determined significant (p<0.02) and 
were included for building the GLM model in a stepwise manner in addition to the 
miRNA expression levels. However, none of the variables were significant in predicting 
aGVHD severity and therefore no GLM was fitted.  
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No. % No. %
0.895
No 12 80 3 20
Yes 20 77 6 23
Female 17 89 2 11
Male 26 74 9 26
Female 12 86 2 14
Male 27 75 9 25
BM 3 50 3 50
PBSC 40 83 8 17
ALL 11 73 4 27
AML 6 86 1 14
CLL 11 79 3 21
CML 7 78 2 22
MDS 2 100 0 0
MM 2 67 1 33
MPS 2 100 0 0
NHL 1 100 0 0
SAL 1 100 0 0
Myeloblative 9 82 2 18
RIC 34 79 9 21
Flu Mel Alem 32 80 8 20
Flu Bus Alem 4 80 1 20
Cy Alem 5 83 1 17
FluAmCyCycloAlem 2 67 1 33
0.973
30 mg 21 84 4 16
60 mg 21 75 7 25
90 mg 1 100 0 0
SIB 18 90 2 10
MUD 25 74 9 26
Negative 18 75 6 25
Positive 25 83 5 17
Negative 28 88 4 13
Positive 15 68 7 32
None 41 80 10 20
One 2 67 1 33
None 25 89 3 11
One 13 76 4 24
Two 5 56 4 44
Alive 27 82 6 18
Dead 16 76 5 24
No 29 76 9 24
Yes 14 88 2 13
CR 2 100 0 0
CR1 18 86 3 14
CR2 10 83 2 17
CR3 3 60 2 40
Unt 5 83 1 17
Difference (p-value)
Patient age (median years) 54.53 (19.85-67.63)
cGVHD 1.000
Cohort Characteristics (n=54)
Grades 0-I aGVHD (%) (n=43) Grades II-III aGVHD (%) (n=11)
0.292
Donor gender 0.705
Graft source 0.091
Underlying Disease 1.000
Patient gender
1.000
Protocol 0.914
CsA prophylaxis at Day+28 (ng/ml) 159 (68-333)
Campath 0.609
Regimen
0.181
Patient CMV status 0.510
Donor CMV status 0.100
HLA Class I 
mistmatches 0.502
Relationship
0.074
Survival status 0.733
Relapse status 0.474
Disease status at 
Transplant 0.712
HLA Class II 
mismatches
 
 
Table 6.7 Frequency of patient characteristics in patients with aGVHD grades 0-I 
and II-III. Fisher’s exact test was used to estimate the difference in frequencies 
between the four different aGVHD groups. Significant p-values are in bold and 
underlined. Abbreviations:- cGVHD: chronic GVHD, BM: Bone marrow, PBSC: 
Peripheral blood stem cells, ALL: Acute lymphocytic leukaemia, AML: Acute myeloid 
leukaemia, CLL: Chronic lymphocytic leukaemia, CML: Chronic myeloid leukaemia, HD: 
Hodgkin’s Disease, MDS: Myelodysplastic syndrome, MM: Multiple myeloma, MPS: 
Multiple proliferative syndrome, NHL: Non-Hodgkin’s lymphoma, SAL: Secondary Acute 
Leukaemia, RIC: Reduced intensity conditioning, Flu: Fludarabine, Mel: Melphalan, Bus: 
Busulfan, Cy: Cytrabine, Cyclo: Cyclophosphamide, TBI: Total body irradiation, Alem: 
Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, CR (1-3) Complete remission, 
Unt: Untreated, SIB: Sibling, MUD: Matched unrelated donor. 
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6.2.4 Associations with Relapse, OS and NRM 
 
6.2.4.1 MiR-146a-5p and miR-155-5p expression in whole blood was 
not associated with relapse 
 
Subsequently, tests were performed to assess whether the clinical factors, as well as 
miR-146a-5p and miR-155-5p expression levels in whole blood at Day+28 post allo-
HSCT, were associated with OS, relapse and NRM. The finding of Section 5.2.2 showed 
that the Day+28 time-point was highly significant in predicting aGVHD incidence, and 
thus the expression values at this time were used for all subsequent analyses. 
The association between various clinical risk factors and relapse was evaluated using 
Kaplan-Meier log-rank test for dichotomized variables and univariate Cox regression 
for continuous variables (Table 6.8). In addition to the miRNA expression levels, patient 
gender, transplant protocol, donor CMV status and mismatches in HLA Class I were 
determined significant (p<0.02) and were included for performing the multivariate Cox 
regression analysis using the stepwise, Forward-LR method. Cox regression model 
showed that only mis-matches in HLA class I was marginally predictive of patient risk of 
relapse [p=0.048, HR=4.744 (95% CI: 1.016-22.154)]. Neither the miRNA expression 
levels nor other clinical risk factors were associated with relapse. 
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No. % No. %
0.847†
No 9 60 6 40
Yes 17 65 9 35
No aGVHD (Grade 0) 18 69 8 31
Yes aGVHD (Grades I-III) 20 71 8 29
Female 16 84 3 16
Male 22 63 13 37
Female 11 79 3 21
Male 23 64 13 36
BM 3 50 3 50
PBSC 35 73 13 27
ALL 5 71 2 29
AML 9 60 6 40
CLL 1 50 1 50
CML 1 100 0 0
MDS 10 71 4 29
MM 3 100 0 0
MPS 2 100 0 0
NHL 6 67 3 33
SAL 1 100 0 0
Myelobblative 7 64 4 36
RIC 31 72 12 28
Flu Mel Alem 28 70 12 30
Flu Bus Alem 5 100 0 0
Cy Alem 4 67 2 33
FluAmCyCycloAlem 1 33 2 67
0.132†
30 mg 16 64 9 36
60 mg 21 75 7 25
90 mg 1 100 0 0
SIB 13 65 7 35
MUD 25 74 9 27
Negative 15 63 9 38
Positive 23 77 7 23
Negative 20 63 12 38
Positive 18 82 4 18
None 37 73 14 28
One 1 33 2 67
None 17 61 11 39
One 13 77 4 24
Two 8 89 1 11
Alive 27 82 6 18
Dead 11 52 10 48
CR 1 50 1 50
CR1 14 67 7 33
CR2 9 75 3 25
CR3 4 80 1 20
Unt 4 67 2 33
Disease status at 
Transplant 0.932†
HLA Class I 
mistmatches 0.027*
HLA Class II 
mismatches 0.410†
Survival status 0.001*
Relationship 0.634*
Patient CMV status 0.401*
Donor CMV status 0.166*
Protocol 0.198†
CsA prophylaxis at Day+28 (ng/ml) 159 (68-333)
Campath 0.648†
Graft source 0.294*
Underlying Disease 0.929†
Regimen 0.647*
cGVHD 0.543*
Patient gender 0.094*
Donor gender 0.538*
aGVHD incidence 0.914*
Cohort Characteristics (n=54) Difference (p-value)
Patient age (median years) 54.53 (19.85-67.63)
No Relapse (%) (n=43) Relapse (%) (n=11)
Table 6.8 Frequency of patient characteristics for those who did not relapse and 
those that relapsed. *To estimate the difference in frequencies between the no 
relapse and relapse group, Kaplan-Meier log-rank test was used for the binary 
variables and †univariate Cox regression for continuous variables. Significant p-values 
are in bold and underlined. Abbreviations:- cGVHD: chronic GVHD, BM: Bone marrow, 
PBSC: Peripheral blood stem cells, ALL: Acute lymphocytic leukaemia, AML: Acute 
myeloid leukaemia, CLL: Chronic lymphocytic leukaemia, CML: Chronic myeloid 
leukaemia, HD: Hodgkin’s Disease, MDS: Myelodysplastic syndrome, MM: Multiple 
myeloma, MPS: Multiple proliferative syndrome, NHL: Non-Hodgkin’s lymphoma, SAL: 
Secondary Acute Leukaemia, RIC: Reduced intensity conditioning, Flu: Fludarabine, 
Mel: Melphalan, Bus: Busulfan, Cy: Cytrabine, Cyclo: Cyclophosphamide, TBI: Total 
body irradiation, Alem: Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, CR 
(1-3) Complete remission, Unt: Untreated, SIB: Sibling, MUD: Matched unrelated 
donor. 
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6.2.4.2 Low miR-146a-5p expression was associated with better 
overall survival 
 
Both miR-146a-5p and miR-155-5p expressions were measured on a continuous scale. 
To reduce observer bias and lack of the decision threshold (cut-off) present in the 
literature for both miRNAs, it was deemed useful to determine a cut-off for each 
miRNA via ROC curve analysis.  
 
Thus, ROC curve analyses showed that the expression of miR-146a-5p (A=0.623, 
p=0.129) and miR-155-5p (A=0.530, p=0.716) were diagnostically not significant in 
classifying patients who were alive from those that died (Table 6.9, Figure 6.4, A). 
However, the cut-off value calculated for dichotomising miR-146a-5p expression was 
considered as valid as the sensitivity (true positive) was 90% (Table 6.9).  
 
MicroRNAs Cut-off value Sensitivity Specificity AUC (95% CI) p-value for AUC
miR-146a-5p >-4.69 0.91 0.42  0.62 (0.47-0.77) 0.129
miR-155-5p <0.01 1.00 0.03  0.53 (0.37-0.69) 0.716  
Table 6.9 ROC curve analysis of miRNA expression with overall survival. Log-
transformed miRNA expression values were used to derive the cut-off value for 
dichotomising the data. <: lower values signify patient more likely to die; higher values 
signify patient more likely to live. >: higher values signify patient more likely to die; 
lower values signify patient more likely to live. 
 
To reinforce the ROC’s dichotomy, the Kaplan-Meier log-rank-test (incorporating the 
time element) was then performed to compare the resulting two different levels (low 
and high) of miRNA expression with regards to OS. MiR-146a-5p expression, when 
dichotomised, was statistically significant in predicting patient OS (log-rank p=0.015) 
(Figure 6.4 B). MiR-155-5p could not be dichotomised based on the cut-off value 
determined as per the ROC curve analysis. Thus, Kaplan-Meier log-rank test could not 
be performed as there was only one value for the survival factor (dead).  
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Figure 6.4 ROC curve and Kaplan-Meier survival analysis for miR-146a-5p. (A) The 
cut-off value was determined from the ROC test and used to dichotomise miR-146a-5p 
expression for the log-rank test. (B) The clear separation of the Kaplan-Meier curves 
showed that the dichotomy for miR-146a-5p expression could be used to predict OS 
post-HSCT (p=0.015). Black line = low miRNA expression and grey line= high miRNA 
expression.  
 
The chi-square statistic was employed to establish if the dichotomy used for each 
miRNA was sufficient to differentiate between patients who were deceased and 
patients who were alive. Overall there were 21 dead (events) and 33 alive (censored) 
cases. Exact p-values for the chi-square test were used to ensure the accuracy 
regardless of the size, distribution, sparseness, or balance of the data. Only miR-146a-
5p dichotomy proved significantly associated with survival [p=0.000] (Table 6.10). This 
result agreed with those of the log-rank tests from a Kaplan-Meier analysis: miR-146a-
5p [p =0.015] (Figure 6.4). Together, low miRNA expression level was shown to be 
indicative of higher cumulative survival probability for miR-146a-5p only. 
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Total Dead Chi-Square
Exact
p-values
Low expression 16 2 14 87.5
High expression 38 19 19 50
miR-146a-5p 0.000
microRNAs Expression levela
Alive
N N N %
 
Table 6.10 Case processing summaries for all the 11 validated miRNAs showing 
the number of events and censored cases per group. a grey shade: level containing a 
larger proportion of patients who died. 
 
6.2.4.3 HLA class I mismatches was associated with risk of death  
 
Subsequently, multivariate Cox regression analysis was performed to estimate the 
predictive value of miRNAs when expression levels were used on a continuous scale to 
perform the analysis. This would reinforce the accuracy of the dichotomy used in for 
the Kaplan-Meier log-rank test. It would also test whether the miRNA expression levels 
retained their significance when clinical risk factors were included in the study. Hence, 
miRNA expression values were entered as continuous variables and significant clinical 
risk factors were either selected by performing Kaplan-Meier log-rank test or 
univariate Cox regression as mentioned, previously. The following clinical risk factors 
were entered for performing the stepwise Forward-LR method for variable selection 
procedure in addition to the miRNA expression values: Patient and donor gender, 
underlying disease, transplant protocol, dose of Campath and mismatches in HLA class 
I (Table 6.11).  
Interestingly, mis-matches in HLA class I was the only variable that was associated with 
patient risk of death and was entered into the Cox regression equation [p=0.004, 
HR=6.667 (95% CI: 1.837-24.202)]. For every single mis-match in HLA class, I between 
the patient-donor pair the risk of dying increased by 6.7 folds. These results showed 
that the miRNA-146a-expression was not significantly associated with improved OS 
when clinical risk factors such as mis-matches in HLA class I were included as variables 
in the analysis 
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No. % No. %
0.990
No 10 67 5 33
Yes 14 54 12 46
No aGVHD (Grade 0) 16 62 10 38
Yes aGVHD (Grades I-III) 17 61 11 39
Female 14 74 5 26
Male 19 54 16 46
Female 6 43 8 57
Male 23 64 13 36
BM 5 83 1 17
PBSC 28 58 20 42
ALL 3 43 4 57
AML 10 67 5 33
CLL 1 50 1 50
CML 1 100 0 0
MDS 8 57 6 43
MM 1 33 2 67
MPS 2 100 0 0
NHL 7 78 2 22
SAL 0 0 1 100
Myeloblative 6 55 5 45
RIC 27 63 16 37
Flu Mel Alem 24 60 16 40
Flu Bus Alem 5 100 0 0
Cy Alem 4 67 2 33
FluAmCyCycloAlem 0 0 3 100
0.728
30 mg 15 60 10 40
60 mg 18 64 10 36
90 mg 0 0 1 100
SIB 11 55 9 45
MUD 22 65 12 35
Negative 14 58 10 42
Positive 19 63 11 37
Negative 18 56 14 44
Positive 15 68 7 32
None 33 65 18 35
One 0 0 3 100
None 16 57 12 43
One 13 76 4 24
Two 4 44 5 56
No 27 71 11 29
Yes 6 38 10 63
CR 1 50 1 50
CR1 11 52 10 48
CR2 9 75 3 25
CR3 3 60 2 40
Unt 4 67 2 33
Relapse status 0.079
Disease status at 
Transplant
0.789
Donor CMV status 0.579
HLA Class I 
mistmatches
0.001
HLA Class II 
mismatches
0.731
Campath 0.147
Relationship 0.641
Patient CMV status 0.908
Regimen 0.661
Protocol 0.023
CsA prophylaxis at Day+28 (ng/ml) 159 (68-333)
Donor gender 0.123
Graft source 0.284
Underlying Disease 0.027
cGVHD 0.640
aGVHD incidence 0.986
Patient gender 0.128
Cohort Characteristics (n=54) Difference (p-value)
Patient age (median years) 54.53 (19.85-67.63)
Alive (%) (n=33) Dead (%) (n=21)
Table 6.11 Frequency of patient characteristics which were alive and those who 
were deceased. To estimate the difference in frequencies between the alive and dead 
group, Kaplan-Meier log-rank test was used for the binary variables and univariate Cox 
regression for continuous variables. Significant p-values are in bold and underlined. 
Abbreviations:- cGVHD: chronic GVHD, BM: Bone marrow, PBSC: Peripheral blood stem 
cells, ALL: Acute lymphocytic leukaemia, AML: Acute myeloid leukaemia, CLL: Chronic 
lymphocytic leukaemia, CML: Chronic myeloid leukaemia, HD: Hodgkin’s Disease, MDS: 
Myelodysplastic syndrome, MM: Multiple myeloma, MPS: Multiple proliferative 
syndrome, NHL: Non-Hodgkin’s lymphoma, SAL: Secondary Acute Leukaemia, RIC: 
Reduced intensity conditioning, Flu: Fludarabine, Mel: Melphalan, Bus: Busulfan, Cy: 
Cytarabine, Cyclo: Cyclophosphamide, TBI: Total body irradiation, Alem: Alemtuzumab, 
CsA: Cyclosporine, CMV: Cytomegalovirus, CR (1-3) Complete remission, Unt: 
Untreated, SIB: Sibling, MUD: Matched unrelated donor. 
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6.2.4.4 Clinical risk factors were associated with relapse and non-
relapse mortality 
 
Competing risk analysis was performed using R (version 3.0.1) for all the 54 patients to 
estimate the cumulative incidence of NRM and disease relapse (relapse and death act 
as competing risks). Gray’s test (Gray, 1988) was performed to test for equality of 
cumulative incidence functions across the different clinical risk factor groups. Results 
showed that the cumulative incidence curves were not statistically significant for NRM, 
but there were sometimes trends toward significance (Table 6.12). Mismatches in HLA 
class I showed borderline significance (p=0.051) towards a greater incidence of relapse 
for those with one HLA mismatch when compared to those with no mismatch (Figure 
6.5, A). However, this result must be interpreted with caution as there were only three 
transplantations with HLA I class mismatches. Likewise, transplantations with 
mismatches in the HLA class II had a trend (p=0.077) towards more incidence of NRM 
(Figure 6.5, B). Patient gender showed a trend (p=0.084) towards higher incidence of 
relapse in males compared to females (Figure 6.5, C) while in donor gender there was a 
trend (p=0.109) towards significance of NRM in patients with female donors compared 
to those with male donors (Figure 6.5, D). 
Clinical risk factors Relapse (p-value) Non-Relapse Mortality (p-vaule)
Transplant type 0.601 0.827
Patient CMV status 0.354 0.453
Donor CMV status 0.161 0.61
HLA class I mismatches 0.051 0.469
HLA class II mismatches 0.259 0.077
Conditioning regimen 0.688 0.88
Graft source 0.2 0.216
Patient gender 0.084 0.543
Donor gender 0.425 0.109
Patient age 0.743 0.276  
Table 6.12 Gray’s test summary for relapse and non-relapse mortality (difference 
indicated by p-values).  
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 Figure 6.5 Estimated cumulative incidence curves for NRM and relapse. (A) HLA 
class I mismatches (B) HLA class II mismatches (C) Patient gender and (D) Donor 
gender.  
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6.2.5 Correlation assessment between the miRNAs and their targets 
 
6.2.5.1 Positive correlation was present among miR-146a targets at 
the mRNA level both at pre and post allo-HSCT time-points 
 
Both miR-146a-5p and miR-155-5p have been shown to have increased expression 
levels upon exposure to LPS that results in the activation of Toll-like receptor 4 (TLR4) 
and in turn in the NFκB signalling pathway (Taganov et al., 2006; Rai et al., 2008). As 
shown earlier, miR-146a-5p is the main miRNA involved in predicting the incidence of 
aGVHD and improving OS, thus in order to better understand its role in the disease 
pathway and inflammation, its established targets (TRAF6, IRAK1, STAT1-α and IRF-5) 
were quantified both at the mRNA and protein levels, respectively. Analysis was 
performed by segregating the cohort into two groups (Grade 0 and Grades I-III) and 
then testing for correlation between the miRNA expression levels and their respective 
mRNA targets at pre-transplant, Day+28 and three months.  
MiRNA expression levels that were quantified in the Section 5.2 were used for 
performing correlation statistics. The correlation was performed separately for those 
who never developed aGVHD (grade 0) by the time of the last follow-up and those who 
went on to develop grade II-III aGVHD post Day+ 28 time-points (for all the correlation 
tables, please see Appendix B, tables 1-8). 
In the patients with no aGVHD (grade 0), results showed that the mRNA expression 
levels of TRAF6, IRAK1, STAT1-α and IRF-5 did not significantly correlate with miR-
146a-5p expression levels in whole blood obtained from the patients’ pre- allo-HSCT. 
As all the targets are involved together in the same pathways, it was interesting to 
assess whether their levels correlated with each other or not at every time-point. Not 
surprisingly, there was a significant positive correlation between TRAF6 and IRAK1 
(rs=0.79, p=0.001) as well as TRAF6 and STAT1-α (rs=0.59, p=0.027). Whole blood 
samples collected at Day+28 were then assessed for target correlation and results 
showed that there was no correlation between miR-146a-5p and its targets at this 
time-point. However, there was a trend towards the negative correlation between 
miR-146a-5p and TRAF6 mRNA expression (rs=-0.37, p=0.061). Statistically significant 
(p≤0.002) positive correlation was present between all the targets. In whole blood 
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collected at three months post-transplantation, there was no relationship between 
miR-146a-5p expression and its mRNA targets or among the targets. 
Likewise, correlation between miR-146a-5p and its targets was also assessed in the 
aGVHD patient cohort (Grades I-III). Measurements at Day+28 showed that there was 
no correlation between miR-146a-5p and its targets, but there was statistically 
significant (p≤0.02) positive correlation present between all the targets. At 3 months 
post-transplantation there was a significant negative correlation (rs=-0.69, p=0.019) 
between miR-146a-5p and IRF5 mRNA expression. At the same time-point, TRAF6 and 
IRAK1 expression positively correlated with each other (rs=0.86, p=0.001). 
6.2.5.2   IRF5 mRNA expression positively correlated with its protein 
levels measured in whole blood at Day+28 in aGVHD patients 
Subsequently, the protein levels of the targets were quantified using commercially 
available ELISA kits in a representative subset of the cohort (Grade 0, n=5; Grades I-III, 
n=10). However, only STAT1-α and IRF5 proteins were detectable by the assays. 
Therefore, it was concluded that the biological protein levels of TRAF6 and IRAK1 were 
below the sensitivity of the assay, as the standards for each of the proteins quantified 
as per the manufacturer’s guidelines.  
The pre-transplant protein levels of STAT1-α and IRF5 neither correlated with their 
mRNA expression nor with miR-146a-5p expression levels (p>0.05). The Day+28 
protein levels of STAT1-α and IRF5 in the no aGVHD cohort significantly positively 
correlated with each other (rs=0.90, p=0.037). At three months post-transplantation, 
there was no correlation between miR-146a-5p and its protein targets. Similarly, miR-
146a-5p correlation with its protein targets was also assessed in the aGVHD patient 
group (Grades I-III). At Day+28, there was a trend towards a positive correlation 
between miR-146a-5p and STAT1-α protein levels (rs=0.53, p=0.092). Likewise, there 
was also a trend towards STAT1-α mRNA and protein levels (rs=0.57, p=0.068). Results 
showed a significant positive correlation (rs=0.71, p=0.009) between IRF5 mRNA and its 
protein levels. At 3 months post-transplantation there was a significant negative 
correlation (rs=-0.69, p=0.019) between miR-146a-5p and IRF5. However, some 
patients at three months were receiving prophylactic steroids so this result must be 
interpreted with caution.  
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6.2.5.3 In the whole blood of aGVHD patients at Day+28, MiR-155-5p 
and miR-146a expression correlated with the transcription 
factor, SPI1  
 
SPI1 (PU.1) is an important transcription factor in haematopoietic differentiation 
(Rosenbauer et al., 2006) and has been shown to regulate the expression of miR-146a-
5p and miR-155-5p. In a murine study, it was demonstrated that Spi1 binds to pre-miR-
146a-5p locus permanently to regulate its expression. In the same study, SPI1 bound to 
the miR-155-5p locus only during HSC differentiation (Ghani et al., 2011).  Thus, miR-
155-5p expression was tested against its target SPI1 in whole blood samples at Day+28 
and results showed that there was a significant negative correlation (rs=-0.534, 
p=0.004) in the aGVHD patient cohort (Grades I-III) only (Figure 6.6, A). Interestingly, in 
the same cohort there was a significant negative correlation between miR-146a-5p and 
SPI1 (rs=-0.45, p=0.016) (Figure 6.6, B). 
 
Figure 6.6 MiR-155-5p and miR-146a-5p expression directly correlated with SPI1 
mRNA levels. There was a significant negative correlation for both (A) miR-155-5p and 
(B) miR-146a-5p expression. The correlation was only significant in aGVHD patients 
with grades I-III (n=26). The x-axis shows the miRNA expression levels and the y-axis 
the SPI1 mRNA levels. Spearman correlation was used to test for correlation. 
Spearman rho: rs. Significance was set as p<0.05.  
 
 
 
 
229 
 
6.2.6    MicroRNA expression levels between normal volunteers and 
transplant patients 
 
To find if there was any difference in miRNA expression levels between normal and 
diseased populations, whole blood samples were tested across three groups; normal 
volunteers, pre-transplant patients and post allo-HSCT patients. Surprisingly, miR-
146a-5p expression levels were not significantly different between any of the groups 
(Figure 6.7, A). However, miR-155-5p expression varied between the pre-transplant 
patients and normal samples as well as post allo-HSCT patients (Figure 6.7, B). This 
further highlight that the main effect and interaction identified between miR-146a-5p 
and miR-155-5p expression may be as a result of the disease state. 
 
 
Figure 6.7 MiRNA expression levels in the whole blood of normal volunteers and 
transplant patients. (A) MiR-146a-5p expression was not varied between normal 
volunteers, pre-transplant patients and those who underwent allo-HSCT (B) Normal 
volunteers had significantly higher miR-155-5p expression levels compared to the pre-
transplant patients. Kruskal-Wallis analysis of variance was used to calculate the 
difference. Significance was set at p<0.05. Pre-Tx: pre-transplant; ns: not significant  
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6.2.7 In Vitro Stimulation Studies assessing the impact of miRNA 
expression levels 
    
6.2.7.1 MiR-146a-5p expression declines upon stimulation with IFN-γ  
 
All the patients in this study had no GVHD at Day+28, yet it was possible to predict 
aGVHD incidence. Thus, it was hypothesized that the miRNA expression levels were a 
marker of inflammation in phase II of aGVHD development cycle before aGVHD had a 
clinical or histological manifestation in the target organs. IFN-γ is one of the main 
proinflammatory cytokines secreted during phase II of aGVHD development (Ferrara et 
al., 1999). Thus, to test this hypothesis, PBMCs were challenged with two different 
concentrations of IFN-γ to see whether this inflammatory cytokine had any impact on 
miR-146a-5p and miR-155-5p expression levels in a more diverse population of cells 
that was more representative of the whole blood population. The cells were 
stimulated with 50 ng/ml and 100 ng/ml IFN-γ for 24 and 48hrs. For both miRNAs, IFN-
γ stimulation for 24 hrs had no effect on their expression levels when compared to the 
unstimulated PBMCs (0 ng/ml) (Figure 6.8, A). Interestingly; miR-146a-5p expression 
was significantly reduced upon stimulation after 48 hrs with 50 ng/ml and 100 ng/ml 
IFN-γ while miR-155-5p expression remained still unaltered. However, there was a 
trend towards the reduction of miR-155-5p expression after 48 hrs IFN-γ stimulation 
(Figure 6.8, B).  
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 Figure 6.8 PBMCs stimulated with IFN-γ for 48 hrs showed significantly reduced 
miR-146a-5p expression. PBMCs (n=4) from healthy volunteers were stimulated with 
IFN-γ (50 and 100 ng/ml) for 24 and 48 hrs prior to total RNA extraction. MiR-146a-5p 
and miR-155-5p expression levels were quantified using RT-qPCR. IFN-γ stimulation for 
(A) 24 hrs and (B) 48 hrs. Repeated measures ANOVA was used to calculate the 
statistical difference between unstimulated controls (0 ng/ml) and samples stimulated 
with 50ng/ml and 100 ng/ml of IFN-γ.  
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6.2.7.2    Stimulation with Cyclosporine A had no direct impact on 
miRNA expression levels 
 
Cyclosporine A is one of the calcineurin inhibitors administered routinely to post allo-
HSCT patients at the Newcastle Transplantation centre. Cyclosporine A inhibits IFN-γ 
secretion (Kalman and Klimpel, 1983; Sica et al., 1997) so theoretically, it should 
indirectly up-regulate miR-146a-5p expression levels.  In the patient cohort, it was 
found that Cyclosporine A concentrations at Day+28 did not correlate with either of 
the miRNA expression levels (rs≤1.00, p≥0.05). To confirm that Cyclosporine A had no 
impact on miR-146a-5p and miR-155-5p expression levels, in vitro experiments were 
set-up. Cyclosporine A was co-cultured at various doses in mis-matched MLRs for 96 
hours. In parallel, unstimulated auto-MLRs were also set up as a control for allogeneic 
response. Unstimulated mis-matched MLR was set up as a control for the different 
Cyclosporine A doses used in the experiment. Results showed that miR-146a-5p and 
miR-155-5p expressions were unaffected by the different doses of Cyclosporine A, and 
direct correlation was absent (Figure 6.9). However, an interesting observation was 
that the miR-155-5p expression was almost unaffected by the MLR response.  
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Figure 6.9 Cyclosporine A had no impact on the expression of miR-146a-5p and 
miR-155-5p. Cyclosporine A was co-cultured at different doses with mis-matched MLRs 
(n=3) for 96 hours (A) MiR-146a-5p expression was higher in mis-matched MLRs, but it 
was not statistically significant. MiR-146a-5p expression did not vary when low to high 
concentrations of Cyclosporine A were co-cultured with the MLRs. (B) MiR-155-5p 
expression was unaffected by both the allogeneic response in the mismatched MLRs as 
well as the different doses of Cyclosporine A used in the experiment. Auto-MLRs were 
set up as controls for the allogeneic response and unstimulated mis-matched MLRs as 
controls for the stimulated MLRs. Repeated-measures ANOVA was used to test for 
statistical significance.  
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6.3 Discussion       
                                                                                                                                                                                                                 
Both miR-146a and miR-155 have been experimentally shown to be indispensable in 
regulating several immune-related pathways under steady and diseased conditions 
(Pauley et al., 2008; Nahid et al., 2009; Banerjee et al., 2010; Lu et al., 2010). They 
have also been shown to be prognostic biomarkers of aGVHD state, SLE and RA (Pauley 
et al., 2008; Wang et al., 2010; Ranganathan et al., 2012). It is known in HSCT that miR-
155 expressions are overexpressed when target organ damage has already occurred in 
the patient (Ranganathan et al., 2012). It is also known that GVT effect is required to 
prevent disease relapse (Bleakley and Riddell, 2004). Tailoring treatments to maintain 
a balance between GVHD and GVT/GVL is, therefore, important in the clinic. This study 
aimed to assess whether the expression of both miRNAs could be used to predict 
aGVHD incidence and/or severity prior to histological and clinical disease 
manifestations. This knowledge could make clinical interventions possible prior to 
disease onset and, therefore, prevent the complications associated with aGVHD 
severity. Understanding the miRNA regulation involved in the pathophysiology of 
aGVHD could also be reflective of the GVH reaction and in particular the essential GVT 
effect. It could, therefore, be used for monitoring the GVH reaction and could direct 
therapies for more enhanced GVT effect. Thus, for prediction analyses all the patients 
in this cohort were aGVHD-free at the 28 days post-transplantation time-point. 
This study also applied a new approach to statistical model fitting, as it looked at both 
the main effects and the interactions between miR-146a-5p and miR-155-5p with 
regards to predicting aGVHD outcome (incidence and severity). An appropriate model 
can aid researchers in interpreting quantitative data and finding the impact of the 
biological deregulation of molecules/genes or miRNAs in both health and disease. 
There are two main elements that need to be considered in model fitting, (1) selecting 
an appropriate model that fits with the type of data and complexity of condition as 
well as (2) selecting factors that are necessary for the prediction of outcomes and 
probabilities. Inclusion of nonessential variables in the model increases variability of 
predictions. For this reason, candidate selection was carried out for the model building 
in this investigation to eliminate imprecise probability estimates. In many biological 
investigations, in particular in the field of allo-HSCT, interactions are often overlooked 
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even though they are one of the keys to better understanding the biological 
relationships and combinations.  
Therefore, the expression levels of both miR-146a-5p and miR-155-5p were used for 
model fitting that showed that miR-146a-5p had the main role in the prediction of 
aGVHD incidence when it interacted with miR-155-5p expression. The interaction 
observed is in support of the differential ‘check-point’ mechanism of action shown by 
Schulte et al., (Schulte et al., 2012). Lipopolysaccharides trigger the expression of miR-
146a (Taganov et al., 2006). Using various immune system stimulators such as LPS, 
they showed that miR-146a was the initial player in exhibiting an inflammatory 
response and that miR-155 expression was only altered when miR-146a levels of 
inflammatory tolerance had been surpassed. This may explain why higher miR-155 
expression levels have been observed in both serum and gut of patients at the time of 
aGVHD onset, which is the effector phase in the GVHD cycle (Ferrara, 1993; 
Ranganathan et al., 2012; Xie et al., 2014).  
Additionally, this study has shown that lower expression of both miRNAs was 
predictive of aGVHD incidence. This is in support of the very recent aGVHD study in 
mouse that showed that miR-146a expression levels were lower in aGVHD mice 
(Stickel et al., 2014).  Nahid et al., also showed that over-expression of miR-146a 
prevents an inflammatory response and thus, has a protective role in innate immunity 
(Nahid et al., 2009). 
MiR-146a had the main role when detected in pre- aGVHD onset samples at Day+28 in 
this study. To understand the miR-146a-5p regulatory mechanism of action, its four 
highly cited and experimentally validated targets were investigated both at the mRNA 
and protein level. There was no correlation between miR-146a-5p expression levels 
and its mRNA targets at pre-transplant, Day+28 and three months post allo-HSCT. 
Boldin et al., have shown that miR-146a expression affects the expression of TRAF6 
and IRAK1 at the protein level rather than at the mRNA-level (Boldin et al., 2011).  But 
in this study using ELISAs, the protein level of IRAK1 and TRAF6 were not undetectable 
in the sera of normal volunteers as well as allo-HSCT patients. IRF5 and STAT1-α 
proteins were detected in the allo-HSCT patients, but they did not correlate with miR-
146a-5p expression levels. Human IRF5 belongs to a family of genes that functions 
both in the IFN signalling and the immune system. IFN-α, TNF-α, IL-6, IL-12 and IL-23 
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are all stimulated by IRF5. Recently, IRF5 has been shown to be involved in 
inflammation and in humans, higher expression of IRF5 as a consequence of 
polymorphisms in the gene has been implicated with autoimmune diseases (SLE and 
RA) (Graham et al., 2006; Dieguez-Gonzalez et al., 2008). Low expression of IRF5 
results in up-regulation of IL-10 (Krausgruber et al., 2010). IL-10 is an anti-
inflammatory cytokine which is also associated with autoimmune diseases, due to its 
ability to lower the expression of TNF and other inflammatory cytokines (Fiorentino et 
al., 1991). The findings of this study showed that IRF5 mRNA expression positively 
correlated with its protein levels measured in whole blood at Day+28 in patients who 
went on to develop aGVHD and not in patients who did not develop aGVHD. However, 
there was no correlation between miR-146a-5p expression and IRF5 levels at both the 
mRNA and protein level. Not surprisingly, positive correlation was present among miR-
146a-5p targets at the mRNA level both at pre and post allo-HSCT time-points. This 
showed that their expressions were dependent on one another. These results may 
suggest that miR-146a-5p and miR-155-5p act as ‘paramedics’ in the initial phases of 
inflammation due to their characteristic sensitivity. Thus, their levels are deregulated 
pre- aGVHD onset. However, once the limit of miR-146a-5p tolerance is breached, and 
miR-155 is overexpressed to compensate, the immune system is alarmed (Schulte et 
al., 2012). It is at heightened inflammatory stage that their expression reaches a level 
that impacts the expression levels of their targets. This may be the reason why no 
correlation was seen between miR-146a-5p and its targets pre- aGVHD onset while the 
same miRNA has been shown to regulate TRAF6 expression at the time of aGVHD 
onset (Stickel et al., 2014). This also explains the significant main effect of miR-146a-5p 
and its interaction with miR-155-5p observed in this study pre- aGVHD disease onset.  
Mice deficient in miR-146a develop autoimmune disorders and die prematurely 
(Boldin et al., 2011). The mutant mice had a loss of peripheral T cells as a result of the 
absence of miR-146a. Thus, a low expression of miR-146a could result in an 
inflammatory phenotype as noted in mice and impact survival (Luo et al., 2010). Next, 
the impact of miRNA expression levels on survival was tested, and results showed that 
higher miR-146a-5p expression was indicative of poor survival outcome. This may 
suggest that patients with lower miR-146a-5p expression have more GVT effect due to 
exacerbated GVH reaction, and this eventually leads to GVHD.  When the important 
clinical risk factors were included in the study, results showed that mismatches in HLA 
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class I were associated with risk of death. This finding shows that the miR-146a-5p 
expression is not associated with survival outcome when clinical risk factors are 
included in the analysis.   
Interferons and TNF-α have been found to function in pathogenesis of GVHD (Klimpel 
et al., 1990; Cooke et al., 1998). The IFNs play an integral role in the regulation of both 
innate and adaptive immune reactions. Even though there have been investigations to 
determine the role of type I and II IFNs in GVHD, this yet remains unclear. IFN-γ (Type 
II) has been shown to either reduce or escalate the disease (Welniak et al., 2000; Lu 
and Waller, 2009). In contrast, very limited studies have focused on the role of IFN-α 
(Type I) in the pathogenesis of GVHD (Reyes and Klimpel, 1987; Pavord et al., 1992). 
Reyes and Klimpel, were able to show that the serum level of IFN-α correlates with 
GVHD severity (Reyes and Klimpel, 1987) and other studies have shown that STAT1 is 
the main signal transducer for both IFN-α and IFN-γ (Schindler and Plumlee, 2008). 
Recently in murine models, higher expression of Stat1 and Stat1-dependent cytokines 
(Cxcl10, Cxcl9) have been shown to be involved in the development of GVHD (Ma et 
al., 2011).   
Using the available online database, microrna.org it was found that miR-146a-5p and 
miR-155-5p only bind to STAT1-α rather than STAT1-β. It is STAT1-α which is 
responsible for IFN-γ induction (Lee and Benveniste, 1996).  However, in this 
investigation STAT1-α did not correlate with the expression of either miRNAs. As part 
of their conditioning regimens, 88% of allo-HSCT patients in this study had been 
administered fludarabine as part of their conditioning regimen. It reduces the levels of 
both variants of STAT1 (STAT1-α and STAT1-β). In fact the study by Frank et al, has 
shown that PBMCs exposed to fludarabine for only 24 hrs and then washed and 
stimulated with phytohemagglutinin (PHA) have significantly lower levels of IFN-γ 
secretion (Frank et al., 1999). The authors suggested that the fludarabine does not 
have a transient impact on lymphocytes (LoVecchio et al., 1999). A major criticism of 
the work is that the cells were only washed after exposure with fludarabine and then 
stimulated with PHA. The half-life of fludarabine is 20 hrs thus; when the cells were 
triggered with PHA the effect of fludarabine was still present. Also, under allogeneic 
conditions the impact of fludarabine might be less pronounced as the patients are 
infused with donor lymphocytes that have not been exposed to fludarabine. As a 
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future study, it might be interesting to set up a dose-response experiment with 
fludarabine in MLR and check for differences in the expression levels of the miRNAs. 
However, the terminal life of the drug should be considered in the experimental 
design. 
The master transcription factor SPI1 (PU.1) (Vangala et al., 2003) controls miR-155 
expressions (Ghani et al., 2011).  Both miRNAs are predicted to target SPI1 according 
to microrna.org. Experiments have also shown that this transcription factor controls 
the expression of both miRNAs in HSCs (Ghani et al., 2011).  To test whether this 
critical transcription factor had any role in allo-HSCT, its levels were quantified in 
patients who went on to develop aGVHD (grades I-III) after Day+28. Interestingly, miR-
155-5p and miR-146a-5p expression levels negatively correlated with SPI1 mRNA 
levels. This may suggest that during GVH reaction the miRNAs are triggered by 
chemokines and cytokines which results in their regulation of SPI1 rather than their 
activation by it (Ghani et al., 2011; Joyce and Novina, 2013). 
The normal or steady-state levels of both miRNAs were detected in the whole blood of 
healthy volunteers. MiR-146a-5p expression was not altered between normal 
volunteers, pre- and post allo-HSCT while the levels of miR-155-expression were 
under-expressed between normal and pre-transplantation. In addition, there was a 
difference in the levels of miR-155-expression between pre- and post allo-HSCT. This 
further confirmed that the main effect and interaction identified between miR-146a-
5p and miR-155-5p expression was a result of the disease state. 
Additionally, PBMCs were stimulated with IFN-γ and miRNA expression levels detected 
after 24 and 48hrs. Interestingly, exposure of PBMC for 24hrs with IFN-γ had no 
influence on the miRNA expression levels. However, after 48hrs there was a significant 
reduction in miR-146a-5p expression levels in comparison to the unstimulated cells. 
Experiments have shown that IFN-γ can reduce miR-146a expression levels in CD14+ 
monocytes present in both cord blood and adult peripheral blood (Takahashi et al., 
2012). In contrast, miR-155-5p expression only showed a trend in reduction and this 
might mean that higher doses, as well as longer exposure periods, are needed for miR-
155-5p expression to be significantly repressed. This finding is also supported by the 
differential ‘check-point’ hypothesis mentioned earlier and also shows that miR-146a-
5p is more sensitive to the dose of IFN-γ and its exposure time. 
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In SLE patients, no association was observed between miR-146a expression and high 
levels of steroids (Tang et al., 2009). In the present study, all the patients were 
steroids-free at Day+28. In Jurkat cell lines Cyclosporine A reduces miR-146a and IL-2 
levels (Curtale et al., 2010). Cyclosporine A is prescribed to patients routinely one day 
before transplantation with a target dose of 250 ng/ml, for up to nearly 3-6 months 
post-transplantation. However, the dose may vary depending on the type of transplant 
(HLA-matched), risk of GVHD and other HSCT complications that might arise post-
transplantation. To address the question of whether Cyclosporine A had any direct 
impact on miRNA expression levels both correlation statistics was performed as well as 
in vitro experiments using MLR reactions as the allogeneic response. Results showed 
that there was no significant correlation between either of the miRNAs and 
Cyclosporine A concentration in the peripheral blood at Day+28. Stimulation with low 
and high doses of Cyclosporine A had no impact on the miRNA expression levels in the 
MLR.   
MiR-146a-5p is located on 5q33.33. Chromosome 5q is significant in MDS in which 
subgroups of patients develop 5q deletions and significantly lower miR-146a-5p 
expression (Starczynowski et al., 2009). Even though 26% patients in this cohort had 
MDS as their underlying disease they were all in complete remission on 
transplantation. In addition, karyotype reports showed that only two out of the 14 
patients had 5q deleted regions. One patient had deletion of both 5q31 and 5q33 
while the other had both copies of 5q33 deleted regions. This further shows that the 
lower miR-146a-5p expression associated with aGVHD incidence is not due to the prior 
underlying diseases. 
In summary, the results of this Chapter have shown that miR-146a-5p and miR-155-5p 
are lower in patients who go on to develop aGVHD (grade I-III). Results have also 
shown that SPI1 is regulated by both miRNAs during the early stages of inflammation 
and that there is no detectable difference between the miRNA target levels and the 
respective miRNAs. It has also been shown that Cyclosporine A has no impact on the 
expression levels of both miRNAs while IFN-γ reduces miR-146a expression levels 
significantly after 48 hr exposure. Figure 6.10 summarises the findings and postulations 
of this Chapter. However, the results need to be validated in a larger cohort with more 
severe aGVHD grades III-IV to be able to discern whether both miRNAs can be used as 
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predictive biomarkers for severity. This study has shown that their interaction with the 
response may be used as a predictive biomarker of incidence of aGVHD and this 
provides further insight into both the biology of the miRNAs and their targets in 
aGVHD disease biology. 
 
 
Figure 6.10 MiR-146a-5p and miR-155-5p mechanism of action during early stages 
of inflammation (adopted from (Taganov et al., 2007; Rusca and Monticelli, 2011; 
Shen et al., 2012). During the early stages of inflammation in GVHD, the TLR and Janus 
Kinase (JAK)-STAT1 pathway are activated by LPS and IFN-γ respectively. Both miR-
146a-5p and miR-155-5p have reduced expression levels. This results in minor changes 
in the miRNA target levels but there alterations are not sufficient to be distinguishable 
from the uninflammed or normal conditions as they are the initial changes occurring in 
the system that ultimately leads to GVHD. 
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Chapter 7. Concluding Remarks and Future Work 
 
 
 
 
 
 
 
 
“The more I read, the more I acquire, the more certain I am that I know nothing.” 
-Voltaire 
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7.1 Introduction 
 
Since 1968, when the first successful allo-HSCT procedure was performed, globally 
thousands of patients have been cured of malignant haematological diseases. 
Currently, more than 70 disease types are treated with HSCTs that can be autologous 
or allogeneic. Last year, 2013 marked the one million HSCTs performed worldwide 
since 1957, when E. Donnall Thomas, treated the first patient with HSCTs. However, 
GVHD is still the primary complication of allo-HSCT. Similar to the global ‘antibiotic 
discovery crisis’, new GVHD treatment options are limited and fewer discoveries are 
made. Likewise, GVHD diagnosis still relies on manifestation of symptoms at the time 
of clinical evaluation. Over the last couple of decades, numerous potential biomarkers 
have been reported yet there is an absence of a fully validated biomarker that can be 
used in the transplantation clinic. This is mainly due to several reasons; (1) GVHD 
complexity, (2) lack of worldwide united multicenter collaborations with transparent 
regular reporting of results, (3) lack of standardized conditioning and prophylactic 
regimens and (4) inaccurate record keeping. As mentioned earlier (Chapter 1), the 
biomarker discoveries have looked at genes, proteins and SNPS. Therefore, this 
investigation aimed to study miRNAs that are the regulatory molecules that exist 
between mRNA transcripts and proteins. Investigating the regulatory mechanisms was 
proposed as being necessary for bridging the existing genomic and proteomic 
knowledge. Thus, this research sought to answer the following questions by 
incorporating both a screening based approach and the more traditional literature or 
evidence-based hypothesis-driven method of research.  To my knowledge, the findings 
of this research have all been novel and no reports have been presented where the 
same methodology or experiments have been performed in the context of aGVHD and 
allo-HSCT. 
(4) Does aGVHD lead to the deregulation of miRNAs in the primary damaged target 
organ, skin? 
a. Could the deregulated miRNAs be identified and used as diagnostic 
aGVHD biomarkers? 
i. Could the deregulated miRNAs be predictive of OS and disease relapse? 
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ii. What were the downstream effects of the deregulated miRNAs? 
(5) Do the immune-specific miRNAs (miR-146a and miR-155) in whole blood function 
in aGVHD? 
a. Could these miRNAs be used as predictive biomarkers of aGVHD incidence 
and severity? 
b. Would there be any relationship between the miRNAs and their 
established targets? 
In addition, using pathway mining techniques it was interesting to assess whether 
there was any overlap between the miRNAs identified via the screening experiment 
and those found to target the 18 genes. Since molecular interaction is a natural 
biological phenomenon, this study also looked for interactions between miRNAs as 
well as their targets.  
7.1.1 Eighteen genes were associated with immune-related, 
inflammatory, hematological and cutaneous conditions  
 
Pathway mining analyses performed in Chapter 3 showed that the 18 genes were 
involved in NFĸB and p53 pathway as well as associated with TCR signaling. It was also 
shown that some of the genes were influenced by IFN-γ. The list of miRNAs identified 
to target the 18 genes directed the miRNA signature list selection. This was an 
additional consideration to the significant differential expression observed between 
allo-HSCT skin biopsies and that of normal controls in the discovery cohort. The main 
limitation of the study in this Chapter was the lack of samples that overlapped with the 
miRNA skin investigation in Chapter 4. It would be interesting if matched samples were 
studied at the miRNA and mRNA expression levels to elucidate the regulatory 
mechanism involved with regards to the common pathways.  
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 7.1.2 Screening experiment in skin biopsies: MiR-503-5p, miR-34a and 
let-7c-5p were associated with allo-HSCT outcomes 
 
The screening experiments performed on a discovery cohort and then a validation 
cohort showed that miR-503-5p, miR-34a-5p/-3p and let-7c-5p were associated with 
aGVHD severity, OS and relapse. Therefore, miRNA expression was confirmed to be 
deregulated upon allo-HSCT and aGVHD in the target tissue, skin. The deregulation 
quantified also showed promising biomarker potential that would need to be further 
confirmed in a larger cohort potentially with skin biopsies collected from different 
transplantation centres. An attribute of a robust aGVHD biomarker would be its 
precision and accuracy in distinguishing the disease from that of controls independent 
of the conditioning regimens. Otherwise, the biomarker will only have a limited single 
centre application. Moreover, the miRNA targets are also required to be tested to 
understand the impact of their differential expression levels downstream and their link 
to the pathways already highlighted in Chapter 3. It would also be interesting to assess 
the miRNA expression levels and their 18 gene targets in the same skin biopsies both 
at the mRNA and protein level. The major limitation of this investigation has been the 
availability of cutaneous GVHD biopsies required to perform multiple studies. 
However, this limitation could be circumvented if biopsies of at least 2-4 mm were 
collected from five patients with skin histopathological aGVHD grades II-IV and five 
without aGVHD and run on a miRNA-mRNA Nanostring chip. This proposed study 
would both reduce the amount of starting total RNA material required to perform this 
research and also permit multiple matched comparisons to be performed looking at 
the main effects and interactions. The protein targets could always be detected by 
immunohistochemistry methods using FFPE blocks. The limiting factor in protein 
investigations is the availability of sensitive and specific antibodies.  
7.1.3 miR-34a-5p positively correlated with p53-positive cells in the 
epidermis 
 
The findings of Chapter 5 showed that there was a positive relationship between miR-
34a-5p expression and p53-positive cells. It would be interesting to extend this section 
by looking at Sirt1 expression levels using immunohistochemical methods and then 
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assessing its relationship with both miR-34a-5p and p53. The finding would elucidate 
whether the direct control mechanism of p53 by miR-34a-4p through Sirt1 that is 
described in the literature is true under allo-HSCT conditions. The preliminary 
functional work optimisations showed the potential in inhibiting miR-34a-5p and 
observing lower T cell proliferation. Further knockdown optimisations in particular for 
miR-34a-3p and additional T cell proliferation experiments are required to assess the 
impact of miR-34a inhibition on T cells. A limitation of the RT-qPCR detection of the 
inhibited miRNA is that the miRNAs are not degraded by the inhibitors but inhibited or 
inactivated by a duplex formation of inhibitor-miRNA as they compete with the 
endogenous levels of miRNAs for binding to the RISC complex. Thus, when RT- qPCR is 
performed the duplex will dissociate and what is measured could be the miRNA that 
was released from the already formed duplex as if it was actively present in the 
sample. This increases the bias in RT-qPCR knockdown measurements. To eliminate 
this bias, detection of the downstream miRNA targets and/or luciferase-reporter 
assays are essential.  In addition, co-transfection of the miR-34a strands would provide 
a more complete picture of the downstream impacts of miR-34a.  
7.1.4 Whole blood investigation of immune-specific miRNAs: miR-146a-
5p and miR-155-5p were associated in the prediction of aGVHD 
incidence 
The findings of Chapter 6 were independent of the first three results Chapters as they 
were based on evidence present in the literature with regards to both miR-146a-5p 
and miR-155-5p. However, the results are novel and interesting as  it is the first 
reported study in which peripheral blood of allo-HSCT patients has been used to 
predict disease incidence and severity. The results are also in support of the recently 
published murine study where lower levels of miR-146a-5p were present in mice with 
severe aGVHD manifestation (Stickel et al., 2014).  
Unlike, miR-155-5p that was significantly differentially expressed in the skin at the time 
of aGVHD diagnosis, miR-146a-5p expression was not deregulated. This may have been 
due to the hierarchical pattern of expression mentioned in Chapter 6. The skin biopsies 
were collected at the time of aGVHD diagnosis which was indicative of the presence of 
damage to the host tissue and therefore severe levels of inflammation. This level might 
have breached miR-146a-5p level of control and therefore, miR-155-5p was 
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deregulated at this stage. Thus, to test this hypothesis it would be interesting to 
measure miR-146a-5p and miR-155-5p expression levels in skin biopsies prior to 
aGVHD onset. Another proposed reason might be that miR-146a-5p expression is 
mainly present in whole blood rather than skin tissues. This would qualify for the cell 
and tissue specificity of miRNAs. Therefore, it would be interesting to sort the different 
subsets of cells present in whole blood and quantify miRNA expression levels, likewise 
sort the different cells present in the skin and then detect miRNA expression levels. In 
all, the main limitation of this whole blood investigation was the lack of severe aGVHD 
patients. However, this has been a general limitation of this research which reiterates 
the need for multicenter-based investigations.  
Overall, the research presented in this thesis was performed by looking at miRNAs at 
the tissue level. Therefore, to better understand the role of the miRNAs in allo-HSCT 
and in GVHD it would be ideal to step closer to the cellular level and investigate the 
expression levels in specific cell subsets (sorting by flow cytometry for whole blood and 
skin as well as electro-microdissection for skin tissues). At present all the conclusions 
have been made on a general basis rather than as per cell type. Allogeneic HSCT 
patient receive HSCT grafts and thus it would be reasonable to propose that to be able 
to segment these patients for specific therapies and discover new therapeutics it is 
essential to localize the miRNA expression levels at the cellular level. Likewise, to be 
able to take the miRNAs identified from this research into functional investigation it 
would be necessary to optimize the human in vitro skin explant model to reflect the 
changes in the clinical treatment regimens. The assay is a valuable tool for human 
based experiments, and it would, therefore, provide more informative results than 
animal-based model if they were to be used for extensions of the miRNA functional 
studies.  
Taken together, the findings of this research has highlighted the complexity involved in 
GVHD and has shown that there is a combination of miRNAs involved that are 
controlling inflammation via interactions.  In my opinion, it may not be feasible to have 
a systemic miRNA-based treatment available in the future to treat GVHD but there 
maybe be better topical options available that could deliver miRNAs such as via 
fabricated hydrogel dressings. These could then be used in steroid-resistant patients or 
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those suffering from severe skin GVHD. It would be interesting to investigate the 
impact of miRNAs on the GVL effect which was not investigated during this study. 
In summary, this research has been novel in firstly, investigating miRNAs in one of the 
target organs of GVHD, the skin and also using peripheral blood to predict GVHD 
incidence prior to disease occurrence. The statistical approach has also been novel in 
the context of GVHD especially with regards to using miRNAs and their interactions to 
diagnose as well as predict disease incidence and relapse.    
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Appendix I 
No. % No. %
1.000
Female 1 33.3% 2 66.7%
Male 5 38.5% 8 61.5%
Female 1 20.0% 4 80.0%
Male 5 50.0% 5 50.0%
BM 1 100.0% 0 0.0%
PBSC 5 33.3% 10 66.7%
ALL 1 50.0% 1 50.0%
AML 0 0.0% 3 100.0%
MDS 3 75.0% 1 25.0%
MF 0 0.0% 1 100.0%
NHL 0 0.0% 1 100.0%
CLL 1 100.0% 0 0.0%
MM 1 25.0% 3 75.0%
Myeloablative 1 33.3% 2 66.7%
RIC 5 38.5% 8 61.5%
Cy TBI Alem 1 33.3% 2 66.7%
Flu Bus Alem 1 33.3% 2 66.7%
Flu Mel Alem 4 40.0% 6 60.0%
30 mg 3 75.0% 1 25.0%
60 mg 3 30.0% 7 70.0%
90 mg 0 0.0% 2 100.0%
SIB 2 66.7% 1 33.3%
MUD 4 30.8% 9 69.2%
Negative 1 20.0% 4 80.0%
Positive 4 40.0% 6 60.0%
Negative 4 44.4% 5 55.6%
Positive 2 33.3% 4 66.7%
None 5 45.5% 6 54.5%
One 1 20.0% 4 80.0%
None 3 60.0% 2 40.0%
One 2 28.6% 5 71.4%
Two 1 25.0% 3 75.0%
Alive 4 44.4% 5 55.6%
Dead 2 28.6% 5 71.4%
No 3 27.3% 8 72.7%
Yes 3 60.0% 2 40.0%
CR 1 100.0% 0 0.0%
CR1 0 0.0% 6 100.0%
CR2 2 40.0% 3 60.0%
PR 1 50.0% 1 50.0%
0-I 6 60.0% 4 40.0%
II-III 0 0.0% 6 100.0%
Skin histopathological grade
0.034
Survival status 0.633
Relapse status 0.299
Disease status at Transplant 0.126
Donor CMV status 1.000
HLA class I compatibility 0.588
HLA class II compatibility 0.537
Campath 0.264
Relationship 0.518
Patient CMV status 0.600
Underlying Disease 0.293
Regimen 1.000
Protocol 1.000
Patient gender 1.000
Donor gender 0.580
Graft soruce 0.375
Cohort Characteristics
aGVHD overall clinical grades     
Difference (p-value)0-I II-III
Patient age (median years) 50.5 (19-65)
 
Table 1 Patient characteristic for the validation of the miRNA signature list 
(n=16) using the overall clinical aGVHD grades. Fisher exact test was used to estimate 
the difference in frequencies between the aGVHD groups. Abbreviations:- BM: Bone 
marrow, PBSC: Peripheral blood stem cells, ALL: Acute lymphocytic leukaemia, AML: 
Acute myeloid leukaemia, CLL: Chronic lymphocytic leukaemia, MDS: Myelodysplastic 
syndrome, MM: Multiple myeloma, MPS: Multiple proliferative syndrome, NHL: Non-
Hodgkin’s lymphoma, RIC: Reduced intensity conditioning, Flu: Fludarabine, Mel: 
Melphalan, Bus: Busulfan, Cy: Cytrabine, TBI: Total body irradiation, Alem: 
Alemtuzumab, CsA: Cyclosporine, CMV: Cytomegalovirus, CR (1-3) Complete remission, 
PR: Progression, SIB: Sibling, MUD: Matched unrelated donor. 
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 Figure 1 Validation of miRNAs in clinical skin biopsies using histopathological 
grades. Scatter plots show (A) miR-493-3p, (B) miR-142-3p, (C) miR-21-3p, (D) miR-24-
3p, (E) miR-2110, (F) miR-200b-3p, (G) miR-23b-3p expression with error bars for SEM. 
RT-QPCR studied expression of miRNAs. Kruskal-Wallis analysis of variance was used to 
determine the significance set at p<0.05. Normal: normal controls, Pre-Tx: Pre-
transplant 
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Appendix II 
 
 
Figure 1 MiRNA targets for miR-146a and miR-155. The targets were predicted 
using the online database microrna.org. IRAK1, TRAF6, STAT1-α, IRF5 and SPI1 were all 
predicted to be targets of miR-146. STAT1-α and SPI1 were predicted as targets of miR-
155.  The figures show the alignment and partial complementarity between the seed 
sequences of the miRNAs and their predicted mRNA targets. The vertical lines show 
the binding.  
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TRAF6 IRAK1 STAT1A IRF5  SPI1  miR-146a -5p miR-155 -5p aGVHD incidence
p-value 0.000 0.000 0.000 0.000 0.264 0.229 0.140
p-value 0.000 0.000 0.000 0.024 0.392 0.438 0.118
rs 0.77 0.58 0.65 0.54 0.00 -0.12 0.23
p-value 0.000 0.000 0.000 0.000 0.981 0.394 0.109
p-value 0.000 0.000 0.000 0.005 0.542 0.504 0.360
p-value 0.000 0.024 0.000 0.005 0.040 0.010 0.226
rs -0.16 -0.12 0.00 -0.09 -0.28 0.22 0.07
p-value 0.264 0.392 0.981 0.542 0.040 0.114 0.632
rs -0.17 -0.11 -0.12 -0.10 -0.35 0.22 -0.21
p-value 0.229 0.438 0.394 0.504 0.010 0.114 0.120
rs 0.20 0.22 0.23 0.13 0.17 0.07 -0.21
p-value 0.140 0.118 0.109 0.360 0.226 0.632 0.120
miR-155-5p
aGVHD incidence
0.17
TRAF6 
IRAK1
STAT1-α 
IRF5  
SPI1  
miR-146a -5p
-0.10 0.13
rs 0.48 0.32 0.54 0.39 -0.28 -0.35
-0.12 -0.11 0.22
rs 0.68 0.70 0.65 0.39 -0.09
rs 0.80 0.58 0.70 0.32
rs 0.80 0.77 0.68 0.48 -0.16 -0.17 0.20
Spearman Correlation
 
 
Table 1 Spearman correlation showed significant positive correlation between 
all the mRNA targets in whole blood collected from allo-HSCT patients (n=51- 54) on 
Day+28. Significant negative correlation was present for both miR-146a-5p and miR-
155-5p with SPI1. 
 
miR-146a-5p TRAF6 IRAK1 STAT1-a IRF5
rs 1.00 0.16 -0.24 -0.19 -0.24
p-value 0.573 0.437 0.574 0.511
rs 0.16 1.00 0.79 0.59 -0.13
p-value 0.573 0.001 0.027 0.697
rs -0.24 0.79 1.00 0.52 0.48
p-value 0.437 0.001 0.102 0.162
rs -0.19 0.59 0.52 1.00 0.24
p-value 0.574 0.027 0.102 0.426
rs -0.24 -0.13 0.48 0.24 1.00
p-value 0.511 0.697 0.162 0.426
Spearman Correlation
Pre-transplant
miR-146a-5p
TRAF6
IRAK1
STAT1-a
IRF5
 
 
Table 2 Spearman Correlation statistics between miR-146a-5p expression and 
its validated targets at pre-transplant. 
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 miR-146a-5p TRAF6 IRAK1 STAT1-a IRF5
rs 1.00 -0.37 -0.22 -0.26 -0.24
p-value 0.061 0.294 0.214 0.250
rs -0.37 1.00 0.81 0.77 0.85
p-value 0.061 0.000 0.000 0.000
rs -0.22 0.81 1.00 0.60 0.89
p-value 0.294 0.000 0.002 0.000
rs -0.26 0.77 0.60 1.00 0.64
p-value 0.214 0.000 0.002 0.001
rs -0.24 0.85 0.89 0.64 1.00
p-value 0.250 0.000 0.000 0.001
rs 1.00 -0.60 -0.10 -0.20 -0.20
p-value 0.400 0.873 0.704 0.704
rs -0.60 1.00 0.50 -0.40 0.80
p-value 0.400 0.667 0.600 0.200
rs -0.10 0.50 1.00 0.30 0.80
p-value 0.873 0.667 0.624 0.104
rs -0.20 -0.40 0.30 1.00 -0.03
p-value 0.704 0.600 0.624 0.957
rs -0.20 0.80 0.80 -0.03 1.00
p-value 0.704 0.200 0.104 0.957
3 months
miR-146a-5p
TRAF6
IRAK1
STAT1-a
IRF5
Grade 0
Spearman Correlation
Day+28
miR-146a-5p
TRAF6
IRAK1
STAT1-a
IRF5
 
Table 3 Spearman Correlation statistics between miR-146a-5p expression and 
its validated targets at Day+28 and three months in the no aGVHD cohort (Grade 0).  
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miR-146a-5p TRAF6 IRAK1 STAT1-a IRF5
rs 1.00 0.06 -0.02 0.25 0.10
p-value 0.765 0.928 0.201 0.634
rs 0.06 1.00 0.75 0.64 0.52
p-value 0.765 0.000 0.000 0.006
rs -0.02 0.75 1.00 0.47 0.45
p-value 0.928 0.000 0.013 0.019
rs 0.25 0.64 0.47 1.00 0.62
p-value 0.201 0.000 0.013 0.001
rs 0.10 0.52 0.45 0.62 1.00
p-value 0.634 0.006 0.019 0.001
rs 1.00 -0.42 -0.35 -0.39 -0.69
p-value 0.229 0.298 0.235 0.019
rs -0.42 1.00 0.86 0.45 0.62
p-value 0.229 0.001 0.224 0.077
rs -0.35 0.86 1.00 0.28 0.41
p-value 0.298 0.001 0.425 0.244
rs -0.39 0.45 0.28 1.00 0.51
p-value 0.235 0.224 0.425 0.110
rs -0.69 0.62 0.41 0.51 1.00
p-value 0.019 0.077 0.244 0.110
Grades I-III
Spearman Correlation
Day+28
miR-146a-5p
TRAF6
IRAK1
STAT1-a
IRF5
3 months
miR-146a-5p
TRAF6
IRAK1
STAT1-a
IRF5
 
 
Table 4 Spearman Correlation statistics between miR-146a-5p expression and 
its validated targets at Day+28 and three months in the aGVHD cohort (Grades I-III).
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 miR-146a-5p STAT1-a STAT1-α  protein IRF5 IRF5 protein
rs 1.00 -0.19 -0.05 -0.24 0.53
p-value 0.574 0.873 0.511 0.096
rs -0.19 1.00 0.30 0.24 0.41
p-value 0.574 0.403 0.426 0.244
rs -0.05 0.30 1.00 0.40 -0.01
p-value 0.873 0.403 0.250 0.980
rs -0.24 0.24 0.40 1.00 -0.20
p-value 0.511 0.426 0.250 0.580
rs 0.53 0.41 -0.01 -0.20 1.00
p-value 0.096 0.244 0.980 0.580
Spearman Correlation
Pre-transplant
miR-146a-5p
STAT1-a
IRF5
STAT1-α  protein
IRF5 protein
 
Table 5 Spearman Correlation statistics between miR-146a-5p expression and 
STAT1-α and IRF5 protein targets at pre-transplantation. 
 
miR-146a-5p STAT1-a STAT1-α  protein IRF5 IRF5 protein
rs 1.00 -0.26 0.60 -0.24 0.30
p-value 0.214 0.285 0.250 0.624
rs -0.26 1.00 -0.10 0.64 0.20
p-value 0.214 0.873 0.001 0.747
rs 0.60 -0.10 1.00 -0.80 0.90
p-value 0.285 0.873 0.104 0.037
rs -0.24 0.64 -0.80 1.00 -0.60
p-value 0.250 0.001 0.104 0.285
rs 0.30 0.20 0.90 -0.60 1.00
p-value 0.624 0.747 0.037 0.285
rs 1.00 -0.20 0.10 -0.20 -0.10
p-value 0.704 0.873 0.704 0.873
rs -0.20 1.00 0.60 -0.03 1.00
p-value 0.704 0.400 0.957
rs 0.10 0.60 1.00 -0.40 0.50
p-value 0.873 0.400 0.600 0.391
rs -0.20 -0.03 -0.40 1.00 -0.40
p-value 0.704 0.957 0.600 0.600
rs -0.10 0.50 -0.40 1.00
p-value 0.873 0.391 0.600
STAT1-a
STAT1-α  protein
IRF5
IRF5 protein
Day+28
Grade 0
Spearman Correlation
3 months
miR-146a-5p
STAT1-a
STAT1-α  protein
IRF5
IRF5 protein
miR-146a-5p
 
 
Table 6 Spearman Correlation statistics between miR-146a-5p expression and 
STAT1-α and IRF5 protein targets at Day+28 and three months in the no aGVHD 
cohort (Grade 0). 
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miR-146a-5p STAT1-a STAT1-α  protein IRF5 IRF5 protein
rs 1.00 0.25 0.53 0.10 -0.03
p-value 0.201 0.092 0.634 0.914
rs 0.25 1.00 0.57 0.62 0.34
p-value 0.201 0.068 0.001 0.286
rs 0.53 0.57 1.00 0.35 0.35
p-value 0.092 0.068 0.293 0.293
rs 0.10 0.62 0.35 1.00 0.71
p-value 0.634 0.001 0.293 0.009
rs -0.03 0.34 0.35 0.71 1.00
p-value 0.914 0.286 0.293 0.009
rs 1.00 -0.39 0.35 -0.69 0.45
p-value 0.235 0.356 0.019 0.224
rs -0.39 1.00 0.00 0.51 -0.18
p-value 0.235 1.000 0.110 0.702
rs 0.35 0.00 1.00 -0.57 0.08
p-value 0.356 1.000 0.180 0.829
rs -0.69 0.51 -0.57 1.00 -0.32
p-value 0.019 0.110 0.180 0.482
rs 0.45 -0.18 0.08 -0.32 1.00
p-value 0.224 0.702 0.829 0.482
IRF5 protein
miR-146a-5p
STAT1-a
STAT1-α  protein
IRF5
IRF5 protein
Grades I-III
Spearman Correlation
Day+28
3 months
miR-146a-5p
STAT1-a
STAT1-α  protein
IRF5
 
Table 7 Spearman Correlation statistics between miR-146a-5p expression and 
STAT1-α and IRF5 protein targets in the aGVHD cohort (Grades I-III). 
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“I am Winter, that do keep 
Longing safe amidst of sleep: 
Who shall say if I were dead 
What should be remembered?” 
-William Morris (Verses for Pictures) 
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